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ABSTRACT 
 The eukaryotic stress response involves translational suppression of non-
housekeeping proteins, and the sequestration of unnecessary mRNA transcripts into stress 
granules (SGs). This process is dependent on mRNA binding proteins (RBPs), such as T- 
cell intracellular antigen (TIA-1). RBPs interact with unnecessary mRNA transcripts 
through prion and poly-glutamine like domains, and their aggregation mirrors proteins 
linked to neurodegenerative diseases. Recent advances in molecular genetics emphasize 
the importance of SG biology in disease by associating multiple RBPs linked to SGs with 
neurodegenerative disease. The major difference between SG proteins and aggregation 
prone proteins in neurodegeneration is that aggregation of SGs is transient and rapidly 
reverses when the stress is removed. In contrast, aggregates associated with disease are 
stable and accumulate over time. 
This study identifies overabundant SGs as a novel pathology in Alzheimer’s disease 
and related tauopathies. The data suggest that TIA-1 is intimately linked to tau 
pathogenesis, acting as a modifier of tau aggregation and associated toxicity. TIA-1 is 
present in a protein complex with tau protein including hyper-phosphorylated and 
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misfolded tau. The expression of WT or P301L mutant tau increases the formation and 
size of TIA-1 positive SGs, and the localization and dynamics of these SGs are altered. 
Conversely, the expression of TIA-1 increases the formation and stabilization of 
phospho- and misfolded tau inclusions, as well as visible alterations in microtubule 
morphology, perhaps reflecting a loss of tau function. The data further show that co-
expression of TIA-1 and tau leads to dendrite shortening, increases in caspase cleavage, 
and apoptosis in primary neurons, suggesting that an interaction between TIA-1 and tau 
results in neurotoxicity. This toxicity is SG-dependent and is rescued by microtubule 
stabilizing drugs. 
The results of this thesis research suggest that the aggregation of tau may proceed 
through the SG pathway, with SG formation accelerating the pathophysiology of tau 
aggregation. These studies propose that these tau aggregates serve as a nidus for further 
accelerated aggregation of SGs, leading to formation of long-lived pathological SG. 
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CHAPTER ONE: INTRODUCTION 
Section One: Alzheimer’s Disease 
Epidemiology 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the most 
common cause of dementia. According to the World Health Organization, an estimated 37 
million people worldwide currently have dementia, and AD affects about 18 million of 
them. Risk of developing AD approximately doubles every five years after the age of 60—
one in 10 individuals over 65 years and nearly half of those over 85 are affected by the 
disease (1). Keeping this in mind, with the baby-boomer population reaching elderly status, 
Alzheimer’s disease poses one of the greatest threats to the future of healthcare systems due 
to the demographic shift to an aging population. It is expected that by 2050 the number of 
people aged 65 and older with AD will be between 11-16 million (1).  
Neuropathology 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the most 
common cause of dementia (1). AD is characterized is by progressive cognitive decline 
and specific pathological changes in the brain. The pathophysiology of AD has been 
studied extensively and is well characterized.  Pathological properties of AD include: 
extracellular neuritic plaques composed of β-amyloid (Aβ), intracellular neurofibrillary 
tangles (NFTs) of hyperphosphorylated tau, astrocytic gliosis, reactive microglia and 
inflammation, and neuronal and synaptic loss (2-4).  
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Pathogenesis 
The β-amyloid cascade hypothesis suggests that the elevation of soluble Aβ 
monomers then oligomers, cleaved products of the amyloid precursor protein (APP), and 
their subsequent deposition into amyloid fibrils and plaques gradually leads to synaptic, 
neuronal, and glial malfunction. These changes lead to the hyperphosphorylation of 
microtubule associated protein tau, which accumulates into NFTs.  These alterations are 
accompanied by declining memory, dementia, and neuroinflammation (2).   
If the above stated β-amyloid cascade hypothesis is correct, the main underlying 
toxicity in AD that leads to its development and progression is the increase in Aβ 
oligomers and neuritic plaques. Aβ arises from the proteolytic processing of Amyloid 
Precursor Protein (APP), and autosomal dominant mutations in the APP gene that 
increase the 42 amino acid form of Aβ are causal factors for early-onset familial AD 
(FAD)(5). While amyloid deposition represents an established hallmark of AD pathology, 
the true physiologic functions of APP and Aβ are unknown and the cellular processes 
underlying these pathological events remain poorly understood.  
There are several lines of evidence to support the notion that Aβ is the main 
underlying toxicity in AD, including the observation that Aβ is the earliest 
neuropathological deposition seen in AD. Other studies have shown that Aβ is toxic to 
cultured neurons. Perhaps most convincing is the fact that missense mutations in APP, 
which cause overproduction of Aβ, are sufficient to cause early-onset AD (6). Much of 
the research done in the past decade has focused on the role of Aβ as the key pathology in 
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AD, with NFTs considered a downstream event (2).  However, dominantly inherited 
mutations in tau are sufficient to cause neurodegeneration in Fronto-Temporal Dementia 
with Parkinsonism linked to chromosome 17 (FTDP-17), with disruption in tau 
homeostasis being the causal feature of the disease in the absence of amyloid pathology. 
Although NFTs are a defining feature of AD, no mutations in tau have been linked with 
either the familial or sporadic form of the disease (7-9). Interestingly, multiple studies 
examining the relationship of amyloid load and NFTs to clinical status suggest that NFTs 
correlate better with the decline in cognitive ability in AD patients (4, 10). Interestingly, 
in transgenic mouse models of the disease it has been found that tau is required for Aβ 
induced toxicity at synapses and the resulting neurodegeneration (11-13). However, the 
link between the production of toxic Aβ species, the hyperphosphorylation of tau, and 
their subsequent deposition has not been elucidated.   
Neuroinflammation 
Neuroinflammation is another major feature of AD. Although inflammation does not 
represent an initiating factor in the disease, sustained inflammatory responses involving 
microglia and astrocytes can significantly contribute to disease progression. This 
sustained inflammation can result in neurotoxic factors that exacerbate the disease state. 
In AD there is an increase in microglial activation and astrogliosis, and inflammatory 
changes are observed overall, particularly around Aβ deposits where a high density of 
activated microglia are found. Microglial cells represent the innate immune system in the 
brain and thus the first line of defense against invading pathogens and serve as 
specialized sensors for brain tissue injury (14). Under pathological conditions microglia 
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become activate and migrate to the damaged area. The microglia-driven response results 
in the release of a wide variety of inflammatory mediators including cytokines and free 
radicals, which can contribute to neuronal dysfunction and apoptosis (15). Microglia may 
also have beneficial roles, as they are able to reduce Aβ accumulation by increasing its 
phagocytosis, clearance, and degradation (16). In the healthy brain, astrocytes provide 
essential services for brain homeostasis and neuronal function, including metabolic 
support for neurons in the form of lactate, glutamate uptake and conversion into 
glutamine, and synthesis of glutathione and its precursors. However, in AD a large body 
of evidence now suggests that by transforming from basal to a reactive state, astrocytes 
neglect their neurosupportive functions, thus rendering neurons vulnerable to neurotoxins 
including pro-inflammatory cytokines and reactive oxygen species (17). Microglia and 
astrocytes perform crucial homeostatic functions in the normal brain, however in AD 
these cells neglect these roles and transform into inflammatory cells that actively 
contribute to neurodegeneration and the progression of disease.   
Current Pharmacological Treatments 
Current treatment options are limited and only target the symptoms of AD. There are 
currently two classes of drugs approved for the treatment of symptoms of AD: acetyl-
cholinesterase inhibitors and N-Methyl-D-aspartate (NMDA) receptor antagonists. These 
drugs can lead to improvements in cognition, mood, and behavior, but only show modest 
effects early in the disease (18, 19). Neither of these drugs stops the underlying 
degeneration of brain cells, or reverses the progression of Alzheimer’s disease. Disease 
modifying drugs, which aim to slow or reverse the neuronal loss and cognitive decline 
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seen with AD, are desperately needed. The majority of attempts have been to slow or stop 
Aβ production, and clear Aβ pathology from the brain. Unfortunately only modest effects 
of these therapeutics have been produced, none of which have been shown to alter the 
disease time course (20). This has been a main cause of the shift away from the β-
amyloid hypothesis, as it is evident that AD is a complex disease, and there are other 
underlying changes that account for the toxicity independent of Aβ. 
Section Two: Tau and Tauopathies 
Gene and Protein Structure 
The cytoskeletal structure provides neuronal morphology and is essential in the 
formation of axons and dendrites. Without these structures and the essential microtubule 
(MT) components that regulate them, transport and neurotransmission would be 
impossible. The stability and dynamics for the assembly of MTs is promoted by proteins 
that are referred to as ‘microtubule associated proteins’ (MAPs). Among these MAPs, 
microtubule associated proteins tau (MAPT) is a major protein that dynamically regulates 
the association-dissociation of the MTs. The human MAPT gene is located on 
chromosome 17q21 and occupies over 100 kb, containing 16 exons. There are six 
isoforms of tau produced by alternative splicing of exons 2, 3, and 10, resulting in 
proteins of 352–441 amino acids. The alternative splicing of tau results in proteins that 
differ by having 3 or 4 semi-conserved repeats of 31 residues in the microtubule binding 
domain (MTBD) and 0-2 insertions in the N-terminal projection domain (21, 22). 
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Characteristically, tau protein is divided into two domains: a projection domain and a 
MTBD, as seen in Figure 1. The projection domain has an acidic region (negative charge) 
and contains a proline-rich region (positive charge). The acidic region of the projection 
domain is responsible for the interaction with other cytoskeletal and plasma proteins. The 
proline-rich region regulates the interaction of Tau with MTs through the 
phosphorylation of serine/threonine amino acids (23). The MTBD is important for 
promoting microtubule assembly, although it binds to microtubules only with low affinity 
(21). Tau protein also undergoes different post-translational modifications in addition to 
phosphorylation, such as acetylation, glycosylation, ubiquitinylation, deamidation, 
oxidation, tyrosine nitration, cross-linking, and glycation all of which can regulate its 
function (23, 24). 
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Figure 1:  Tau protein domains, net charge, and post-translational modifications.  
All isoforms of Tau protein are divided in a projection domain localized on N-terminal 
region, and microtubule-binding domain region (MTBD) in C-terminal charge in region. 
Tau has a positive charged in MTBD and part of the proline-rich region and, on the other 
hand, the rest of the molecule has negative charged. Tau is a substrate of phosphorylation 
(P), glycosylation or glycation (G), nitration (N), and truncation ( ). Tau is able to 
interact with members of the Src family, non-associated receptor tyrosine-kinase Fyn, 
through a motif in the proline-rich region. Adapted from (23). 
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General Biological Function 
Tau localizes predominantly in the axons of neurons with the primary function in 
maintaining MT stability, axonal transport, and the viability of neurons. As a property of 
its effect on MT dynamics tau promotes neurite outgrowth and is key to the sophisticated 
transport machinery that allows signaling molecules, trophic factors and other essential 
cellular constituents, including organelles, to travel along the axons (21, 25). Tau also 
interacts with various other proteins in addition to tubulin, including the SH3 domains of 
Src family tyrosine kinases such as Fyn and c-Abl, whose interactions have been shown 
to result in Aβ-induced tau phosphorylation (26). Additionally via its projection domain 
tau is known to facilitate enzyme anchoring, although this is not as well studied (21). We 
also know tau interacts with the Hsp90/CHIP complex for triage and degradation (25).  
Tau stabilizes microtubules by binding to them via an interaction with the three or 
four microtubule-binding domains at the C terminus of the protein. The ratio of 3R and 
4R tau isoforms is 1:1 in most regions of the adult brain, and deviations from this ratio 
are characteristic of neurodegenerative tauopathies (22). 4R tau has a higher affinity for 
microtubules than 3R tau owing to the increased number of microtubule-binding domains 
(21, 27). The MT-binding ability of tau is post-translationally regulated primarily by 
serine/threonine-directed phosphorylation, which can effectively modulate the binding 
affinity of tau for MTs, although other post-translational modifications, such as 
glycosylation, may also have a direct impact on the dynamic equilibrium of tau on and 
off the MTs (21).  
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Pathogenic Mutations in Tau 
The increased affinity of 4R tau for microtubules compared with 3R tau implies that 
changing the ratio of 3R to 4R tau isoforms could cause changes in its normal function 
(28). Thus, alterations in the alternative splicing of tau in the brain could be causative in 
tau-associated neurodegeneration. Because of its importance in microtubule binding, the 
alternative splicing of exon 10 has been extensively studied. Alternative splicing is 
regulated by both cis-elements within exon 10 and in introns surrounding it, in addition to 
trans-acting factors (29). Many mutations in the coding region of the tau gene have been 
found to cause FTDP-17 or other tauopathies, as indicated in Figure 2 (30). All of these 
mutations have effects either on tau interactions with microtubules, tau fibrillogenicity, or 
on the 3R to 4R tau ratio, which cause pathogenic changes that lead to the 
neurodegenerative conditions termed tauopathies (30). The type of tau found in deposits 
of the different tauopathies provides evidence that tau splicing might have a role in 
degeneration. Tau deposits in progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD), argyrophilic grain disease, and FTDP-17 consist mainly of 4R tau. 
A subtle increase in 4R tau can also be observed in AD (31). Thus, a change in 3R to 4R 
ratio, either by mutations as seen in tauopathies, or via splicing alterations in the 
Alzheimer brain seems to lead to neurotoxicity, but the exact mechanism is uncertain. 
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Figure 2: Mutations in tau lead to dementia. 
Schematics of the tau protein isoforms show that exons 2 (yellow), 3 (blue) and 10 (red) 
are alternatively spliced to make six isoforms ranging from 352 to 441 amino acids in 
length. Dementia-associated mutations in the coding region of the tau protein are shown 
below the longest isoform. There are also at least eight mutations in the noncoding region 
that affect exon 10 splicing (not shown). Adapted from (22).
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Pathogenesis of Tauopathies 
Tau aggregation is a pathological hallmark of more than 20 different 
neurodegenerative diseases, including AD and FTDP-17. It is clear that tau is important 
for neuronal viability, and that alterations in the protein directly cause neurodegenerative 
disease. Tau protein itself is highly disordered and requires binding partners for its 
stabilization and function, in the case of MT stability tau is bound to tubulin allowing it 
to become ordered and regulate cytoskeletal organization. As mentioned earlier, tau 
undergoes many post-translational modifications that regulate its function including 
phosphorylation, acetylation, glycosylation, ubiquitinylation, deamidation, oxidation, 
tyrosine nitration, cross-linking, and glycation. In disease conditions changes in these 
modifications cause tau to lose its normal functions, resulting in mislocalized tau that is 
able to interact and aggregate with itself. Of these disease-linked changes the best studied 
are hyperphosphorylation and truncation.  
Tau contains two motifs that have a regional trend to form β-sheet structures flanked 
by the second (275–280 amino acids) and the third (306–311 amino acids) repeats of the 
MTBD. When this structure is altered by modifications such as hyperphosphorylation or 
truncation, such as the case for AD, the protein loses the affinity to MTs and begins to 
self-assemble, first into oligomers and intermediate aggregates and ultimately resulting in 
the formation of paired helical filaments (PHFs) and NFTs (23). Tau oligomers are rich 
in β-sheet structures and can promote the formation of fibrils once the oligomers reaches 
a size of 20 nm (32). Oligomeric tau contains both 3R and 4R tau that has been 
structurally modified via truncation and/or phosphorylation. The presence of 
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hyperphosphorylated tau in these oligomers is able to sequester normal tau, as well as 
other MAPs such as MAP1 and MAP2 (33). 
Phosphorylation 
The normal function of tau including its interaction with other molecules is regulated 
by site-specific phosphorylation and dephosphorylation of tau. These principal sites of 
phosphorylation are on serine and threonine residues, principally located in the projection 
domain and the MTBD, which lead to the regulation of MT interaction and 
consequentially cytoskeletal stability (23, 34). When this process becomes dysregulated, 
tau becomes hyperphosphorylated resulting in tau’s release from MTs and an increase in 
the level of free tau. Tau is found to be phosphorylated at over 30 serine/threonine 
residues, some of which are only found in disease conditions. Hyperphosphorylated tau is 
more prone to aggregate into oligomeric pre-tangles, PHFs, and finally into mature NFTs 
(21, 32). 
Two types of kinases that phosphorylate tau are proline directed serine-threonine 
protein kinases and non-proline directed protein kinases. Proline-directed kinases 
responsible for tau phosphorylation include glycogen synthase kinase 3β (GSK3β), p38 
mitogen-activated protein kinase (p38/MAPK), and cyclin-dependent kinase 5 (Cdk5), 
these phosphorylate Ser-Pro or Thr-Pro tau motifs. Non-proline directed protein kinases 
include MT-affinity regulatory kinase (MARK), and cAMP-dependent protein kinase 
(PKA), these phosphorylate serine or threonine residues not preceded by proline (23, 34, 
35). Phosphorylation of tau by these kinases at T231, S262, and S356 in the MTBD 
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inhibits its activity to stimulate MT assembly and phosphorylation in the proline-rich 
region dramatically reduces tau capacity for de novo MT assembly (34). 
Truncation 
Hyperphosphorylation of tau in association with its independent cleavage by caspases 
and calpain, which is a significant posttranslational modification instigates the formation 
of PHFs. Hyperphosphorylation of tau can be seen as an initiating event in the 
pathological changes that occur in tauopathies, this causes an increase in free tau which 
promotes the formation of tau aggregates. The truncation of tau also promotes the 
phosphorylation and aggregation of tau. It appears that these two modifications can 
exacerbate the other, with tau truncation promoting phosphorylation, and tau 
hyperphosphorylation promoting cleavage (35).   
Cleavage of tau at its C-terminus (a.a. residues 386 or 421) by caspases makes it 
vulnerable to hyperphosphorylation and the formation of NFTs. Calpain cleaves the N-
terminus of tau which results in conformational change from an unfolded state to a β-
sheet structure that makes the C-terminus vulnerable to cleavage by caspases (35). There 
is conflicting evidence about whether the 15/17kDa fragments of cleaved tau result in 
altered toxicity. In neurons that bear tangles, in vivo imaging studies show that cell 
survival is facilitated by a decrease in caspase activity. If truncation of tau is prevented, 
the executioner caspase will remain active, possibly facilitating neurodegeneration. Thus, 
the truncation of tau makes it more fibrillogenic, promoting an aggregate that sequesters 
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toxic tau species potentially delaying cell death, while also blocking cell transport and 
clogging protein-degradation pathways (22).  
Misfolding and aggregation 
The exact process by which tau misfolds and forms aggregates is unclear, but we do 
know that phosphorylation and/or truncation of tau can promote this process. In order for 
tau misfolding and aggregation to occur, tau must first be dissociated from MTs so that 
free cytosolic concentrations can exceed that to support aggregation (23, 36). This 
dissociation could be mediated by site-specific phosphorylations, truncation, or 
aggregation inducers, all of which could lead to a conformational change and promote the 
adoption of aggregation-competent tau (37). These changes in tau increases the formation 
of β-sheet structures, leading to an electrostatic modification that allows for side 
chain/side chain interactions ending in the eventual formation of the first tau dimers. 
Once stable dimers form, nucleation continues in an organized manner over time forming 
fibrils and PHFs that will grow to become mature NFTs (23). 
Tau toxicity 
Recent studies into how tau is responsible for neurotoxicity, has challenged the view 
that the insoluble NFT aggregates are the toxic species accumulating in disease. In a 
mutant tau transgenic Drosophila model progressive neurodegeneration occurred without 
NFT formation (38). In a repressible tau transgenic mouse model of tauopathy, turning 
off tau expression attenuated the memory impairment and neuronal loss, but NFTs 
continued to accumulate (39). These studies indicate that mature tau tangles can be 
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dissociated from neuronal loss and cognitive deficits, and it can be hypothesized that an 
intermediate pre-fibrillar tau aggregate is the predominant neurotoxic tau species. One 
study also showed that inhibiting tau phosphorylation is able to prevent the typical motor 
deficits and markedly reduce soluble aggregated hyperphosphorylated tau in tau 
transgenic mice, suggesting that PHF or other soluble lower-mass hyperphosphorylated 
tau aggregates are neurotoxic (40).  
The toxicity of tau aggregation includes loss of physiological functions of native 
monomeric tau and gain of pathological functions of a pre-fibrillar soluble tau species. 
Mature tau tangles appear to be relatively inert and may represent cytoprotective efforts 
of protein quality control machineries in response to accumulating toxic tau species. 
These recent developments have led to an increased interest in elucidating a mechanism 
of tau induced toxicity, and potential mediators and modifiers of tau aggregation. 
Mislocalization 
A recent study supports this view of early stage tau oligomers conferring toxicity, 
Hoover et al. studied the localization of abnormal pre-fibrillar tau in dendritic spines 
using rTg4510 tau mice. They found that early tau-related deficits develop not from the 
loss of synapses or neurons, but rather as a result of synaptic abnormalities caused by the 
accumulation of hyperphosphorylated tau within intact dendritic spines. This indicates 
that one mode of tau toxicity is one where these early-stage pre-fibrillar aggregates of tau 
become mislocalized and result in synaptic malfunctions (41).  Interestingly, a follow up 
experiment on this showed that Aβ causes tau missorting resulting in a perturbation of 
	  	   	   17	  
MT-based traffic, especially of mitochondria, resulting in toxicity. In neurons from Tau -
/- mice, Aβ‐induced toxicity is greatly reduced.  These experiments indicate that tau 
missorting can confer toxicity by two modes: synaptotoxicity and breakdown of the MT 
network (42). Investigation into tau missorting as a novel source of tau toxicity may yield 
novel insights into the cascade of events that lead to tau-linked neurodegeneration.  
Tau and RNA 
It has been shown that polyanions such as heparin and polyglutamate can induce tau 
filament formation (43). In 1975, it was shown that the presence of RNA (an anionic 
species), inhibits tubulin assembly, and it was proposed that the presence of high levels of 
RNA results in a loss of tau function, and that this in turn would inhibit MT assembly 
(44). This was recently proven, showing that RNA blocks the assembly of MTs and that 
this was dependent on tau protein (45). Other groups have shown that RNA (mRNA, 
tRNA, rRNA) is able to stimulate tau aggregation into Alzheimer-like PHFs (46, 47), and 
in fact RNA is found in NFTs in Alzheimer’s disease (48). Interestingly the fibrilization 
of tau in the presence of RNA, varied with tau isoform. The four-repeat tau isoform 
htau40 gave straight filaments when incubated with RNA, similar to other poly-anionic 
species such as heparin. Interestingly, incubation of the three-repeat tau isoform htau37 
with RNA resulted in the unique formation of twisted filaments.  
RNA has also been shown to stimulate the phosphorylation of tau by Cdk5, GSK3β, 
and p38/MAPK, which may also influence tau detachment from microtubules and 
fibrilization (47). There is a clear interaction between RNA and tau, and it was found that 
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the MTBD and proline rich region interact with RNA through electrostatic interactions 
(46). These data indicate that RNA can interact with tau, promoting its phosphorylation 
and release from tubulin, allowing self-interaction and fibrilization.  Binding of RNA to 
tau may induce or stabilize a conformation of tau that brings the microtubule-binding 
repeats of individual tau molecules in close proximity, creating sites which favor 
polymerization of tau into filaments. 
Section Three: RNA Binding Proteins 
Overview 
Regulating mRNA translation and protein synthesis allows a cell to rapidly alter the 
proteome in response to various signals. The discovery of RNA binding proteins (RBPs), 
RNA granules, and their critical role in determining the fate and activity of mRNA 
transcripts has brought the importance of translational control into sharp focus. The 
interaction between RBPs and the types of granules described here controls the stability 
and translational activity of mRNAs and plays a critical role in fine-tuning protein 
expression under both normal conditions and under conditions of stress (49).  
The RBP family is comprised of about 800 proteins that share conserved domains 
structures and related functions.   These RBPs generally contain two types of conserved 
domains: glycine rich domains and RNA recognition motifs (RRM).  The glycine rich 
domain is hydrophobic and mediates the reversible aggregation of these proteins. The 
RRMs have broad specificity, but differ in the spectrum of transcripts bound, and this 
specificity can also be dependent on the type of stress presented to the cell (50).  RBPs 
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and the granules they form regulate all aspects of RNA biogenesis including RNA 
maturation, surveillance, transport, subcellular localization, translation, and RNA 
degradation. RBPs form dynamic interactions with coding, untranslated, and non–
protein-coding RNAs in functional units called ribonucleoprotein (RNP) complexes. The 
RBPs within RNP complexes can remain stably bound to the RNA throughout its journey 
from synthesis to degradation, or associate with the RNAs selectively in a temporal and 
spatial manner (51).  
The functions of RBPs can generally be divided into nuclear and cytoplasmic 
activities. In the nucleus, RBPs regulate mRNA maturation, including splicing, RNA 
helicase activity, RNA polymerase elongation, and nuclear export. In the cytoplasm, 
RBPs regulate RNA transport, silencing, translation, and degradation. These cytoplasmic 
RBPs regulate transcript activity and distribution by forming RNA granules that are 
macromolecular complexes containing RBPs, translational machinery, and mRNA 
transcripts consolidated to form granules through protein/protein interactions mediated by 
the glycine rich domains and protein/mRNA interactions mediated by RRMs.  RNA 
granules vary by molecular composition and function.  RNA degradation is mediated by a 
type of RNA granule, termed Processing-bodies or P-bodies (PBs).  Transport granules 
play important roles in neurons, where they move transcripts from the soma into the 
dendritic, and possibly axonal, arbors. Stress granules (SGs) are important for the 
mammalian stress response, sequestering mRNAs and allowing for dynamic sorting of 
mRNAs for translation, storage, or degradation to allow for cell survival (50) (Figure 3).  
The pathophysiology of neurodegenerative diseases and many aging processes are 
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characterized by the continual presence of oxidative stress. The stress response in 
eukaryotic cells involves the activation of defense mechanisms that either promotes 
survival or the initiation of apoptosis. The cellular response depends on the type of stress 
presented, and can be finely tuned by the response of RBPs and their ability to control 
translation in both a global and transcript dependent manner. A key component of stress-
induced translational suppression, SGs play a dynamic role in mRNA triage by sorting 
sequestered mRNAs for re-initiation, storage, or degradation, and may be required to 
allow optimal translation of stress-responsive anti-apoptotic mRNAs (52). Non-
translating mRNAs, translation initiation components, and many additional proteins 
effecting mRNA function are shuttled into SGs comprised of a number of RBPs, 
including T-cell intracellular antigen 1 (TIA-1), tristetraprolin (TTP), and Ras-GTPase 
activating protein SH3-domain-binding protein (G3BP). These proteins contain prion-like 
and poly-glycine rich domains, and their aggregation mirrors that of proteins linked to 
neurodegenerative diseases (53). Neurodegenerative-linked proteins Huntingtin, PrP 
prion protein, and TAR DNA-binding protein 43 (TDP-43) have all been shown to 
associate with SGs, and mutations or malfunctions in some of these RBPs can directly 
cause neurodegeneration (51).  
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Figure 3: Hypothetical model of the relationship between SGs and PBs.  
Proteins found exclusively in SGs are shown in yellow; proteins found in both SGs and 
PBs are depicted in green; and proteins restricted to PBs are shown in blue type. Adapted 
from (54). 
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RNA Granules 
RBPs regulate all aspects of RNA biogenesis including RNA maturation, 
surveillance, transport, subcellular localization, translation, and RNA degradation. RBPs 
are able to interact with mRNA and other protein components and consolidate to form 
discrete granules in the cytoplasm, and based upon their composition and function can be 
identified as transport RNPs, SGs, or P-bodies. These RNA granules share common 
protein components, but each kind of RNA granule contains a distinct population of 
proteins and performs separate functions as designated in Table 1: (i) RNA transport 
granules deliver transcripts to dendrites while inhibiting RNA translational activity. RBPs 
such as fragile X mental retardation protein (FMRP) and Pumilio (PUM1) participate in 
dendritic transcript transport and function as translational repressors. (ii) Stress granules 
(SGs), which will be the main focus of this review, form transiently to reprogram RNA 
translation under stressful conditions. The primary nucleating SG proteins include TIA-1, 
G3BP, TIA-1 related protein (TIAR), FMRP, and survival of motor neuron protein 
(SMN), but a number of disease-linked proteins also associate with SGs as they expand; 
these proteins include fused in sarcoma (FUS), TDP-43, and ataxin-2 (ATXN2). (iii) 
Processing-bodies (PBs) are the sites for mRNA degradation, often integrating with 
miRNA machinery. Dcp1a (decapping enzyme 1a) is a RBP that is classically used to 
identify PBs. These granules are dynamic and are able to interact with each other and 
with active polysomes; this regulated trafficking can allow the cell to tailor translation to 
changes in its environment (49). 
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Table 1: The classification of RNA granules. 
Adapted from Kiebler et al., 2006 (55). 
came from several laboratories that have identified
mRNA binding proteins involved in mRNA localization
in polarized cells. One key player is Staufen, a double-
stranded RNA binding protein that plays important roles
in localization of bicoid and oskar RNA to the anterior
and posterior pole, respectively, in Drosophila oocytes
(St Johnston, 2005). Ko¨hrmann and colleagues were
the first to express the mammalian Staufen homolog
tagged with GFP in hippocampal neurons and to ob-
serve the MT-dependent recruitment of Staufen into
RNAgranules, which exhibited rapid bidirectionalmove-
ments in dendrites (0.1–0.4 mm/s). This was the first
demonstration of dynamicmovement of an RNA binding
protein in transport RNPs in living neurons (Ko¨hrmann
et al., 1999). This approach was subsequently used by
Zhang and colleagues to analyze themovement of gran-
ules (over 1 mm/s) containing the b-actin mRNA binding
protein zipcode binding protein 1 (ZBP1) into growth
cones of developing axons (Zhang et al., 2001). Further-
more, anterograde trafficking of RNA granules contain-
ing ZBP1 and b-actin mRNA was stimulated by the
neurotrophin NT-3, suggesting that granules can be reg-
ulated by physiological signals. Rook and colleagues
took a different approach to visualize RNPs in neurons
by employing the MS2-GFP tagging system to show
that movement of granules containing the 30-UTR for
CaMKIIa mRNA in dendrites is dependent on synaptic
activity (Rook et al., 2000). Neuronal depolarization in-
creased the fraction of the CaMKIIa reporter mRNA
that was in the anterograde motile pool, suggesting
that oscillatory granules were capable of sampling mul-
tiple nearby synapses. These finding indicate a possible
role of synaptic input in the regulation of RNA granule
motility in dendrites and localization at synapses. Taken
together, these studies underscore that not only are
mRNAs packaged into transport RNPs for directed
movement but that there are signaling mechanisms
likely regulating distinct populations of these transport
RNPs and their dynamic interrelationships.
Live cell imaging studies are consistent with the no-
tion that transport RNPs may be propelled by molecular
motors. First, MT-depolymerizing drugs were shown to
decrease the levels of RNAs or mRNA binding proteins
in neuronal processes (Knowles et al., 1996; Ko¨hrmann
et al., 1999; Rook et al., 2000). Second, the observed ve-
locities of RNA granules (0.2–1.5 mm/s) and their antero-
grade or retrograde trajectories over long distances fur-
ther suggest that they depend on kinesin and dynein
motors. Indeed, previous work from the Carson group
showed that antisense knockdown of the conventional
kinesin heavy chain (KIF5b) impaired the ability of micro-
injectedMBPmRNA to translocate into oligodendrocyte
processes. Kanai and colleagues found that KIF5b asso-
ciates with large RNA granules that contain 42 proteins
and two well-studied dendritically localized mRNAs,
CaMKIIa and Arc (Kanai et al., 2004). Overexpression
of KIF5b increased mRNA localization into distal den-
drites, whereas mRNA localization was reduced follow-
ing its knockdown. Further work is needed to define the
specific molecular interactions between transport RNP
components and kinesin subunits to enable directed
RNA movement. Nonetheless, this study provides com-
pelling evidence that the anterograde transport of at
least some transport RNPs is mediated by conventional
kinesin in hippocampal neurons. It will also be important
to study how transport RNPs that are capable of bidirec-
tionally trafficking may become selectively captured
within stimulated dendritic spines.
Based on the landmark findings of Carson and others,
a compelling model has been put forth of how mRNA
Table 1. Diversity of Cytoplasmic RNA Granules in Neurons
Name Synonyms Definitions Key Components Key References
Transport RNPs Neuronal RNA
granules,
RNA particles
Motile granules transporting mRNA. Staufen1, Staufen2,
FMRP, ZBP1,
hnRNPA2, CPEB,
Pura, SMN
Knowles et al., 1996;
Ko¨hrmann et al., 1999;
Zhang et al., 2001, 2006;
Tang et al., 2001;
Huang et al., 2003;
Kanai et al., 2004
Contain translational components.
mRNAs in these RNA granules are
translationally arrested during
transport by the action of
regulatory RNAs and RNA-binding
proteins.
Biochemical evidence for RNA
granules with and
without ribosomes.
Stress granules Heat stress granules Harbor translationally arrested
mRNAs that form in cells
exposed to a broad range
of stresses.
TIA-1, TIAR, PABP,
G3BP, 40S
ribosomal subunit
Anderson and Kedersha, 2006;
Vessey et al., 2006
Sort, remodel, and export specific
RNAs for reinitiation or storage.
Processing bodies
(P bodies)
Cytoplasmic bodies,
Dcp1 bodies,
GW bodies
Sites of translational repression
and/or mRNA degradation.
Dcp1a, Lsm proteins,
Rck/p54, GW182
Anderson and Kedersha, 2006;
Schratt et al., 2006;
Vessey et al., 2006Contain RISC machinery
including microRNAs.
Do not contain ribosomal subunits.
Since the first description of motile transport RNPs in oligodendrocytes and neurons, at least two additional classes of neuronal RNA granules
exist: stress granules and P bodies that are sites for RNA storage and degradation, respectively. With regard to possible shared components
between these neuronal RNA granules, there is evidence that several mRNA binding proteins, i.e. staufen1, staufen2, FMRP, SMN, CPEB,
nd pumilio2, can associate with SGs upon overexpression (Anderson and Kedersha, 2006). The presence of components in more than one
type of RNA granule suggests that these RNPs are not homogeneous, but represent dynamic structures that a cell uses to sort mRNAs and reg-
ulate their translation and degradation.
Neuron
686
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Neuronal transport granules 
Many mRNAs have localization elements within their 3’ or 5’ UTRs; RBPs are able 
to recognize these elements and direct message localization while suppressing translation 
until the message is delivered to its destination. These mRNAs are delivered by transport 
granules composed of RBPs and silenced transcripts. Transcripts may also be stored in 
the cytoplasm in a repressed state by similar RNA storage granules, which act as a pool 
of mRNA that, depending on metabolic state and environmental changes, can be directed 
for activation, repression, or decay (49). 
Normal neuron physiology largely depends on the presence of these types of 
granules, which are the functional units for transport and translation regulation of 
mRNAs from the soma out into the dendrites to synapses.  These RBPs also mediate the 
process of activity dependent protein synthesis, which is critical in all aspects of biology, 
but has attracted particularly strong attention at the synapse where it controls synaptic 
plasticity, habituation and memory. For example, the synaptic function of FMRP has 
been studied extensively and is known to regulate dendritic sprouting.  
Neuronal RNA transport granules are distinct from other RNA granules, although 
they can share some components and get in close contact with other RNA granules likely 
allowing a flow of mRNAs and proteins. There is also an apparent relationship between 
neuronal RNA granules and SGs, as both contain polyadenylated mRNAs, ribosomal 
subunits and a number of common RBPs, including SMN, Staufen, FMRP, Pumilio, 
TDP-43, and FUS, among others (56). 
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Stress granules 
The stress response in eukaryotic cells involves the activation of defense mechanisms 
that either promotes survival or the initiation of apoptosis. The cellular response depends 
on the type of stress presented. Type I stress, including hypoxia, heat-shock, and 
oxidative stress, inhibits translation initiation and induces the formation of SGs as a 
defense mechanism promoting cell survival (57). SGs contain non-translating mRNAs, 
translation initiation components, and many additional proteins effecting mRNA function 
(52). 
In metazoans, five eukaryotic initiation factor 2 alpha (eIF2α) kinases monitor 
environmental stress and directly modulate the translation machinery. These include: (i) 
PKR (protein kinase R), a double-stranded RNA-dependent kinase that is activated by 
viral infection, heat and UV irradiation; (ii) PERK (PKR-like endoplasmic reticulum 
kinase, also known as PEK, or pancreatic eIF2α kinase), a resident endoplasmic 
reticulum (ER) protein that is activated when unfolded proteins accumulate in the ER 
lumen; (iii) GCN2 (general control nonderepressible 2), a protein that monitors amino 
acid levels in the cell and responds to amino acid deprivation; (iv) HRI (heme-regulated 
initiation factor 2α kinase), a protein that ensures the balanced synthesis of globin chains 
and heme during erythrocyte maturation and senses oxidative stress produced by arsenite; 
and (v) Z-DNA kinase, an enzyme involved in the host antiviral response. Stress-induced 
phosphorylation of eIF2α on Ser51 inhibits global protein translation through depletion of 
the eIF2–GTP–tRNA-met ternary complex, thus permitting the RBP TIA-1 to bind the 
48S complex instead of the ternary complex. This promotes polysome disassembly and 
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the consequent recruitment of mRNAs to SGs (58, 59). The model of stress granule 
assembly is illustrated in Figure 4. 
These non-translating mRNAs are necessary for SG formation and lead to primary 
nucleation of SGs involving RBPs including TIA-1, TTP, and G3BP, with specific 
mRNA transcripts (Figure 4, stage 2). This family of proteins contains prion domains and 
poly-glutamine rich domains, which confer the ability to reversibly aggregate (53). The 
primary aggregation of mRNA binding proteins with stalled mRNA transcripts induces 
protein-protein interactions and cross-linking by proteins such as poly-A binding protein 
(PABP-1) that seed an increase in aggregation with non-mRNA binding proteins (Figure 
4, stage 3). This results in the secondary aggregation of proteins with diverse 
physiological roles that can be modulated by SGs. The composition of SGs includes 
translation initiation components, small ribosomal subunit (40S), PABP, other RBPs, and 
mRNAs coding for most cellular proteins except those involved in the stress response. 
There is also piggy-back recruitment of many important signaling proteins into these 
granules that may effect cell signaling and survival (Figure 4, stage 4) (60). However, SG 
composition may be subtly different according to the nature of the stress stimulus, and it 
may also change progressively during the response (56).  
Once formed, SGs serve as centers of mRNA triage by dynamically sorting 
sequestered mRNAs for re-initiation, storage, or degradation, and may be required to 
allow optimal translation of stress-responsive anti-apoptotic mRNAs and thus appear to 
be protective. SGs have been shown to associate with PBs, with TTP proposed to play an 
integral role in the shuttling of mRNAs destined for decay from SGs to PBs (Figure 4, 
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stage 5). Once the stress is removed there is rapid translational recovery in concert with 
SG disassembly. The mechanism of SG disassembly is poorly understood, but may be 
dependent upon interactions with heat shock proteins, and active transport by dynein and 
kinesin motors (61). SGs can also be disassembled chemically via treatment with emetine 
and cycloheximide. These drugs inhibit translational elongation and block the 
disassembly of polysomes, thereby preventing the translocation of mRNA into SGs and 
PBs. Whereas the drug puromycin promotes premature translation termination and 
promotes SG and PB assembly (54).   
SGs have been suggested to suppress apoptosis by suppressing the stress-activated 
mitogen activated protein kinase (MAPK) pathway (62).  Additional cell survival 
mechanisms linked with SG formation are likely to occur, and an emerging example is 
the sequestration of pro-apoptotic molecules. The TNF receptor associated factor 2 
(TRAF2) was the first case reported. TRAF2 facilitates apoptosis by two independent 
pathways: TNFR activation and caspase activation upon ER-stress induction. TRAF2 
interacts with eukaryotic initiation factor 4G (eIF4G) and is therefore retained in SGs, 
thus avoiding apoptosis. More recently, two key molecules that activate the p38/JNK 
apoptotic pathway, namely RACK1 and ROCK1 were shown to be localized in SGs, thus 
favoring cell survival (56). 
An interesting possibility is that formation of SGs is required to allow optimal 
translation of stress responsive mRNAs. The translational arrest that accompanies 
environmental stress is potentially selective: one study shows that the translation of 
∼25% of mRNAs is significantly reduced, whereas the translation of another 25% of 
	  	   	   28	  
mRNAs (including transcripts encoding heat-shock proteins) is significantly enhanced. 
Stress-induced reprogramming of protein expression also entails stabilizing or 
destabilizing selected groups of mRNAs. Thus, post-transcriptional reprogramming of 
mRNA translation and decay reconfigures the proteome during adverse environmental 
conditions (60). 
The importance of SGs for cytoprotection is highlighted by the effects of knockout of 
SG proteins, such as TIA-1, or inhibition of eIF2α phosphorylation, which render cells 
more vulnerable to acute stresses.  Conversely, inhibiting eIF2α dephosphorylation 
protects against some forms of stress. However, the actual mechanisms by which SGs 
mediate protection are poorly understood (50). 
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Figure 4: A model of stress granule assembly.  
The process of SG assembly can be divided into discrete stages that are marked by the 
specific composition and localization of mRNPs subject to translational arrest. Adapted 
from (60). 
Stage 1: Stalled initiation and ribosome runoff
Phosphorylation of eIF2a [33], or drug-induced inacti-
vation of eIF4A [26,27], result in abortive initation com-
plexes; transcripts thus affected are converted into 48S
mRNPs as their ribosomes ‘run-off’. Conditions preventing
ribosome elongation and run-off (e.g. cycloheximide, mito-
sis, certain viral mRNAs) do not permit SG assembly
[25,31,59].
Stage 2: Primary aggregation and SG nucleation
Free 48SmRNPs are essential substrates for SG assembly.
Numerous SG-associated proteins promote SG assembly
Figure 1. Model of stress granule assembly. The process of SG assembly can be divided into discrete stages that are marked by the specific composition and localization of
mRNPs subject to translational arrest. Stage 1: SG assembly begins with stalled initiation that permits ribosomes to run off polysomes, converting them into mRNPs from
which SGs are assembled. Primary aggregation and SG nucleation (stage 2) occurs when heterogeneous 48S-bound transcripts are bound by RNA-binding proteins that
possess homotypic aggregation properties, such as G3BP (green), TIA-1 (black), TTP (blue), and FMRP (red), each of which binds preferentially to specific transcripts (those
of matched colors). Secondary aggregation and crosslinking (stage 3) occur when PABP-1 (brown), bound to all poly(A)-containing transcripts, crosslinks smaller oligomers
to assemble microscopically visible aggregates. Some transcripts are bound to multiple SG nucleating proteins, which enhances the crosslinking process to form
progressively larger SGs, which can then recruit non-RNA-binding pr teins (e.g. TRAF2, plakophilins, SRC3, FAST) through piggyback recruitment and integrate SG
assembly with other cellular signaling pathways (stage 4). Within SGs, transcripts are subjected to mRNA triage, as the aggregation properties of specific proteins are
modulated by HSP70 (e.g. TIA-1, CPEB), phosphorylation (e.g. G3BP, TTP) or interactions with other proteins (e.g. TTP–14-3-3). Finally (stage 5), specific transcripts are
sorted out of SGs by translation initiation, assembly into other RNP granules, or by transfer into PBs by PB-targeting proteins such as TTP. An important feature of the
model is that the process is reversible: that is, mRNAs that enter the SGs after polysome disassembly can be reinitiated and returned to the polysome fraction.
Review Trends in Biochemical Sciences Vol.33 No.3
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Processing bodies 
P-bodies are another dynamic structure that contains mRNA decay machinery 
components. Core components of PBs are translationally inactive mRNA and the 
decapping factor, which induces mRNA decay and blocks translation by decapping and 
induction of 5’-3’ mRNA decay. Key to these complexes are Dcp1/2 (decapping 
enzymes), the Lsm1-7 complex (activators of decapping), Xrn1 (5’-3’ exonuclease), and 
nonsense mediated decay machinery. P-body assembly factors recruit mRNA into P-
bodies through multimerization domains (49).  
P-bodies are often observed juxtaposed to SGs but are also present in cells not under 
stress. Several observations demonstrate that SGs interact with PBs and are likely to 
exchange mRNAs between them: (i) mammalian PBs and SGs transiently dock with one 
another during arsenite treatment and can show prolonged docking when TTP is 
overexpressed and (ii) PBs and SGs share many protein components and the same mRNA 
species (52). In neurons, FRAP analysis indicates that the turnover of DCP1a in PBs is 
dramatically enhanced by synaptic stimulation, indicating that PB dynamics and the 
release of mRNAs to allow their translation are controlled by neuronal activity, likely 
playing a role in regulating local protein synthesis at the post-synapse (56). 
Microtubule Dependence 
The formation and persistence of RNA granules depends on the movement of RNA 
and proteins in the cytoplasm and their accumulation in particular cytoplasmic foci. It has 
been shown that SG formation is microtubule-dependent process and likely is facilitated 
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by the motor protein-driven movement of individual SG components along microtubules. 
Disruption of MT array with nocodazole treatment abolished the formation of SGs in 
response to a stressor (63). Thus it is possible that the distribution of SGs in cells might 
correlate with the distribution of MTs, and any dysfunction in the MT network would 
prevent normal SG formation and dynamics.  
RNA Granule Markers 
TIA-1  
a. Gene and protein structure 
T-cell intracellular antigen-1 (TIA-1) is a RBP of the RNA recognition motif (RRM)/ 
ribonucleoprotein (RNP) family that regulates pre-mRNA splicing, mRNA translation, 
stress-induced translational arrest, and has been implicated as an effector of apoptotic cell 
death (53, 64). The gene encoding the 43kDa TIA-1 protein locates at chromosome 
2p13.3 (65). TIA-1 has 3 RRM domains at its N-terminus that confer high-affinity 
binding to AU-rich motifs, and a glutamine-rich carboxyl-terminal domain that allows it 
to reversibly aggregate, as shown in Figure 5 (50). 
TIA-1 presents in two major isoforms (TIA-1a and TIA-1b) generated by alternative 
splicing of exon 5 that differ by eleven amino acids as shown in Figure 5. Exon 5 
inclusion generates TIA-1 isoform a, whereas exon skipping produces the shorter b 
isoform.  The eleven-amino acid peptide encoded by exon 5 is located between RRMs 1 
and 2. The relative expression of TIA-1 isoforms varies in different human tissues and 
cell lines, suggesting distinct functional properties and regulated isoform expression. 
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Both TIA-1 isoforms show similar subcellular distribution and RNA binding, but TIA-1b 
displays enhanced splicing stimulatory activity compared with TIA-1a (66). 
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Figure 5: The structure of human TIA-1 gene and protein.	  
A, Alternative splicing of human TIA-1 exon 5. Exons are represented by boxes, introns 
by thick lines, and patterns of alternative splicing by thin lines. Alternative TIA-1 
isoforms generated by inclusion or skipping of exon 5 are indicated. Numbers indicate 
the sizes (in nucleotides) of intronic and exonic sequences from human TIA-1 gene. B, 
Domain structure of human TIA-1 isoforms (65). The eleven-amino acid peptide encoded 
by exon 5 is shown in bold. TIA-1 proteins include three RRMs and a carboxyl-terminal 
glutamine-rich domain. Numbers indicate amino acid residues corresponding to each 
RRM and carboxyl-terminal domain of the TIA-1b isoform. Adapted from (66). 
with 5 !g of siRNAs by using Lipofectin (Invitrogen). Cells were
then incubated 72 h before protein extract preparation and RNA
purification as described (26, 41).
DNA Transfections, RNA Isola-
tion, and RT-PCR Analysis—Expo-
nentially grown HeLa and 293 cells
were transfected at 50–70% conflu-
ency with 0.5 !g of WT/mutant
(U-20C) Fas or FGFR-2 minigenes,
respectively, and 1.5 !g of GFP-re-
porter plasmids using Lipofectin
(Invitrogen) following themanufac-
turer’s instructions for adherent cell
lines. Cells were then incubated
24–48 h before protein and RNA
purifications. Cytoplasmic RNAs
were prepared using the RNeasy kit
(Qiagen), quantified by OD at 260
nm, and analyzed by RT-PCR. After
25 cycles, the products were ana-
lyzed on 2% agarose gels. Control
experiments with different input
amounts of RNA indicated that the
amplification was quantitative under
these conditions (23, 26). The oligo-
nucleotide sequences used in
RT-PCR analysis were: hTIA-1.sense
(5!-GCCCAAGACTCTATACGTC-
GGTAACC-3!) and hTIA-1.anti-
sense (5!-GGTGCAAAAGCAGC-
TTTTATATCTTC-3!) for human
TIA-1 gene; hTIAR.sense (5!-ATG-
ATGGAAGACGACGGGCAGC-
CCCGGACTC-3!) and hTIAR.
antisense (5!-TCTGGACTCAAAT-
CCCCAACAAACACATGG-3!) for
human TIAR gene; h"-actin.sense
(5!-AAAGACCTGTACGCCAA-
CAC-3!) and h"-actin.antisense
(5!-GTCATACTCCTGCTTGC-
TGA-3!) for human "-actin gene;
mTIA-1.sense (5!-GCCCAAGACT-
CTATACGTCGG-3!) and mTIA-
1.antisense (5!-GGTGCAAACGCT-
GCTTTGATG-3!) for mouse TIA-1
gene; mTIAR.sense (5!-ATGGAA-
GACGACGGACAGCCC-3!) and
mTIAR.antisense (5!-AATTT-
CTGGACTCAAATCCCC-3!) for
mouse TIAR gene. PT1 and PT2 as
well as P3 and P4 oligos to analyze
alternatively spliced products from
WT/mutant Fas and FGFR-2 mini-
genes were described previously
(22, 23, 26).
RESULTS
Human TIA-1 isoforms are gen-
erated from a unique gene by exon 5 alternative splicing (Fig.
1A). Exon 5 inclusion generates TIA-1 isoform a, whereas exon
skipping produces the shorter b isoform (Fig. 1A). The eleven-
FIGURE1.Alternative splicingofhumanTIA-1exon5andpredictedprotein isoforms.A, alternative splicingof
humanTIA-1exon5.Exonsarerepresentedbyboxes, intronsby thick lines, andpatternsofalternativesplicingby thin
lines. Alternative TIA-1 isoforms generated by inclusion or skipping of exon 5 are indicated. Numbers indicate the
sizes (in nucleotides) of intronic and exonic sequences fromhuman TIA-1 gene (54). B, domain structure of human
TIA-1 isoforms.Theeleven-aminoacidpeptideencodedbyexon5 isshowninbold. TIA-1proteins includethreeRNA
Recognition Motifs (RRM domains) and a carboxyl-terminal glutamine-rich domain. Numbers indicate amino acid
residues corresponding to each RRM and carboxyl-terminal domain of the TIA-1b isoform.
FIGURE 2. Expression of TIA-1 and TIAR isoforms in human tissues and cell lines. Protein extracts (10 !g)
fromhumanbrain (B), heart (H), small intestine (SI), kidney (K), liver (Li), lung (Lu), skeletalmuscle (SM), testes (T),
pancreas (P), and ovary (O) (panels A and B, lanes 1–11) or HeLa, Jurkat, Daudi, 293, Rh 30, A375, T98G, HCT-116,
and Hep-G2 cell lines (panels D and E, lanes 1–9) were transferred to polyvinylidene difluoride membranes
(INSTA-BlotTM) andprobedwithpolyclonal anti-TIA-1 (panels AandD) andanti-TIAR (panels Band E) antibodies.
RT-PCR analyses of TIA-1 and TIAR isoforms in total RNAs isolated fromhuman tissues are shown (panel C, lanes
2–11,upperandmiddle inserts, respectively). Lane1 is anegative controlwithoutRNA."-actinmRNA levelswere
used as a loading control (panel C, lower insert). Migration of TIA-1 and TIAR isoforms and "-actin mRNA are
indicated by closed arrowheads on the right. Molecular mass markers are shown on the left.
TIAR Regulates Alternative Splicing of TIA-1
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b. General biological functions 
TIA-1 is known to regulate pre-mRNA splicing, mRNA translation, stress-induced 
translational arrest, and has been implicated as an effector of apoptotic cell death (53, 
64). TIA-1 regulates the alternative pre-mRNA splicing of various human and 
Drosophila genes (FGFR-2, msl-2, TIAR, cystic fibrosis transmembrane conductance 
regulator, and Fas) through binding to U-rich stretches, facilitating atypical 5′-splice site 
recognition by U1 small nuclear ribonucleoprotein (snRNP) (66). TIA-1 has also been 
well characterized as a translational regulator. This protein has been implicated in stress-
induced translational arrest, colocalizing after stress with poly(A)+ RNA in the 
cytoplasmic foci known as stress granules. TIA-1 is able to bind to the 3′-untranslated 
regions (UTRs) of the translational regulatory AU-rich elements of tumor necrosis factor 
α (TNFα), human matrix metalloproteinases-13 (MMP13), cyclooxygenase-2 (COX2), β 
2-adrenergic receptor, mitochondrial cytochrome c, GADD45α, and β-F1-ATPase 
mRNAs(66). As a translational silencer, TIA-1 binds to these transcripts and suppresses 
their translation. Thus, mutant mice lacking TIA-1 have a hyperinflammatory phenotype 
because of the lack of suppression of TNFα and COX2 that results in increased cytokine 
levels (60, 67, 68).  
Interestingly, the aggregation of TIA-1 is regulated by molecular chaperones (53) and 
is blocked by HSP70 overexpression. Minimal constitutive levels of HSP70 are 
continuously required to prevent TIA-1 aggregation. Stress-induced denaturation of other 
cytoplasmic proteins recruits HSP70 for protein renaturation, thus diverting HSP70 away 
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from TIA-1, promoting TIA-1 aggregation and consequent SG nucleation. The successful 
refolding of denatured proteins releases HSP70 and the free HSP70 then solubilizes TIA-
1, the subsequent TIA-1 disaggregation promotes SG disassembly (60). 
c. Mutations linked to disease 
Recently, a single missense mutation in TIA-1 (p.E384K) was found to cause 
Welander Distal Myopathy (WDM). WDM is a dominant late-onset muscular dystrophy 
mainly found in Finland and Sweden. Onset is usually at 40-60 years of age, presenting 
with weakness and atrophy in the fingers, progressing to the hand muscles and lower 
legs. Rare homozygotes exhibit earlier onset, faster progression, and proximal muscle 
involvement. These homozygous patients become wheelchair-bound by age 50 (69).  
Pathologically there are myopathic changes and prominent rimmed vacuoles in distal 
muscles. TIA-1 increased cytoplasmically and granules or bulky aggregates appeared in 
some atrophic and rimmed-vacuolated fibers. These rimmed vacuoles consistently 
showed strong LC3b, ubiquitin, and p62 reactivity indicating a potential deficit in protein 
clearance mechanisms. The mutation in TIA-1 is present in the glutamine-rich C-terminal 
domain, this domain is both required for enhanced interaction with the U1 splicing 
complex as well as the self-assembly of TIA-1, thus an assessment of both of these 
functions was necessary. Assessments of splicing patterns in known TIA-1 splice targets 
(FAS, PLOD2, and TIAR) suggested that there was no splicing abnormality associated 
with the mutation. In vitro assessments of mutant E384K TIA-1 indicates that the 
mutation is able to increase SG formation slightly, and that these stress granules exhibit 
altered trafficking (69).  
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TTP 
a. Gene and protein structure 
Tristetraprolin (TTP) is an mRNA-binding protein containing tandem CCCH zinc 
fingers, involved in post-transcriptional regulation of AU-rich element (ARE)-containing 
mRNAs. The gene encoding the 34kDa protein is located on chromosome 19q13.2. TTP 
protein has two tandem CCCH zinc finger motifs that allows it to bind mRNAs (65).  
b. General biological functions 
TTP binds mRNAs through two tandem CCCH zinc finger motifs and promotes their 
decay. TTP target mRNAs typically contain the AU-rich sequence, where TTP can bind 
and destabilize its targets including TNF-α, granulocyte macrophage colony stimulating 
factor (GM-CSF), COX-2, Interleukin 3 (IL-3), IL-10, and interferon-γ (IFN- γ). Mice 
that lack TTP spontaneously develop erosive arthritis, cachexia, alopecia, dermatitis, 
autoantibodies, and myeloid hyperplasia indicating its importance in regulating the 
inflammatory response. TTP is a protein associated with PBs, and may receive transcripts 
from TIA-1 positive SGs in a hand-off mechanism (70).  
Although TTP is a phosphoprotein reported to be a substrate for multiple kinases 
including ERK, JNK, p38, and MAPKAP kinase 2 (MK2), the role of phosphorylation in 
regulating TTP function is unclear (71). While extensive TTP phosphorylation has been 
mapped, only the serine–threonine phosphatase PP2A has been established as promoting 
TTP dephosphorylation. TTP can be phosphorylated by MK2, a downstream target of 
p38, at serines 52 and 178 in mouse, 60 and 186 in humans. mRNA binding was not 
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altered in response to phosphorylation, but it did prevent mRNA decay by preventing 
TTPs association with SGs or PBs, instead promoting its association with 14-3-3 proteins 
(70, 72). Thus, exclusion of TTP from SGs correlates with inhibition of TTP activity, 
which suggests that TTP induces the degradation of translationally stalled mRNAs via its 
association with PBs. 
G3BP 
a. Gene and protein structure 
G3BP was initially characterized through its interaction with a Ras-GTPase–
activating protein (RasGAP p120), and is known to both activate and repress mRNA 
transcripts in a transcript dependent manner. There are three isoforms of G3BP: 1, 2a, 2b, 
which are products of two distinct genes. G3BP1 and 2 are encoded by distinct genes on 
human chromosomes 5 and 4. There is a 74% similarity between G3BP1 and G3BP2a 
protein. G3BP2b is a splice isoform of G3BP2a, lacking 33 amino acids in the central 
region. 
G3BP’s C-terminus is comprised of two motifs traditionally associated with RNA 
binding. These are a RRM, and a loosely conserved RGG (arginine-glycine rich) box (73, 
74). The N-terminus of G3BP is a nuclear transport factor-2 (NTF-2)-like domain, which 
influences the cellular localization of proteins and its oligomerization with itself or with 
other partners. G3BP’s central regions comprise varying numbers of proline-rich (PxxP) 
motifs and an acid-rich domain (70, 74).  
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b. General biological function 
The majority of publications concerning G3BP1 support a function in cell 
proliferation and/or survival downstream of Ras, and this is dependent on regulation of 
phosphorylation/dephosphorylation at S149. Thus, G3BP is very important in embryonic 
development and knockout is embryonically lethal (75). Both G3BP1 and G3BP2 are 
dramatically overexpressed in human cancers, in particular breast cancers. Over-
expression of G3BP1 has been demonstrated in a range of human tumors, including 
breast, head, neck, colon, and thyroid (74, 76). 
G3BPs are also found to be components of mRNPs and are necessary to form SG 
complexes. In response to stress, G3BP becomes dephosphorylated at S149 allowing it to 
aggregate. The RRM domain mediates the binding of G3BP to specific mRNA sequences 
so that G3BP can exert its function as a dinucleotide-specific single-strand–specific 
endoribonuclease. G3BP can bind to the 3′ untranslated region (3′UTR) of human c-Myc 
mRNA in a phosphorylation-dependent manner to increase its degradation in vitro (77). 
Supporting this, several studies implicate G3BP1 in cell cycle regulation, with  G3BP1 
over-expression increasing S-phase entry and this was dependent on an intact RNA-
binding domain (74, 76). 
There is also an interaction between G3BP1 and the de-ubiquitinating enzyme, 
USP10. Two substrates for the USP10/G3BP1 de-ubiquitinating complex have been 
discovered so far: Sec23, a component of the COPII complex involved in anterograde 
protein export from the endoplasmic reticulum (ER) to the Golgi network and β-COP, a 
component of the COPI complex required for retrograde protein transport from the Golgi 
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to the ER. De-ubiquitination of Sec23 and β-COP rescues them from degradation by the 
proteasome, thereby maintaining the activity of the retrograde and anterograde protein 
secretion pathways (74, 77).  
RNA Binding Proteins and Neurodegeneration 
Stress granules are also important in the context of unfolded protein diseases. Many 
aspects of SGs resemble aggresomes and unfolded protein aggregates present in 
neurodegenerative pathologies (Table 2). For example, both are mediated by specific 
prion-like and poly-glutamine containing protein-aggregation domains, their dissolution 
requires molecular chaperones, they contain ubiquitinated proteins, and are enhanced by 
inhibitors of protein degradation machineries. These commonalities make it tempting to 
speculate that SGs and intracellular protein aggregates may interact. However, the 
aggregation processes characterizing the biology of RBPs differ from the conventional 
models of protein aggregation in that they serve distinct biological functions and are 
reversible. In addition, aggresomes tend to form a single large inclusion, originating at 
the microtubule-organizing center, whereas SGs occur as multiple complexes scattered 
throughout the cytoplasm. 
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Stress Granules Unfolded protein aggregates 
Similarities 
Induced by several stressors Present in several pathologies (ER-stress and/or 
oxidative stress involved)  
Induced by proteasome or 
autophagy inhibitors 
Dissolution requires proteasome activity or 
autophagy. 
Aggregation modulated by 
HSP70 
Miss-folded protein aggregation modulated by 
chaperones. 
Contain ubiquitinated proteins Contain ubiquitinated proteins. 
Contain O-glycosylated 
proteins 
Contain O-glycosylated proteins  
Microtubule and dynein-
dependent 
Microtubule and dynein-dependent.  
 
Differences 
Highly dynamic Quite static 
Transient Long-lived 
Protective Pathogenic or protective 
 
Table 2: Similarities and differences between SGs and unfolded protein aggregates. 
Adapted from (56).
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RNA binding proteins in neurological diseases 
Perhaps most convincing of the increased recognition of RBPs in neurodegeneration 
is that mutations or malfunctions in some of these proteins can directly cause 
neurological disorders. For instance, impaired expression of FMRP, due to trinucleotide 
repeat expansions is the cause of fragile X mental retardation syndrome (FXS), which is 
the most common cause of inherited mental retardation, and with aging also leads to a 
related neurodegenerative condition. Expanded trinucleotide repeats in several different 
ataxin genes are the cause of spinocerebellar ataxia. Mutations in survival of motor 
neuron (SMN1) are linked to spinal muscular atrophy (SMA), and mutations in TDP-43, 
FUS, ATX2, optineurin (OPT) and angiogenin (ANG) all cause motor neuron diseases 
including amyotrophic lateral sclerosis (ALS). These disease processes have now been 
linked to dysfunctional or dysregulation of neuronal RNA granules and SGs (50, 78).  
Regulated protein aggregation 
The potential importance of SGs for neurodegenerative disease becomes apparent 
because the process of SG formation presents a biological pathway that could be 
vulnerable to the protein aggregates that accumulate in disease. RBPs are a group of 
proteins that naturally form insoluble aggregates, yet the aggregated material can disperse 
and resolubilize. Most, if not all, RBPs linked to neurodegenerative diseases associate 
with SGs in cell culture. TDP-43, FUS, ATX2, SMN, OPT, and ANG have all been 
shown to co-localize with classic SG markers (TIA-1, TTP, and/or G3BP) in cells 
undergoing stress. SG proteins such as TIA-1, eIF3, and PABP also co-localize with 
neuropathology in brain tissue of subjects with FTDP-17, FTLD-TDP, and ALS, or 
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animal models of these diseases In addition, as mentioned above with respect to ALS, 
SMA, and FXR the dysfunctions of the disease may actually be linked to dysregulation of 
RNA granules (50). 
Recently our lab (50), proposed that the aggregation of many pathological, 
intracellular proteins, including TDP-43 and FUS, proceeds through the SG pathway. 
Mutations in genes coding for SG associated proteins or prolonged physiological stress, 
lead to enhanced SG formation, which accelerates the pathophysiology of protein 
aggregation in neurodegenerative diseases. Alternatively, the formation of long-lived 
stable insoluble protein aggregates seen in disease may lead to accelerated, long-lived SG 
formation. These highly insoluble aggregates could also serve as a nidus for further 
aggregation of SGs, by binding with other RBPs and also binding RNA as part of the 
process of SG maturation. The result would be an overactive SG pathway. Over-active 
stress granule formation could act to sequester functional RBPs and/or interfere with 
mRNA transport and synthesis, each of which might potentiate neurodegeneration 
(Figure 6A – normal, Figure 6B – stress/normal SG formation, Figure 6C – chronic 
stress/ pathologic SG formation). The reversibility of the SG pathway also offers novel 
opportunities to stimulate endogenous biochemical pathways to reverse these 
pathological stress granules and also perhaps delays the progression of disease (50, 79). 
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The process of SG formation is best understood for
pathways mediated by phosphorylation of eIF2α. Stress-
ful conditions prompt phosphorylation of eIF2α at serine
51, which inhibits formation of a complex containing
eIF2, GTP and tRNAi
met [31]. Stress also induces trans-
location of many RNA binding proteins from the nu-
cleus to the cytoplasm. During stressful conditions,
capped mRNA remains bound to the pre-initiation com-
plex, which contains the other elongation factor binding
proteins EF-4A, E and G (Figure 4). This mRNA-protein
complex is bound by eIF3, poly-A and nucleating RNA
binding proteins, such as TIA-1, TIAR, tristetraprolin
(TTP) or GTPase activating protein binding protein
(G3BP), which bind the “naked” transcripts in the cyto-
plasm (Figure 4) [28]. The SGs are initially small, but in-
crease in size as the RNA binding proteins consolidate
by binding to each other through the glycine rich pro-
tein aggregation domains. This process of secondary
maturation of SGs specifically containing G3BP is a
prominent cytoplasmic function of TDP-43 [32]. Muta-
tions in RNA binding proteins appear to increase their
propensity to aggregate and to form SGs. For instance,
disease-linked mutations of TDP-43, FUS and ataxin-2
promote aggregation, either by directly increasing the ten-
dency of the protein to aggregate, or (for many FUS muta-
tions) by preventing nuclear translocation [16,17,33-37].
The SG complex initially forms a structure that is concep-
tually analogous to a tree, with the glycine rich aggrega-
tion domains forming the core of the structure, and the
mRNA bound to the RRMI, hanging off the RNA binding
proteins. The complex of aggregated RNA binding pro-
teins grows with time as other RNA binding proteins are
recruited through binding to the associated transcripts
and binding to the protein aggregation domains of other
RNA binding proteins (Figure 4). Mature granules contain
many RNA binding proteins recruited after the initial
Figure 4 Mechanism of normal and pathological stress granule formation. A) In normal, physiological conditions, neurons synthesize
specialized proteins from capped transcripts. The proteins eIF4A, E and G complex to form the eIF4F pre-initiation complex, which interacts with
the ribosome (40S) as well as other translational regulators to synthesize proteins. Association with the 60S ribosome complex allows protein
synthesis to begin. B) Stress leads to phosphorylation of eIF2α, dissociation of ribosomes and many of the translation initiation factors, leaving
mRNA bound eIF4G and poly-A binding protein. Nucleating RNA binding proteins bind the free RNA and also form protein/protein complexes,
which initiate stress granule formation. Once initiated, other RNA binding proteins bind to the mRNA and to the nucleating RNA binding proteins
to increase the size and complexity of SGs. These SGs are rapidly reversible upon removal of the stress, however prolonged SG formation affects
cell biology by interacting with biological systems regulating apoptosis, signaling and RNA decay. C) Pathological proteins, such as TDP-43, FUS
and tau, have a strong tendency to form oligomers, and then fibrils. The consolidation of RNA binding proteins during SG formation might
promote oligomerization by creating cellular domains with higher concentrations of these proteins. Conversely, the increased stability of
oligomers and fibrils might serve as a nidus for SG formation, leading to over-active SG formation. Microtubule associated protein tau also
participates in this process because it mislocates to the soma and dendritic arbor leading to interactions with SG proteins and potentially
stimulating SG formation [41]. Tau also directly binds RNA [42].
Wolozin Molecular Neurodegeneration 2012, 7:56 Page 5 of 12
http://www.molecularneurodegeneration.com/content/7/1/56
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Figure 6: Mechanism of normal and pathological stress granule formation. 
A, Under normal, physiological conditions, neurons synthesize specialized proteins from 
capped transcripts. The proteins eIF4A, E and G complex to form the eIF4F pre-initiation 
complex, which interacts with the ribosome (40S) as well as other translational regulators 
to synthesize proteins. Association with the 60S ribosome complex allows protein 
synthesis to begin. B, Stress leads to phosphorylation of eIF2α, dissociation of ribosomes 
and many of the translation initiation factors, leaving mRNA bound eIF4G and poly-A 
binding protein. Nucleating RBPs bind the free RNA and also form protein/protein 
complexes, which initiate SG formation. Once initiated, other RBPs bind to the mRNA 
and to the nucleating RBPs to increase the size and complexity of SGs. These SGs are 
rapidly reversible upon removal of the stress, however prolonged SG formation affects 
cell biology by interacting with biological systems regulating apoptosis, signaling and 
RNA decay. C, Pathological proteins, such as TDP-43, FUS and tau, have a strong 
tendency to form oligomers, and then fibrils. The consolidation of RBPs during SG 
formation might promote oligomerization by creating cellular domains with higher 
concentrations of these proteins. Conversely, the increased stability of oligomers and 
fibrils might serve as a nidus for SG formation, leading to over-active SG formation. 
Adapted from (50). 
The process of SG formation is best understood for
pathways mediated by phosphorylation of eIF2α. Stress-
ful conditions prompt phosphorylation of eIF2α at serine
51, which inhibits formation of a complex containing
eIF2, GTP and tRNAi
met [31]. Stress also induces trans-
location of many RNA binding proteins from the nu-
cleus to the cytoplasm. During stressful conditions,
capped mRNA remains bound to the pre-initiation com-
plex, which contains the other elongation factor binding
proteins EF-4A, E and G (Figure 4). This mRNA-protein
complex is bound by eIF3, poly-A and nucleating RNA
binding proteins, such as TIA-1, TIAR, tristetraprolin
(TTP) or GTPase activating protein binding protein
(G3BP), which bind the “naked” transcripts in the cyto-
plasm (Figure 4) [28]. The SGs are initially small, but in-
crease in size as the RNA binding proteins consolidate
by binding to each other through the glycine rich pro-
tein aggregation domains. This process of secondary
maturation of SGs specifically containing G3BP is a
prominent cytoplasmic function of TDP-43 [32]. Muta-
tions in RNA binding proteins appear to increase their
propensity to aggregate and to form SGs. For instance,
disease-linked mutations of TDP-43, FUS and ataxin-2
promote aggregation, either by directly increasing the ten-
dency of the protein to aggregate, or (for many FUS muta-
tions) by preventing nuclear translocation [16,17,33-37].
The SG complex initially forms a structure that is concep-
tually analogous to a tree, with the glycine rich aggrega-
tion domains forming the core of the structure, and the
mRNA bound to the RRMI, hanging off the RNA binding
proteins. The complex of aggregated RNA binding pro-
teins grows with time as other RNA binding proteins are
recruited through binding to the associated transcripts
and binding to the protein aggregation domains of other
RNA binding proteins (Figure 4). Mature granules contain
many RNA binding proteins recruited after the initial
Figure 4 Mechanism of normal and pathological stress granule formation. A) In normal, physiological conditions, neurons synthesize
specialized proteins from capped transcripts. The proteins eIF4A, E and G complex to form the eIF4F pre-initiation complex, which interacts with
the ribosome (40S) as well as other translational regulators to synthesize proteins. Association with the 60S ribosome complex allows protein
synthesis to begin. B) Stress leads to phosphorylation of eIF2α, dissociation of ribosomes and many of the translation initiation factors, leaving
mRNA bound eIF4G and poly-A binding protein. Nucleating RNA binding proteins bind the free RNA and also form protein/protein complexes,
which initiate stress granule formation. Once initiated, other RNA binding proteins bind to the mRNA and to the nucleating RNA binding proteins
to increase the size and complexity of SGs. These SGs are rapidly reversible upon removal of the stress, however prolonged SG formation affects
cell biology by interacting with biological systems regulating apoptosis, signaling and RNA decay. C) Pathological proteins, such as TDP-43, FUS
and tau, have a strong tendency to form oligomers, and then fibrils. The consolidation of RNA binding proteins during SG formation might
promote oligomerization by creating cellular domains with higher concentrations of these proteins. Conversely, the increased stability of
oligomers and fibrils might serve as a nidus for SG formation, leading to over-active SG formation. Microtubule associated protein tau also
participates in this process because it mislocates to the soma and dendritic arbor leading to interactions with SG proteins and potentially
stimulating SG formation [41]. Tau also directly binds RNA [42].
Wolozin Molecular Neurodegeneration 2012, 7:56 Page 5 of 12
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Potential for Pharmacological Intervention 
The RBPs addressed in this section (TIA-1, G3BP, TTP, SMN, and TDP-43) are 
essential players in RNA metabolism, with the RNPs forming a dynamic regulatory 
system for all aspects of the life of an mRNA, including nuclear processing, transport, 
translation, and decay. These proteins are key in the coordination of gene expression of 
many proteins, and their disruption could impair cell function and interfere with 
appropriate distribution and translation of mRNA in response to signaling (79). Protein 
levels of RBPs are known to change with aging perhaps making cells more susceptible to 
dysfunction and disease processes. 
Whether hyperactive SG formation is good or bad remains to be determined. Acutely 
SG formation is known to be protective and anti-apoptotic, until the stress is resolved. In 
neurodegeneration and other aging-associated diseases, there is no resolution and the 
stress is chronic. At this point SG formation and recruitment of RBPs from their normal 
functions act as a loss of function situation where RNPs become dysfunctional, and RNA 
metabolism is no longer in check.  Neurons require SGs for an effective stress response, 
but overactive, overly stable SG complexes could easily interfere with neuronal function 
by silencing transcripts and sequestering important proteins.  Mutations associated with 
disease-linked RBPs increase the aggregation propensity or cause dysfunctional RNPs, 
which provides a direct mechanism for overactive SG formation.  Chronic stressful 
diseases or environmental conditions might also stimulate overactive SG formation.  For 
instance, the oxidative stress associated with aging, the trophic stress associated with 
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diabetes, or the cellular stress associated with cancer all enhance SG formation creating 
the conditions for overactive SG aggregation (50).    
The effect of modulating the protein synthesis/SG pathway was recently evaluated in 
an animal model of Creutzfeld Jacob disease, where pathological misfolding of PrP 
precipitates neurodegeneration.  Mallucci and colleagues forced expression of GADD34, 
a phosphatase to reduce eIF2α phosphorylation, inhibit SG formation and stimulate 
protein synthesis (80).  This intervention reduced PrP-induced neurodegeneration. In 
contrast, salubrinal, which increases and prolongs eIF2α phosphorylation, increased SG 
formation, inhibited protein synthesis, and accelerated neurodegeneration (80).  These 
results suggest that inhibiting the SG pathway and stimulating protein synthesis can 
inhibit PrP-mediated neurodegeneration.  The discovery of over-active SG formation in 
other diseases raises the possibility that these pathways are over-active in multiple 
neurodegenerative diseases and other aging processes, and pharmacotherapy that targets 
SG formation might be protective (50). A major challenge in the future will be to define 
the components of each RNP complex and pinpoint the defects associated with RBP 
dysfunction. An important issue to resolve is why the absence of certain RBPs or 
accessory proteins leads to cell-specific defects (51).  
Section Four: Overview of the Studies 
Hypothesis and Aims 
Stress induces aggregation of RBPs to form inclusions called SGs. Recent evidence 
suggests that SG proteins also colocalize with neuropathological structures, and aberrant 
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SG formation has been identified in many neurodegenerative diseases, but whether this 
occurs in AD and related tauopathies was unknown. The goal of this dissertation is to 
identify and understand the interplay between RNA granule formation, RBPs, and the 
pathogenic protein tau. We hypothesize that SGs form in response to tau pathology and 
act as a nidus for aggregation in AD and tauopathies, leading to co-regulation of protein 
aggregation and enhanced toxicity.  We will first investigate whether SG pathology 
would form over the course of disease in mouse models of AD and tauopathies. 
Aim 1:  To determine whether the process of SG formation induced by pathological changes in 
Aβ differs from that induced by pathological changes in tau.  
The goal of the Aim 1 (Chapter Three) of this dissertation is to compare the SG response to the 
major pathogenic proteins Aβ and tau, using validated mouse models of AD. We examine the SG 
response over time in the tau driven Tg4510 and JNPL3 mouse, the Aβ driven Tg 5x-FAD mouse, and 
in the Tg3X-AD mouse, which contains both amyloid and tau-linked pathology.  
Our results from Aim 1 suggest that the biology of tau in mouse models of AD may 
be intimately linked to TIA-1, with the proteins accumulating concomitantly with each 
other. We further investigate whether there could be a co-regulation of protein 
aggregation of tau on SG formation and TIA-1 on tau aggregation leading to enhanced 
neurodegeneration.  
Aim 2: To determine if tau alters TIA-1 positive granule formation and dynamics in vitro 
In Aim 2 (Chapter Four) we will examine the effects of tau on TIA-1 positive SG 
formation, first in dividing cells, and we will follow up this data in primary hippocampal 
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neurons using TIA-1 and tau viral expression to examine SG formation, localization, and 
trafficking.  
Aim 3: To determine if TIA-1 modulates pathological changes in tau and 
subsequent neurodegeneration in vitro 
In Aim 3 (Chapter Five) we will determine if the presence of TIA-1 positive SGs can 
induce pathogenic changes in tau (phosphorylation, conformation, insoluble deposition), 
using dividing cells and primary neurons. We will further investigate whether this 
interaction would result in a loss of tau function and neurotoxicity. 
Significance 
 The results presented in this dissertation highlights previously uncharacterized 
molecular pathologies in the brains of patients with AD and related tauopathies, with 
specific emphasis on understanding the interaction between the RBP TIA-1 and tau 
leading to pathogenic changes leading to neurotoxicity in vitro. Collectively our findings 
suggest that tauopathies can be added to the list of diseases where the dysfunction in 
RBPs or RNA granules contributes to pathophysiology of neurodegeneration. The data 
present novel insights to the molecular mechanisms underlying tauopathies, and sheds 
light on critical unanswered research questions that may be highly relevant to a further 
understanding the pathophysiology of neurodegeneration.  
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CHAPTER TWO: MATERIALS AND METHODS 
Section One: Materials 
Animals 
MAPT -/- mice 
These tau knockout mice were originally generated as described by Dawson and 
colleagues (81). Briefly, they created tau deficient mice by disrupting the MAPT gene. 
The engineered mice do not express the tau protein, appear physically normal and are 
able to reproduce. Embryonic hippocampal cultures from tau deficient mice show a 
significant delay in maturation as measured by axonal and neuritic extensions (81). Both 
MAPT-/- mice and control strain (B57Bl/6) breeders were obtained from Jackson 
Laboratory and bred in the Boston University Laboratory Animal Science Center. 
TIA-1 -/- mice 
These TIA-1 knockout mice were originally generated as described by Piecyk et al. 
(68). These mice are viable, though they develop mild arthritis and are more susceptible 
to endotoxin shock.  These mice also exhibit altered polysome disassembly. Primary 
neurons from these mice were obtained in Paul Anderson’s lab at Brigham and Women’s 
Hospital, Boston, MA. 
Tissue Samples 
JNPL3 mutant tau mice 
The JNPL3 line of mice were generated as described by Lewis et al (82) and 
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backcrossed to homozygous status on Swiss Webster background.   This mouse line 
expresses the human P301L mutant 4R tau isoform driven by the mouse prion promoter. 
Mice exhibit motor deficits that correlate with an age- and gene-dose-dependent 
development of neurofibrillary tangles (NFT) and neuronal loss (82). Mice from different 
age ranges were classified for severity of disease phenotype using a motor test (wire hang 
test and hind limb clasping), which has been shown to correlate well with degree of 
pathology in hindbrain and spinal cord. Mice were classified as Normal, Mild, Moderate, 
or Severely affected based on motor tests noted above. 
Male JNPL3 mice were sacrificed by cervical dislocation and brains were dissected 
into hemispheres. One half was dissected and frozen, the other half was drop fixed in 4% 
paraformaldehyde (PFA) over night. Serial sections through the amygdala were taken 
from each mouse brain for IHC (N=3 from each of the four groups). Swiss-Webster non-
transgenic mice (N=3) age-matched to the 11-month-old group (correlating with the 
oldest Tg mouse sample) were used for the control group. Tissue samples were obtained 
from Dr. Karen Duff’s Lab at Columbia University.  
Inducible rTg4510 tau mice 
The rTg4510 line of tau transgenic mice was generated as described by Ashe and 
colleagues (39).  Similar to the JNPL3 line, these mice express the human P301L mutant 
4R tau isoform, but the transgene is conditionally expressed in the forebrain and 
hippocampus under control of the Ca2+-calmodulin kinase II promoter. Pre-tangles of tau 
appear in the brain at early stages (2.5 months), with silver staining of tau aggregates and 
sarkosyl insoluble tau appearing at 4+ months.  Severe pathology, mature NFTs and 
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neuronal loss are reported by 7+ months (39). For this study, 3 male mice at 2.5, 5, and 8 
months of age were used. Mice were sacrificed by cervical dislocation and cortical brain 
tissue was dissected for biochemical analysis. Tissue samples were obtained from Dr. 
Karen Duff’s lab at Columbia University. 
5x-FAD mice  
The Tg 5x-FAD line was generated as described by Vassar and colleagues (83). 
Briefly, five known FAD mutations were incorporated into a single mouse line (5xFAD), 
for the significant overexpression of primarily Aβ42 in the brain. Intraneuronal Aβ 
accumulates at 6 weeks in the subiculum and deep layers of the frontal cortex in 5xFAD 
mice, followed by extracellular amyloid plaques and gliosis by 2 months (83). 5xFAD 
mice ultimately develop neuronal loss and impaired working memory, recapitulating the 
regional disease progression observed in humans with AD. 
 3xTg-AD mice 
The 3x-Tg-AD line was generated as described by LaFerla and colleagues (84). 
Briefly, this mouse has point mutations in Presenilin-1 and APP, leading to 
overproduction of Aβ, as well as the P301L mutation in tau, leading to the development 
of NFTs. These mice begin to accumulate Aβ at 2-4 months, with deposition into plaques 
starting at 6mos in the cerebral cortex and hippocampus, which increase with age. The 
mice begin to exhibit tau pathology at 6mo, with severe tangle pathology by 20 months 
(84).  
The 3xTg-AD mice develop both plaque and tangle pathology in AD-relevant brain 
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regions. The 3xTg-AD mice develop extracellular Aß deposits prior to tangle formation, 
consistent with the amyloid cascade hypothesis. Despite equivalent overexpression of the 
human ßAPP and human tau transgenes, Aß deposition develops prior to the tangle 
pathology, consistent with the amyloid cascade hypothesis. In addition, these mice 
exhibit deficits in synaptic plasticity, including long-term potentiation (LTP) that occurs 
prior to extracellular Aß deposition and tau pathology, but is associated with intracellular 
Aß immunoreactivity (84). 3x-Tg-AD brain tissue slices were obtained from 
collaborators Dr. Alpaslan Dedeoglu and Dr. Isabel Carreras at VA- Boston Healthcare 
System.  
Human Tissue 
Brain tissue samples from human frontal cortex were obtained from the Boston 
University Alzheimer Disease Center, Mayo Clinic Jacksonville, the Loyola University 
Stritch School of Medicine, and Rush Medical Center.  Paraffin-embedded post-mortem 
human brain tissue was obtained from healthy (N=3) controls, patients with the diagnosis 
of AD (N=6) and 5 patients with FTDP-17 (Table 3). Demographic and clinical 
information for the human cases is described in Table 1. The sections were used for 
immunohistochemistry with staining for tau and SGs. 
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Table 3: Human brain tissue samples used in studies. 
Abbreviations: PMI, postmortem interval (hours); M, male; F, female; Nml, normal; AD, 
Alzheimer’s disease; FTDP-17, Frontotemporal dementia with parkinsonism linked to 
chromosome 17. 
Alzheimer’s disease (AD). We report that phase transitions of
RNA-binding proteins are evident early in the course of
tauopathies, including cytoplasmic translocation and granule
formation. SGs begin to merge with tau inclusions at the mid-
stage of disease development in a process that appears to be
associated with enlargement of tau inclusions. We demon-
strate that TIA-1-positive SGs are strongly associated with tau
pathology in AD. In contrast, SGs positive for G3BP show little
colocalization with phospho-tau protein, and SGs positive for
tristetraprolin (TTP) show colocalization with phospho-tau
protein in cases with severe pathology.
Materials andMethods
JNPL3 mutant tau mice
The JNPL3 line ofmice were generated as described by Lewis et al. (2000)
and backcrossed to homozygous status on Swiss Webster background.
This mouse line expresses the human P301L mutant 4R tau isoform
driven by the mouse prion promoter. Mice exhibit motor deficits that
correlate with an age- and gene-dose-dependent development of neuro-
fibrillary tangles (NFT) and neuronal loss (Lewis et al., 2000). Mice from
different age rangeswere classified for severity of disease phenotype using
a motor test (wire hang test and hindlimb clasping), which has been
shown to correlate well with degree of pathology in hindbrain and spinal
cord.Mice were classified as normal, mild, moderate, or severely affected
based on motor tests noted above.
Male JNPL3 mice were killed by cervical dislocation and brains were
dissected into hemispheres. One half was dissected and frozen, the other
half was drop fixed in 4% paraformaldehyde overnight. Serial sections
through the amygdala were taken from each mouse brain for IHC (N!
3 from each of the four groups). Swiss-Webster non-transgenic mice
(N ! 3) age-matched to the 11-month-old group (correlating with the
oldest Tg mouse sample) were used for the control group.
Inducible rTg4510 tau mice
The rTg4510 line of tau transgenic mice were generated as described by
Santacruz et al. (2005). Similar to the JNPL3 line, these mice express the
human P301L mutant 4R tau isoform, but the transgene is conditionally
expressed in the forebrain and hippocampus under control of the Ca2"-
calmodulin kinase II promoter. Pretangles of tau appear in the brain at
early stages (2.5 months), with silver staining of tau aggregates and
Sarkosyl insoluble tau appearing at 4" months. Severe pathology, ma-
ture NFTs, and neuronal loss are reported by 7" months (Santacruz et
al., 2005).
For this study, threemalemice at 2.5, 5, and 8months of agewere used.
Mice were killed by cervical dislocation and cortical brain tissue was
dissected for biochemical analysis.
Postmortem human brain tissue
Brain tissue samples from human frontal cortex were obtained from the
Boston University Alzheimer Disease Center, Mayo Clinic Jacksonville,
the Loyola University Stritch School of Medicine, and Rush Medical
Center. Paraffin-embedded postmortem human brain tissue was ob-
tained from healthy (N ! 3) controls, patients with the diagnosis of
AD (N! 6), and five patients with FTDP-17 (Table 1). Demographic
and clinical information for the human cases is described in Table 1.
The sections were used for immunohistochemistry with staining for
tau and SGs.
Biochemical fractionation
Tissue fractionation.Cortical tissuewas extracted from rTg4510 and non-
transgenic mice and homogenized in chilled RIPA buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM sodium fluoride, 1 mM
Na3VO, 1mMPMSF, and 1!g/ml protease inhibitors). The homogenate
was centrifuged at 20,000# g for 20min at 4°C to remove cellular debris.
The supernatant containing the total tau fraction was retained and as-
sayed for total protein concentration.
Triton-X fractions. Lysates from the preparation above were combined
1:1 with RIPA buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40,
0.1% SDS, 0.5 mM sodium deoxycholate) with 1# Halt protease inhibi-
tor cocktail (Ther o Scientific), 1# phosphatase inhibitor cocktail
(PhosSTOP, Roche), and 2%Triton X-100, andmixed. Lysates were first
centrifuged for 1 h at 100,000 # g 4°C, and the supernatants were col-
lected as RIPA buffer soluble proteins. To prevent contamination caused
by carrying over, the pellets were resonicated and recentrifuged at
100,000 # g for 30 min at 4°C. RIPA buffer-insoluble pellets were dis-
solved in urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-
HCl, pH 8.5) and sonicated. Soluble and insoluble proteins were
analyzed by Western blot.
Sarkosyl insoluble and soluble tau fractions. To produce a fraction en-
riched for tau, 10!l of a 10% solution of Sarkosyl detergent was added to
100 !g of supernatant. Additional RIPA was used to produce a final
volume of 100 !l. This sample was rotated at room temperature for 1 h
before a 1 h centrifugation at 100,000# g spin at room temperature. The
supernatant was collected in a separate tube and the Sarkosyl pellet was
resuspended in 100 !l of sample buffer containing 100 mM DTT. The
heat-soluble tau-enriched fractions were generated by boiling the super-
natant for 3 min at 95°C and centrifuging for 20 min at 20,000# g.
Coimmunoprecipitation. Equal amounts of lysate were precleared by
rec-Protein G-Sepharose 4B Conjugate beads (Invitrogen) for 1 h at 4°C.
Samples were spun down and lysates were removed, 0.5 !l of PHF-1
antibody or 1!l of Tau-5 antibody (Abcam)was added to each cell lysate
(300 !g), and the samples were incubated overnight at 4°C on a rotating
wheel. Protein G rec-Protein G-Sepharose 4B Conjugate beads (50 !l)
were added to the samples, then the samples were incubated for an addi-
tional 1 h at 4°C. The beads were spun down and washed three times in
coimmunoprecipitation buffer. The beads were boiled at 95°C for 5 min
in SDS sample buffer. Proteins were then analyzed by Western blot.
Immunohistochemistry: free-floating
Floating transgenicmouse brain tissue sectionswerewashed 2# 5min in
PBS and heated to 85°C in tris-sodium citrate buffer for 30 min. The
sliceswerewashedwith 0.2%TritonX-100 for 15min and blocked for 1 h
with 5% donkey serum in PBS. Incubation was performed with primary
antibodies for tau and SGs overnight in 5% donkey serum/PBS. Primary
antibodies used were used as follows: for tau: MC-1, PHF-1, and Alz-50
(1:1000, generously provided by Peter Davies, Albert Einstein College of
Medicine, Bronx, NY). For stress granules: TIA-1 (1:300, Santa Cruz
Biotechnology, sc-1751), eIF3" (1:300, Santa Cruz Biotechnology, sc-
16377), TTP (1:300, Santa Cruz Biotechnology, sc-14030), TDP-43 (1:
1000, Proteintech, 12892–1-AP), FUS (1:300, Proteintech, 11570-1-AP),
and G3BP (1:200, Becton Dickinson, 611126). The sections were then
washed 3# 10min TBS-Triton X-100 (0.05%) and incubated in second-
ary antibodies for 2 h. Secondary antibodies were as follows: Dylight
488-conjugated donkey anti-host IgG and Dylight 594-conjugated don-
key anti-host IgG (1:600, Jackson ImmunoResearch). The sections were
washed 4# 10 min in TBS/0.02% Tween; the third wash included DAPI
(1 !g/ml). Background fluorescence was then quenched by incubating
for 3 min in 1% sudan black followed by five quick dips in PBS and 4#
Table 1. Human brain tissue samples
Patient Age Gender PMI Diagnosis Brodmann areas
1 78 M Neurologic Nml 8,9
2 82 F 7 Neurologic Nml 8,9
3 83 F 13 Neurologic Nml 8,9
4 96 M 15 AD 8,9
5 88 F 15.5 AD 8,9
6 81 M 6.5 AD 8,9
7 79 F 12.5 AD 8,9
8 82 F 5.75 AD 8, 9
9 87 M 14 AD 8,9
10 65 M 12 AD 8,9
83 44 F 10 FTDP-17 Hippocampus
253 51 F 12 FTDP-17 Hippocampus
268 53 F 18 FTDP-17 Hippocampus
300 53 M — FTDP-17 Hippocampus
315 52 M 32 FTDP-17 Hippocampus
PMI, postmortem interval (hours).
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Section Two: Methods 
SH-SY5Y Culture and Transfection 
SH-SY5Y cells were maintained in 50/50 DMEM/F12 media supplemented with 10% 
fetal bovine serum, 1x PenStrep (Invitrogen), 1x L-Glutamine (Invitrogen), and 1x non-
essential amino acids. Cells were passages twice a week 1:2-3. Cells were seeded on 
18mm poly-D-lysine coated coverslips in 12-well plates (200,000/coverslip) one day 
prior to transfection in serum-free media (1:1 DMEM/F-12, 10% FBS). Cells were 
transfected at 1:2 ratio DNA:Lipofectamine (Invitrogen), delivering 2 mg total DNA per 
well. Lipofectamine in OptiMEM (Invitrogen) is incubated for 5 min prior to the addition 
of the DNA/OptiMEM. The transfection mixture is then allowed to incubate for 20 min at 
room temperature prior to being added to the cells. 500 µl of media is removed and 500 
µl of transfection mixture is added dropwise to each well. Cells were incubated 24 hours, 
after which the addition of 15 µM arsenite may be added to half of the plates and allowed 
to incubate for 24 hours. At 48 hours post-transfection, the cells were fixed in 4% PFA 
and stored in PBS.   
HT22 Culture and Transfection 
HT22 cells were maintained in DMEM (4.5g glucose/L) media supplemented with 
10% fetal bovine serum, 1x PenStrep (Invitrogen), 1x L-Glutamine (Invitrogen), and 1x 
non-essential amino acids. Cells were passages twice a week 1:5. Cells were seeded on 
18mm poly-D-lysine coated coverslips in 12-well plates (75,000/coverslip) one day prior 
to transfection in serum-free media (DMEM, 10% FBS). Cells were transfected at 1:2 
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ratio DNA:Lipofectamine (Invitrogen), delivering 2 mg total DNA per well. 
Lipofectamine in OptiMEM (Invitrogen) is incubated for 5 min prior to the addition of 
the DNA/OptiMEM. The transfection mixture is then allowed to incubate for 20 min at 
room temperature prior to being added to the cells. 500 µl of media is removed and 500 
µl of transfection mixture is added dropwise to each well. Cells were incubated 24 hours, 
after which the addition of 25 µM salubrinal may be added to half of the plates and 
allowed to incubate for 24 hours. At 48 hours post-transfection, the cells were fixed in 
4% PFA and stored in PBS.   
Primary Neuronal Culture 
Primary hippocampal cultures were generated from P0 pups from C57Bl/6 WT or 
Tau KO mice. The hippocampus was dissected out in Hank’s Balanced Salt Solution 
buffered with HEPES and PenStrep, and dissociated with 0.125% trypsin for 15 min at 
37°C, followed by trituration. Dissociated cells were plated on plates of coverslips pre-
coated with Poly-D lysine (100 µg/ml, Sigma). Neurons were grown for 21 days in 
Neurobasal medium supplemented with B-27 (Invitrogen) 
Overexpression Transduction 
At DIV2 neurons were transduced with AAV9-TIA-1-RFP or AAV9-mRFP virus 
(MOI 60) or TIA-1-EGFP or EGFP lentivirus (MOI 10). At DIV7 neurons were 
transduced with AAV1-WT tau or AAV1-P301L tau virus (MOI 60). Neurons were fixed 
for immunostaining and confocal microscopy in 4% PFA, or lysed in via sonication in 
PBS with protease and phosphatase inhibitors.  
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Knockdown Transduction 
At DIV2 neurons were transduced with AAV9-shTIA-1-GFP or AAV9-shControl-
GFP virus (MOI 20). At DIV7 neurons were transduced with AAV1-WT tau or AAV1-
P301L tau virus (MOI 20). Neurons were fixed for immunostaining and confocal 
microscopy in 4% PFA, or lysed in via sonication in PBS with protease and phosphatase 
inhibitors. 
Aβ Preparation 
Lyophilized (1 mg) Aβ (Anaspec) is resuspended in 1.01 ml of filtered DMSO to a 
final concentration of 220 µM. This is sonicated in a water bath on high for 1 min. And 
stored in 90.9 µl aliquots at -20°C.  To make oligomers an aliquot of this was thawed and 
20 µl of 10x F12 was added, followed by 89.1 ul of dH2O. This is incubated at 4°C 
overnight.  
Immunocytochemistry 
Coverslips were washed 3×5 min in PBS and washed with 0.1% Triton-X100 for 15 
minutes. Coverslips were washed 3x 3minutes in PBS and blocked for 1 hr with 10% 
donkey serum in PBS. Incubation was performed with primary antibodies for tau and 
TIA-1 overnight in 5% donkey serum/PBS. Primary antibodies used were used as 
follows: for tau: CP-13, PHF-1, MC1 (1:150, generously provided by Peter Davies, 
Albert Einstein College of Medicine) or Tau13 (1:2,500 generously provided by Lester 
Binder, Michigan State). For stress granules: TIA-1 (1:400, Santa Cruz).  For neuronal 
marker: MAP2 (1:1000, Avis). 
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Immunohistochemistry 
Free-floating tissue 
Floating transgenic mouse brain tissue sections were washed 2×5 min in PBS and 
heated to 85°C in tris-sodium citrate buffer for 30 min. The slices were washed with 
0.2% Triton-X100 for 15 minutes and blocked for 1 hr with 5% donkey serum in PBS. 
Incubation was performed with primary antibodies for tau and SGs overnight in 5% 
donkey serum/PBS. Primary antibodies used were used as follows: for tau: MC1, PHF-1, 
and Alz-50 (1:100, generously provided by Peter Davies, Albert Einstein College of 
Medicine). For stress granules: TIA-1 (1:300, Santa Cruz, sc-1751), eIF3η (1:300, Santa 
Cruz, sc-16377), TTP (1:300, Santa Cruz, sc-14030), TDP-43 (1:1000, Proteintech, 
12892-1-AP), FUS (1:300, Proteintech, 11570-1-AP), and G3BP (1:200, BD, 611126). 
The sections were then washed 3×10 min TBS-triton X-100 (0.05%), and incubated in 
secondary antibodies for 2 hr. Secondary antibodies were: Dylight 488 conjugated 
donkey anti-host IgG and Dylight 594 conjugated donkey anti-host IgG (1:600, Jackson 
ImmunoResearch). The sections were washed 4×10 min in TBS/0.02% Tween; the third 
wash included DAPI (1 µg/ml). Background fluorescence was then quenched by 
incubating 3 min in 1% Sudan black followed by 5 quick dips in PBS and 4×5 min PBS 
washes. Mounting was performed using Prolong-Gold anti-fade reagent (Invitrogen). 
Paraffin-embedded tissue 
Tissue sections were de-paraffinized and rehydrated, then treated with 0.1 M glycine 
for 30 min. The sections were then treated as described for the free-floating sections. 
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Incubation was performed with primary antibodies for tau: CP-13, PHF-1, mouse 
monoclonal Tau-5 (1:1000, Abcam, ab3931-500); and for SG: (as described above).  
Microscopy 
Confocal Microscopy 
Microscopy was performed using a Carl Zeiss LSM 510 META confocal laser-
scanning microscope carrying lasers at 405, 488, 543 and 633 nm. Images were captured 
using a 63X oil objective. LSM proprietary software was used for digital image analysis. 
Images were combined into figures using Adobe Photoshop software.  
Basic Microscopy 
Quantitative and area analysis was done using an Olympus BX-60 (Olympus) 
equipped with epifluorescence optics, digital camera (AxioCam MRm; Zeiss) and 
analyzed with Zeiss Axiovision software and ImageJ (NIH).  
Live Cell Microscopy 
Live cell imaging was performed using an Olympus DSU spinning disk confocal 
capable carrying lasers at 405, 488, 543, and 633 nm. Timecourse images were captured 
using a 63X oil objective. Analysis was done using Imaris/Bitplane software.  
Super-resolution Microscopy 
 Super-resolution images were recorded with a Vutara 200 superresolution microscope 
(Bruker Nano Surfaces., Salt Lake City, UT) commercial microscope based on the Single 
molecule localization (SML) biplane FPALM technology(85). Samples were imaged 
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using 647 nm and 488 nm excitation lasers, respectively, and 405 nm activation laser in 
photoswitching buffer comprising of 20 mM cysteamine, 1% betamercaptoethanol and 
oxygen scavengers (glucose oxidase and catalase) in 50mM Tris+10 mM buffer at pH 
8.0. Images were recorded using a 60x/1.2 NA Olympus water immersion objective and 
Photometrics Evolve 512 EMCCD camera with gain set at 50, frame rate at 50 Hz and 
maximal powers of 647 nm, 488 nm and 405 lasers set at 8, 10, and 0.05 kW/cm2 
respectively.  
Data was analyzed by the Vutara SRX software (version 4.09). Single molecules were 
identified by their brightness frame by frame after removing the background. Identified 
particles were then localized in three dimensions by fitting the raw data in a customizable 
region of interest (typically 16x16 pixels) centered around each particle in each plane 
with a 3D model function which was obtained from recorded bead data sets. Fit results 
were stored as data lists for further analysis. The image resolution capable of 
experimentally being achieved is 20 nm laterally (x 3and y) and 50 nm axially (in z). 
Analysis 
Granule count cells: SG density was quantified using Image J software by calculating the 
number of puncta >1 mm2 per 63x frame controlled for the number of cells. This was 
done by thresholding images, and using the analyze particle functionality. 
Colocalization: To analyze the potential interaction between tau inclusions and stress 
granules, quantification of co-localization was done using the Carl Zeiss LSM software, 
and R-values for the degree of co-localization were recorded.    
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Granule count neurons: Quantifications of granule counts and area in primary neurons 
was done in ImageJ by using a free-hand tool to outline the neuron, thresholding the 
image, creating a mask over the nucleus, and using the particle analyzer tool.  
Dendrite length: Measurements of dendritic processes were done using ImageJ plug-ins 
NeuronJ. Using the software to trace MAP2 positive processes of individual cells yields a 
pixel measurement that can then be back calculated to micrometers using the microscope 
scaling parameters. 
Live cell granule trafficking: Analysis was done using Imaris/Bitplane software using the 
Track functionality with ‘spot’ detection and Brownian motion filter settings. 
Thresholding was maintained constant over conditions and all data was exported to Excel 
for consolidation and organization and then Graphpad Prism for statistics. A Mann-
Whitney unpaired test with one-tailed p value was completed for comparing distances 
traveled, velocity analysis, and the directional percentages of granules within 
populations.  
Biochemical Fractionation 
Tissue Fractionation 
Cortical tissue was extracted from rTg4510 and non-transgenic mice and 
homogenized in chilled RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1mM 
EDTA, 1mM sodium fluoride, 1 mM Na3VO, 1mM PMSF and 1 µg/ml protease 
inhibitors). The homogenate was centrifuged at 20,000 x g for 20 minutes at 4°C to 
remove cellular debris. The supernatant containing the total tau fraction, was retained and 
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assayed for total protein concentration. 
Triton-X Fractions 
Lysates from the preparation above were combined 1:1 with RIPA buffer (50 mM 
Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5 mM sodium deoxycholate) 
with 1x Halt protease inhibitor cocktail (Thermo Scientific), 1x phosphatase inhibitor 
cocktail (PhosSTOP, Roche), and 2% Triton-X-100, and mixed. Lysates were first 
centrifuged for 1 hour at 100,000×g 4°C, and the supernatants were collected as RIPA 
buffer soluble proteins. To prevent contamination caused by carrying over, the pellets 
were re-sonicated and re-centrifuged at 100,000×g for 30 min at 4°C. RIPA buffer-
insoluble pellets were dissolved in urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 
mM Tris-HCl, pH 8.5) and sonicated. Soluble and insoluble proteins were analyzed by 
western blot. 
Sarkosyl Insoluble and Soluble Tau Fractions 
To produce a fraction enriched for tau, 10 µl of a 10% solution of sarkosyl detergent 
was added to 100 µg of supernatant. Additional RIPA was used to produce a final volume 
of 100 µl. This sample was rotated at room temperature for 1 hour prior to a 1-hour 
centrifugation at 100,000×g spin at room temperature. The supernatant was collected in a 
separate tube and the sarkosyl pellet was resuspended in 100 µl sample buffer containing 
100 mM DTT. The heat-soluble tau enriched fractions were generated by boiling the 
supernatant for 3 minutes at 95°C and centrifuging for 20 min at 20,000×g.  
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Immunoblotting 
Immunoblots were preformed using gradient PAGE on a 15-well 4-12% Bis-Tris gel 
(Invitrogen). Blocking was done in 5% milk for 1hr at RT. Primary antibody incubation 
was at 4°C overnight with 1:7,500 mouse monoclonal Tau13, 1:500 mouse monoclonal 
PHF-1, 1:500 goat polyclonal TIA-1 (Santa Cruz), or 1:10,000 mouse monoclonal actin 
(Millipore) in PBS. Secondary antibody was incubated in 5% milk for 1 hr at RT. 
Developing was done using SuperSignal West Pico Substrate (Thermo). 
Immunoprecipitation 
Equal amounts of lysate were pre-cleared by rec-Protein G-Sepharose 4B Conjugate 
beads (Invitrogen) for 1 hour at 4°C. Samples were spun down and lysates were removed 
and 0.5 µl of PHF-1 antibody, 1 µl of Tau-5 antibody (Abcam), 1 µl of MC1 antibody, or 
0.5 µl of TIA-1 antibody (Santa Cruz) was added to each cell lysate (100-300 µg) and the 
samples were incubated overnight at 4°C on a rotating wheel. 50 µl of protein G rec-
Protein G-Sepharose 4B Conjugate beads was added to the samples, then the samples 
were incubated for additional 1 hour at 4°C. The beads were spun down and washed three 
times in co-immunoprecipitation buffer. The beads were boiled at 95°C for 5 min in 
SDS-sample buffer. Proteins were then analyzed by western blot. 
Statistical Analysis 
All statistical calculations were done using one-way ANOVA followed by Tukey’s 
post hoc test.  Statistical calculations were performed using Graphpad Prism® software.  
Error bars in the figures are shown as standard errors of the mean.	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CHAPTER THREE: CONTRASTING PATHOLOGY OF STRESS GRANULE 
PROTEINS IN ALZHEIMER’S DISEASE AND RELATED TAUOPATHIES* 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*Partially adapted from Vanderweyde et al. J Neurosci, 2012 (79) 
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CHAPTER THREE: CONTRASTING PATHOLOGY OF STRESS GRANULE 
PROTEINS IN ALZHEIMER’S DISEASE AND RELATED TAUOPATHIES 
Cellular stress elicits a switch in protein translation from cap-dependent to cap-
independent RNA translation, which inhibits synthesis of non-housekeeping proteins, and 
maintains synthesis of proteins that protect against stress, such as heat shock proteins (52, 
61, 86).  The translational stress switch is associated with cytoplasmic translocation of 
mRNA binding proteins, and consolidation of these proteins with transcripts to form 
RNA protein complexes that are termed the stress granules (SGs). The primary stress 
granule proteins include TIA-1, G3BP, eIF3, and PABP, but there are over 500 RNA 
binding proteins, many of which participate in the formation of SGs (53, 60, 86). Recent 
advances in molecular genetics highlight the potential importance of SG biology in 
disease by genetically associating multiple RNA binding proteins linked to SGs with 
neurologic/neurodegenerative disease (87, 88).  These proteins include TDP-43, FUS, 
SMN, ATX2, ANG, and FMRP, as well as other proteins (86, 89-99). The link between 
SG proteins and motor neuron disease raises the possibility that the stress-response of 
RNA binding proteins and SG formation might also contribute to the pathophysiology of 
other neurodegenerative diseases, such as dementia.  
Recent reports indicate that SGs are associated with the pathological inclusions in 
multiple neurodegenerative diseases, including Huntington’s disease, Creutzfeldt-Jakob 
disease, ALS, and frontotemporal dementia linked to ubiquitin (FTLD-U) (87, 88, 100).  
A potential relationship between SGs and tau is particularly interesting because tau can 
bind to RNA, and RNA is known to promote the assembly of tau to form PHFs (46). The 
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high concentrations of RNA present in SGs raises the possibility that formation of SGs 
might impact on aggregation of tau to form inclusions in tauopathies.   
 In this chapter we investigate the biology of RBPs and SGs in animal models of 
tauopathy and AD, and human cases of AD.  We report that phase transitions of RBPs are 
evident early in the course of tauopathies, including cytoplasmic translocation and 
granule formation. SGs begin to merge with tau inclusions at the mid-stage of disease 
development in a process that appears to be associated with enlargement of tau 
inclusions.  We demonstrate that TIA-1-positive SGs are strongly associated with tau 
pathology. In contrast, SGs positive for G3BP show little co-localization with phospho-
tau protein, and SGs positive for TTP show co-localization with phospho-tau protein in 
cases with severe pathology. Interestingly, we find that this observation is specific to tau 
pathology, with no striking SG pathology in a mouse model with only Aβ pathology. 
Section One: Transgenic Tau Mice 
Stress Granules increase in size and number with disease severity 
To investigate the evolution of SG biology during the course of disease, we examined 
the distribution of markers for SGs and phospho-tau in JNPL3 mice at varying stages of 
disease in the amygdala and cortex respectively. SG inclusions increased in number, size 
and distribution with the severity of the disease (Figure 7).  We examined TIA-1 and eIF-
3η, which are RNA binding proteins that are considered to be primary SG proteins.  TIA-
1 is nuclear under basal conditions, but translocates to the cytoplasm with stress to form 
punctate granules.    The nuclear TIA-1 is not apparent because we used Sudan Black to 
quench low-level fluorescence (such as in nuclei) and highlight consolidated cytoplasmic 
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TIA-1 reactivity, such as occurs in SGs, because this type of fluorescence tends to be 
very bright.   
eIF-3 is constitutively cytoplasmic, but participates in the formation of primary SGs.  
TIA-1 and eIF-3 were both evident in SGs at each stage of disease, and SGs containing 
these two proteins showed similar patterns of evolution during the course of disease, 
increasing in abundance with disease stage (TIA-1 shown in Figure 7; eIF-3 for severe 
only shown in Figure 8 to demonstrate co-localization). Specificity of the TIA-1 and eIF3 
reactivity was demonstrated by immunoabsorption, which eliminated all fluorescence 
(Figure 9, TIA-1 shown), consistent with our prior study using these antibodies (87).    
Statistically significant increases in SG density were evident in the transition from mild 
to moderate and moderate to severe disease (Figure 10, P<0.001).  However, even early 
stage mice showed a trend (p<0.1) towards increased numbers of SGs compared to non-
transgenic mice, which indicates the presence of stress early in the disease course, either 
due to over-expression of tau or the presence of pathological tau that is not yet apparent 
by immunohistochemistry.   
Interestingly, the size distribution of SGs shifted towards larger SGs with increasing 
disease severity (Figure 10, Table 4). JNPL3 tau mice at an early, or pre-disease stage 
showed SGs that were overwhelmingly less than 5 µm, and generally about 1-2 µm in 
diameter, while mice at a moderate stage of disease had large inclusions (Figures 7 & 
11).  The SGs that were present in early stage mice showed a distribution that included 
perinuclear reactivity, as well as reactivity that was distal from nuclei and presumably in 
processes (Figure 7).  The size of SG inclusion showed a distinct transition in mice with 
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moderate disease (Figure 11). The frequency of SGs exhibiting a diameter that was 
greater than 5 µm increased over 10-fold (Figure 11).  Mice at the severely affected stage 
showed SG reactivity that was broadly distributed and generally greater than 5 µm 
(Figures 7- 8, & 11). 
The anatomic distribution of SGs also paralleled the distribution of phospho-tau  
protein. SGs in the JNPL3 mouse tissue were found only in areas where there was tau 
pathology, such as the brain stem and amygdala. SG inclusions were not observed in 
cortex, where only sparse tau pathology is observed in the JNPL3 mouse strain. 
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Figure 7: TIA-1 positive granules increase with disease severity in TgJNPL3 mice. 
Immunohistochemistry for SGs (TIA-1, red) show increased abundance with disease 
state, and that colocalization with phospho-tau (PHF-1, S396,404, green) increases with 
disease state, scale bar, 10 µm. Nuclei are identified with DAPI (blue). Sections were 
treated with Sudan Black to quench endogenous fluorescence and highlight the 
fluorescence associated with pathology, which is brighter. Arrows point to colocalization. 
The bottom set of panels (High Mag) show higher magnification images of the images 
directly above (severe), scale bar, 5 µm. 
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Figure 8: eiF3-positive granules colocalize with phospho-tau in TgJNPL3 mice. 
Colocalization of eIF3-positive (red) granules with PHF-1 positive (green) tau in brain 
tissue from JNPL3 mice. Arrows point to colocalization, scale bar, 5 µm. The bottom set 
of panels (High Mag) show higher magnification images of the images directly above 
(severe), scale bar, 10 µm. Nuclei are identified with DAPI (blue). 
Tg Mild
Tg Moderate
Tg Severe
Tg Severe
(High Mag)
eIF-3 PHF-1 Merge
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Figure 9: Demonstration of TIA-1 antibody specificity by immunoabsorption. 
Sections of amygdala from a JNPL3 mouse with severe disease were probed with 
antibodies to PHF-1 and eTIA-1. Pre-adsorbing the primary antibody with the epitope 
peptides abolished all reactivity for the corresponding antibody. Scale bar, 10 µm. 
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Figure 10: Stress granule density increases with disease severity in TgJNPL3 mice. 
Density of SGs increase greatly during the moderate and severe disease state. Density 
was determined using Fiji software to quantify SG puncta per 63x frame with a threshold 
set to >1 µm2 (controlled for cell number). 
inclusions increased to!70% inmice with severe pathology (Fig.
1A,G).
Inclusions exhibiting both tau and TIA-1 reactivity were exam-
ined to determine the degree of colocalization (R-value). The degree
of colocalization provides insight into the relationship between tau
and the SG proteins within individual inclusions. The degree of tau/
TIA-1 colocalization within inclusions was found to increase with
disease stage, frommild tomoderate to severe,withR-values ranging
from 0.643 to 0.751 to 0.819 respectively (Fig. 1A,H, p " 0.001).
Similar results were obtained for each of the three antibodies used,
PHF-1, MC-1, and Alz-50 (Figs. 1H).
The frequency of large inclusions identified by either phospho-
tau or SG markers increased with disease severity. To investigate
whether the structure of large and small inclusions might differ, we
stratified Tau/TIA-1 colocalization by inclusion size. Colocalization
between inclusions containing phospho-tau and TIA-1 steadily in-
creased with inclusion size (Fig. 1A,F). The correlation between
inclusion size andpercentage of colocalizationwas apparent at every
stage of disease, although the abundance of large tau inclusions was
low in mice at early stages of the disease (Fig. 1A). Large tau inclu-
sions strongly colocalized with the TIA-1 SG marker in all disease
states, but the rare large inclusion in mildly affected mice showed a
lower percentage of colocalization than large inclusions in moder-
ately or severely affectedmice.
Small SG inclusions (including those surrounding large inclu-
sions) did not colocalize with phospho-tau inclusions even in
areas with high SG density and even in mice with severe pathol-
ogy (Fig. 1A,D). A corollary of this observation is that many cells
without visible phospho-tau display abundant SG pathology in
mice with moderate and severe pathology (Fig. 1A,D), which
highlights the presence of a significant stress response in the ab-
sence of visible phospho-tau.
Figure 1. TIA-1-positive SGs increase with disease state. A, Immunohistochemistry for SGs (TIA-1, red) show increased abundance with disease state, and that colocalization with
phospho-tau (PHF-1, S396,404, green) increases with disease state. Nuclei are identified with DAPI (blue). Sections were treated with Sudan Black to quench endogenous fluorescence
and highlight the fluorescence associated with pathology, which is brighter. Arrows point to colocalization. The bottom set of panels (High Mag) show higher magnification images of
the images directly above (severe). Scale bar, 10!m. B, TIA-1 immunofluorescence in amygdala from a non-transgenic mouse (SW Ctrl) or young JNPL3mouse (Nml; age, 2 months). The
endogenous nuclear TIA-1 fluorescence evident in sections not treated with Sudan Black is not evident in sections treated with Sudan Black. C, Colocalization of eIF3-positive (red)
granules with PHF-1-positive (green) tau in brain tissue from JNPL3 mice. Arrows point to colocalization. The bottom set of panels (High Mag) show higher magnification images of the
images directly above (severe). Nuclei are identified with DAPI (blue). D, Demonstration of antibody specificity by immunoabsorption. Sections of amygdala from a JNPL3 mouse with
severe disease were probed with antibodies to PHF-1 and eTIA-1. Pre-adsorbing the primary antibody with the epitope peptides abolished all reactivity for the corresponding antibody.
E, Density of SGs increase greatly during the moderate and severe disease state. Density was determined using Fiji software to quantify SG puncta per 63# frame with a threshold set to
$1!m 2 (controlled for cell number). F, The extent of colocalization between SGs with phospho-tau increase with inclusion size. Colocalization is largely absent in Tg Normal and SW
Control mice and is not reported here. G, Colocalization of Tau with TIA-1 increases greatly in JNPL3 mice with moderate and severe disease. Inclusions that react with PHF-1-positive Tau
and TIA-1 show high levels of colocalization within each inclusion. H, Within each lesion, the TIA-1 and PHF-1 signal were highly localized. Scale bar, 10 !m.
Vanderweyde et al. • Stress Granules in Tauopathy J. Neurosci., June 13, 2012 • 32(24):8270–8283 • 8273
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Figure 11: The extent of colocalization between stress granules  and phospho-tau 
increases with tau inclusion size. 
The percent of tau inclusions that colocalized with TIA-1 was quantified using Fiji 
software. Minimum and maximum parameters of area were used to discriminate between 
tau inclusion size. Data indicates that as tau inclusion size increases the likelihood of 
colocalization with TIA-1 increases. Colocalization is largely absent in Tg Normal and 
SW Control mice and is not reported here. 
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Table 4: Chapter Three summary of quantification of tau and SG pathology (±SD). 
 
Microglia and astrocytes form SGs
We hypothesized that the presence of SGs
in cells lacking visible pathological tau
could be due to the occurrence of SGs in
non-neuronal cells. This hypothesis
prompted us to determine how the distri-
bution of SGs correlated with cell type.
JNPL3 mouse brain tissue sections were
labeledwithmarkers for neurons (NeuN),
reactive astrocytes (GFAP), and microglia
(Iba1), as well as with TIA-1. SGs identi-
fied with TIA-1 were evident in NeuN-
positive cells at every stage of disease (Fig.
3A). Double labeling with NeuN also em-
phasizes the changes in TIA-1 distribu-
tion with disease state. NeuN is a
nuclear protein, while TIA-1 can be nu-
clear or cytoplasmic. TIA-1 reactivity in
non-transgenic and asymptomatic JNPL3
micewas largely evident in nuclei, where it
directly colocalized with NeuN. In con-
trast, TIA-1 reactivity in JNPL3 mice with
more overt pathology was evident in both
cytoplasmic (frequently as granules) and
nuclear domains, which is consistent with
the cytoplasmic translocation and SG for-
mation that is known to occur with TIA-1
in response to stress. SGmarkerswere also
present in astrocytes, and appeared to
steadily increase with disease stage, al-
though total SG load remained far below
that of neurons (Fig. 3B). SGs were evi-
dent in microglia (identified by Iba-1 re-
activity), but appeared to peak at the mild
stage of disease, and then decrease in mi-
croglial localization with increasing sever-
ity of disease (Fig. 3C). Microglial SGs
were most prominent in mice with mild
pathology, and less abundant inmice with
moderate pathology. In brain tissue from cases with severe dis-
ease, cytoplasmic TIA-1 granules overlapped with Iba-1 reactivity
rarely, and overlap that did present was not in the same focal plane,
suggesting that the proteins were not colocalized (Fig. 3C). These
data suggest that the relationship of SGs to the disease processmight
differ between neurons and inflammatory cells, such as microglia.
G3BP and TTP identify RNA granules that often are not
associatedwith PHF-1
The composition of the RNA protein complexes that comprise
RNA granules vary with the complex and the cellular condi-
tions. For instance, while TIA-1 is associated with transla-
tional silencing, G3BP and TTP are associated with
degradation of some mRNA and translational stimulation of
other mRNA, although they both have many different func-
tions (Irvine et al., 2004; Zekri et al., 2005; Ronkina et al.,
2010; Liu-Yesucevitz et al., 2011). We examined the expres-
sion of four other SG-associated proteins to explore specific
SG profiles in neurodegenerative disease. The proteins exam-
ined were G3BP, TTP, FMRP, SMN, and Hu antigen R (HuR)
(Anderson and Kedersha, 2008). Disease-related differences
were observed for G3BP and TTP. Three other secondary SG
protein components, FMRP, HuR, and SMN, did not show
any change in expression pattern with disease state (data not
shown). Analysis of the JNPL3 mouse amygdala showed a
steady increase in the amount of punctate cytoplasmic G3BP
reactivity with disease severity, paralleling the trend for TIA-1
(Fig. 4A). The number of all granules and number of large
granules increased with disease state, suggesting formation of
large RNA granules. However, unlike TIA-1, G3BP-positive
granules showed only weak colocalization with PHF-1 or
Figure 2. SG pathology in P301L tau transgenicmice. The patterns of evolution of reactivity for the RNA-binding proteins were
very similar between the JNPL3 and rTg4510 mouse models, except that the latter develops more severe pathology at end-stage
disease. Few SGs are evident in 2-month-old mice with no evident disease and no evident phospho-tau (PHF-1) reactivity. In
moderatedisease (5months), TIA-1 (red) reactivity is presentbut frequentlydoesnot colocalizewith taupathology (PHF-1, green).
In severe disease (8months), TIA-1 reactivity strongly colocalizes with tau pathology. In contrast, G3BP (red) reactivity frequently
does not colocalize with tau pathology. Nuclei are identified with DAPI (blue). Sections were treated with Sudan Black to quench
endogenous fluorescence. Scale bar, 10!M.
Table 2. JNPL3 taumouse, SW control mouse, human control, and human AD brain
quantification of tau and SG inclusions and colocalization of tau and SG pathology
(!SD)
Tissue
Density of SG/
63! field
Average area of
SG inclusions
(TIA1") (!m2)
% Colocalization of Tau
(PHF1") with SG
Average degree
of colocalization
Mouse
SW control 0.9# 0.7 2.7# 0.7 n/a n/a
Tg normal 3.0# 0.8 2.7# 0.9 n/a n/a
Tg mild 3.7# 0.7 2.8# 1.1 11.1# 11.7 0.692# 0.079
Tg moderate 8.7# 0.9 5.0# 2.3 45.4# 8.8 0.778# 0.084
Tg severe 22.2# 2.5 8.4# 3.8 69.1# 8.7 0.824# 0.098
Human
Control 0.9# 0.5 4.3# 1.8 1.1# 0.6 0.387# 0.172
Alzheimer’s 29.1# 3.2 9.5# 3.0 64.2# 6.6 0.840# 0.069
The term Tg Normal refers to the age of 2 months, when no tau pathology is present.
8274 • J. Neurosci., June 13, 2012 • 32(24):8270–8283 Vanderweyde et al. • Stress Granules in Tauopathy
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Stress granules merge with tau pathology at moderate and severe stages 
Next we investigated the relationship between SG inclusions and 
hyperphosphorylated or conformationally altered tau reactivity across disease state. We 
examined three different antibodies that are associated with tau pathology, PHF-1, MC1 
and Alz-50, and compared co-localization with TIA-1, which is an accepted marker of 
SGs (60, 101).  Results were largely consistent for each tau marker (Figure 12).  Co-
localization of SGs and pathological tau greatly increased with disease severity.  In mice 
at an early stage, with mild pathology, SG and tau inclusions existed largely in distinct 
physical locations; only 10% of tau inclusions co-localized with SG (Figure 7 & 12). As 
disease progressed the percent of co-localized inclusions increased. Approximately 50% 
of tau inclusions co-localized with TIA-1 positive inclusions in mice with moderate 
pathology. Co-localization between tau and TIA-1 inclusions increased to about 70% in 
mice with severe pathology (Figure 7 & 12).  
Inclusions exhibiting both tau and TIA-1 reactivity were examined to determine the 
degree of co-localization (R-value).  The degree of co-localization provides insight into 
the relationship between tau and the SG proteins within individual inclusions.  The 
degree of tau/TIA-1 co-localization within inclusions was found to increase with disease 
stage, from mild to moderate to severe, with R-values ranging from 0.643 to 0.751 to 
0.819 respectively (Figure 7 & 13, P<0.001). Similar results were obtained for each of 
the three antibodies used, PHF-1, MC1, and Alz-50 (Figure 13).  
The frequency of large inclusions identified by either phospho-tau or SG markers 
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increased with disease severity. To investigate whether the structure of large and small 
inclusions might differ, we stratified Tau/TIA-1 co-localization by inclusion size. Co-
localization between inclusions containing phospho-tau and TIA-1 steadily increased 
with inclusion size (Figure 7 & 11).  The correlation between inclusion size and percent 
co-localization was apparent at every stage of disease, although the abundance of large 
tau inclusions was low in mice at early stages of the disease (Figure 7). Large tau 
inclusions strongly co-localized with the TIA-1 SG marker in all disease states, but the 
rare large inclusion in mildly affected mice showed a lower percentage of co-localization 
than large inclusions in moderately or severely affected mice.  
Small SG inclusions (including those surrounding large inclusions) did not co-
localize with phospho-tau inclusions even in areas with high SG density and even in mice 
with severe pathology (Figure 7, 10). A corollary of this observation is that many cells 
without visible phospho-tau display abundant SG pathology in mice with moderate and 
severe pathology (Figure 7, 10), which highlights the presence of a significant stress 
response in the absence of visible phospho-tau.  
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Figure 12: Colocalization of pathogenic tau epitopes with TIA-1 increases with 
disease severity. 
Colocalization of Tau with TIA-1 increases greatly in JNPL3 mice with moderate and 
severe disease. Inclusions that react with both phospho and conformational tau epitopes 
high levels of colocalization with TIA-1 in moderate and severe disease. MC1, 
conformational tau epitope; PHF-1, pS396/S404; Alz-50, conformational tau epitope.  
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Figure 13: Degree of colocalization between tau epitopes and TIA-1 in Tg JNPL3 
mice. 
Within each inclusion, the TIA-1 and conformation and phospho-tau epitope signal were 
highly localized in mild, moderate, and severe stages of the disease. MC1, 
conformational tau epitope; PHF-1, pS396/S404; Alz-50, conformational tau epitope.
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Microglia and astrocytes form SGs 
We hypothesized that the presence of SGs in cells lacking visible pathological tau 
could be due to the occurrence of SGs in non-neuronal cells.  This hypothesis prompted 
us to determine how the distribution of SGs correlated with cell type.  JNPL3 mouse 
brain tissue sections were labeled with markers for neurons (NeuN), reactive astrocytes 
(GFAP) and microglia (Iba1), as well as with TIA-1.  SGs identified with TIA-1 were 
evident in NeuN positive cells at every stage of disease (Figure 14). Double labeling with 
NeuN also emphasizes the changes in TIA-1 distribution with disease state. NeuN is a 
nuclear protein, while TIA-1 can be nuclear or cytoplasmic.  TIA-1 reactivity in non-
transgenic and asymptomatic JNPL3 mice was largely evident in nuclei, where it directly 
co-localized with NeuN.  In contrast, TIA-1 reactivity in JNPL3 mice with more overt 
pathology was evident in both cytoplasmic (frequently as granules) and nuclear domains, 
which is consistent with the cytoplasmic translocation and SG formation that is known to 
occur with TIA-1 in response to stress. SG markers were also present in astrocytes, and 
appeared to steadily increase with disease stage, although total SG load remained far 
below that of neurons (Figure 15).  SGs were evident in microglia (identified by Iba-1 
reactivity), but appeared to peak at the mild stage of disease, and then decrease in 
microglial localization with increasing severity of disease (Figure 16).  Microglial SGs 
were most prominent in mice with mild pathology, and less abundant in mice with 
moderate pathology.  In brain tissue from cases with severe disease, cytoplasmic TIA-1 
granules overlapped with Iba-1 reactivity rarely, and overlap that did present was not in 
the same focal plane, suggesting that the proteins were not co-localized (Figure 16). 
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These data suggest that the relationship of SGs to the disease process might differ 
between neurons and inflammatory cells, such as microglia. 
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Figure 14: TIA-1 positive granules accumulate in neurons across disease severity in 
TgJNPL3 mice. 
Colabeling TIA-1 (red) to identify SGs, and NeuN (green) to identify neurons indicates 
that SG formation in neurons increases with disease state. Nuclei are identified with 
DAPI (blue). Sections were treated with Sudan Black to quench endogenous 
fluorescence. Scale bar, 10 µm.  
NonTg control
Tg Normal
Tg Mild
Tg Moderate
Tg Severe
NeuN TIA-1 DAPI Merge
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Figure 15: TIA-1 positive granules accumulate in astrocytes in TgJNPL3 mice. 
Colabeling identifies SGs (TIA-1, red) and astrocytes (GFAP, green) and shows modestly 
the presence of cytoplasmic SGs in astrocytes at each stage of the disease process.
NonTg control
Tg Normal
Tg Mild
Tg Moderate
Tg Severe
GFAP TIA-1 DAPI Merge
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Figure 16: TIA-1 positive granules are apparent in microglia early in the disease in 
TgJNPL3 mice. 
Double labeling SGs (TIA-1, red) and microglia (Iba-1, green) indicates that SGs are 
present in microglia mainly at the mild stage of disease. White arrows in the merged 
panels point to sites of colocalization. Scale bar, 10 µm. 
NonTg control
Tg Normal
Tg Mild
Tg Moderate
Tg Severe
Iba-1 TIA-1 DAPI Merge
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G3BP and TTP identify RNA granules that often are not associated with PHF-1 
The composition of the RNA protein complexes that comprise RNA granules vary 
with the complex and the cellular conditions.  For instance, while TIA-1 is associated 
with translational silencing, G3BP and TTP are associated with degradation of some 
mRNA and translational stimulation of other mRNA, although they both have many 
different functions (74, 86, 102, 103). We examined the expression of four other SG-
associated proteins to explore specific SG profiles in neurodegenerative disease.  The 
proteins examined were G3BP, TTP, FMRP, SMN and Hu antigen R (HuR) (60). 
Disease-related differences were observed for G3BP and TTP.  Three other secondary SG 
protein components, FMRP, HuR, and SMN did not show any change in expression 
pattern with disease state (data not shown).  Analysis of the JNPL3 mouse amygdala 
showed a steady increase in the amount of punctate cytoplasmic G3BP reactivity with 
disease severity, paralleling the trend for TIA-1 (Figure 17).  The number of all granules 
and number of large granules increased with disease state, suggesting formation of large 
RNA granules.  However, unlike TIA-1, G3BP-positive granules showed only weak co-
localization with PHF-1 or TIA-1 (Figure 17, PHF-1 shown).  Interestingly, large G3BP 
granules were strongly evident at the onset of disease (mild), but not in healthy mice, 
suggesting that G3BP might be a sensitive marker of disease onset (Figure 17).  The 
specificity of the G3BP reactivity was demonstrated by immunoabsorption, which 
eliminated all fluorescence (Figure 18).  
Inclusions containing TTP also increased with disease state (Figure 19).  TTP positive 
inclusions showed a pattern that varied distinctly with disease state.  Up through the 
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moderate stage of disease, TTP showed little if any co-localization with PHF-1 positive 
inclusions, even when apparently occurring within the same cell (Figure 19).  However, 
in severe disease, TTP was found to strongly co-localize with phospho-tau protein 
(Figure 19).  Specificity of the TTP reactivity was demonstrated by immunoabsorption, 
which eliminated all fluorescence (Figure 20). The presence of inclusions composed of 
RNA binding proteins that accumulate with disease but that are often not co-localized 
with PHF-1 reactivity contrasts with the pattern seen for TIA-1 and suggests that the 
strong co-localization of TIA-1 with PHF-1 positive tau reflects a selective association 
between pathological tau protein and particular RNA binding proteins.  This highlights a 
potentially important biological process, and also provides an internal control indicating 
that co-localization between pathological tau and TIA-1 is specific and does not reflect a 
non-specific association between aggregated proteins.  Finally, the presence of G3BP and 
TIA-1 positive inclusions in JNPL3 mouse brains identifies a novel type of inclusion 
occurring in the brain of an animal with tauopathy whose localization appears to be 
largely independent of the classical NFT.  
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Figure 17: G3BP occurs in cells lacking phospho-tau in TgJNPL3 mice. 
The cytoplasmic reactivity of G3BP (red) occurs early in the disease and increases with 
disease state but does not colocalize with phospho-tau protein (PHF-1, green), even at the 
severe stage of disease. Nuclei are identified with DAPI (blue). Sections were treated 
with Sudan Black to quench endogenous fluorescence. The bottom set of panels (High 
Mag) show higher magnification images of the images directly above (severe). Scale bar, 
10 µm. 
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Figure 18: Demonstration of G3BP antibody specificity by immunoabsorption in Tg 
JNPL3 mice. 
Sections of amygdala from a TgJNPL3 mouse with severe disease were probed with 
antibodies to PHF-1 and G3BP. Scale bar, 10 µm. 
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Figure 19: TTP colocalizes with phospho-tau only in severe stages of disease in 
TgJNPL3 mice. 
The cytoplasmic reactivity of TTP (red) increases with disease state and does not 
colocalize with phospho-tau protein (green), until the stage of severe disease, scale bar, 
10 µm. The bottom set of panels (High Mag) show higher magnification of the images 
directly above (severe), scale bar, 5 µm. 
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Figure 20: Demonstration of TTP antibody immunoabsorption in Tg JNPL3 mice. 
Sections of amygdala from a TgJNPL3 mouse with severe disease were probed with 
antibodies to PHF-1 and TTP. Scale bar, 10 µm. 
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TDP-43 and FUS exhibit cytoplasmic translocation early in the disease process 
Some frontotemporal lobar dementias are not associated with tau inclusions but are 
associated with TDP-43 inclusions (FTLD-U).  We recently reported that the TDP-43 
inclusions present in brains of subjects with FTLD-U are associated with other markers 
of SGs, such as TIA-1 (87).  However, TDP-43 inclusions are not reported in cases of 
FTDP-17 associated with tauopathy, such as subjects with the P301L tau mutation.  The 
presence of SGs/RNA granules associated with TIA-1, eIF3, G3BP, and TTP raised a 
question of whether TDP-43 inclusions might also form in the brains of JNPL3 mice.  We 
double labeled sections for TDP-43 and TIA-1 to determine co-localization of TDP-43 
with SGs (Figure 21).  TDP-43 was largely nuclear, and showed a modest increase in 
cytoplasmic inclusion formation with disease severity, with nuclear TDP-43 reactivity 
decreasing with disease severity (Figure 21).  Interestingly, the cytoplasmic TDP-43 
granules tended to occur only in brain tissue from animals with moderate or severe 
pathology, and frequently did not co-localize with TIA-1 or PHF-1 inclusions (Figure 
21). 
Studies of amyotrophic lateral sclerosis have identified mutations in FUS, which is 
another RNA binding protein with properties similar to that of TDP-43 (104, 105).  
Studies in humans show that FUS also forms inclusions in human brain, but that FUS 
inclusions mainly occur in brains lacking TDP-43 inclusions (106).  This background led 
us to investigate the expression of FUS in the JNPL3 mice.  Expression of FUS was 
largely nuclear but demonstrated some formation of cytoplasmic granules with increasing 
disease severity (Figure 22).  Nuclear FUS expression was strong throughout the disease 
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process and exhibited a modest increase with disease severity (Figure 22).  FUS 
expression was localized to neurons, and did not co-localize with PHF-1 reactivity or 
with TIA-1 reactivity (Figure 23).  The pattern of FUS reactivity also differed from that 
of TDP-43 in that nuclear expression remained strong throughout the disease process, and 
FUS formed larger cytoplasmic granules than did TDP-43 (Figures 21, 22).  These data 
suggest that TDP-43 and FUS react to the disease process in mice with tauopathy, but 
exhibit changes that are more modest than that for TIA-1, G3BP, or TTP. 
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Figure 21: TDP43 forms cytoplasmic inclusions in moderate and severe stages of 
disease in Tg JNPL3 mice. 
Immunohistochemical reactivity of TDP-43 (green), TIA-1 (red), and nuclei (DAPI, blue) 
in brains of TgJNPL3 mice of varying disease states. Scale bar, 10 µm. 
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Figure 22: FUS forms cytoplasmic inclusions in moderate and severe stages of 
disease in Tg JNPL3 mice. 
Immunohistochemical reactivity of PHF-1 (green), FUS (red), and nuclei (DAPI, blue) in 
brains of TgJNPL3 mice of varying disease states. Scale bar, 10 µm. 
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Figure 23: FUS reactivity does not colocalize with TIA-1 in the brains of TgJNPL3 
mice. 
Immunocytochemical reactivity of FUS (green), TIA-1 (red), and nuclei (DAPI, blue) in 
brains of mice of moderate disease state. 
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TIA-1 and TTP protein levels increase with disease progression, with soluble TIA-1 
protein complexes interacting with tau protein 
Formation of SGs and other RNA granules is driven by reversible aggregation 
mediated by hydrophobic domains of the RNA binding proteins that frequently have 
homology to prion proteins.  Because the progression of tauopathies is marked by 
development of highly insoluble tau fibrils, we were curious about whether RNA binding 
proteins involved in the pathophysiology of tauopathies might also show progressive 
insolubility   Whole brain lysates were obtained from inducible rTg4510 Tau transgenic 
mice at ages ranging from 3 – 8 months, which represented mild to severe stages of 
disease.  These samples were biochemically fractionated to obtain Triton-X soluble and 
insoluble fractions, as well as a heat stable (soluble tau) fraction that was produced 
separately. The samples were immunoblotted for TIA-1, TTP, G3BP, TDP-43, and FUS.  
Results obtained from the whole brain lysates indicated that the levels of TIA-1, TTP, 
and G3BP increased over the course of the disease, however changes in G3BP were only 
significant in the transition from moderate to severe disease (Figure 24).  The small 
increase in G3BP observed in whole brain lysates contrasts with the large increase in 
G3BP observed on immunocytochemistry and might reflect the enhanced ability to image 
RNA granules due to consolidation of the fluorescence in response to granule formation.   
In contrast, levels of TDP-43 and FUS remained relatively constant throughout the 
disease course (Figure 24). Next we examined the soluble tau (heat stable) fraction to see 
if any of the RNA binding proteins partition into that fraction with tau protein. TIA-1 
partitioned with soluble tau, exhibiting levels that increased with disease severity  (Figure 
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25).  Both TIA-1 and TTP exhibited increased levels in the soluble tau fraction in mice 
with severe pathology, but variable levels in mice with mild or moderate pathology 
(Figure 25). Next, we examined the triton insoluble fractions. TDP-43 and FUS showed 
strong reactivity in the triton insoluble fractions, but TIA-1, TTP, and G3BP were not 
evident (Figure 26).  The absence of TIA-1 is consistent with our results published 
previously (87).  We also examined the sarkosyl insoluble (aggregated tau) fraction.  
None of the RNA binding protein markers were evident in the sarkosyl insoluble fraction.
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Figure 24: RNA binding proteins increase with disease severity in whole brain 
lysates from rTg4510 mice. 
Disease severity modulates levels and biochemical behavior of RNA-binding proteins. A, 
Immunoblots showing levels of TIA-1, TTP, G3BP, FUS, TDP-43, Tau-5, and PHF-1 in 
whole brain lysates from rTg4510 mice at differing levels of disease severity. B, 
Quantification of immunoblots of whole brain lysates from rTg4510 mice (N=3). 
B.  
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Figure 25: RNA binding proteins increase with disease severity in heat stable lysate 
fractions from rTg4510 mice. 
A, Immunoblots showing levels of TIA-1, TTP, G3BP, FUS, and TDP-43 in heat stable 
fractions (soluble tau) from rTg4510 mice at differing levels of disease severity. B, 
Quantification of immunoblots of heat stable fractions (soluble tau) from rTg4510 mice 
(N=3). 
A.  
B.  
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Figure 26: TDP-43 and FUS are present in the triton insoluble fractions, but TIA-1, 
TTP, and G3BP are not. 
Immunoblots showing levels of TIA-1, TTP, G3BP, FUS, and TDP-43 in Triton-X 
insoluble lysates from rTg4510 mice at differing levels of disease severity. Fractionation 
controlled by equal protein loading at beginning of protocol.  
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Soluble TIA-1 protein complexes interact with tau protein 
Next we investigated whether SG proteins, such as TIA-1, directly associate with tau.   
Total and phosphorylated tau was immunoprecipitated with the antibodies Tau-5 (total 
tau) or PHF-1 (phospho-tau), and the resulting immunoprecipitates were immunoblotted 
with antibodies to TIA-1, TTP, or G3BP (Figure 27).  TIA-1 and TTP associate with tau, 
and also exhibit increasing association with phospho-tau with increasing severity of 
disease (Figure 27). G3BP was not detectable in PHF-1 (or tau-5) immunoprecipitates, 
but an immunoreactive band at 35 KD that reacted with the anti-G3BP antibody was 
readily apparent in the tau-5 immunoprecipitates, but only weakly apparent in the PHF-1 
immunoprecipitates (Figure 27).  These data present evidence suggesting a direct 
interaction between tau and some RNA binding proteins. 
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Figure 27: TIA-1 and TTP show increased binding to total and phospho-tau with 
increasing disease severity. 
A, Immunoprecipitation of total tau with the Tau-5 antibody, followed by 
immunoblotting with Tau5, TIA-1, TTP, or G3BP. Note: No immunoreactivity was 
observed at the molecular weight of holo-G3BP (47 KDa), however, a band reactive with 
the anti-G3BP antibody was apparent at 35 KDa. This band is labeled as 35 KDa G3 
band. B, Immunoprecipitation of phosphorylated tau with the PHF-1 antibody, followed 
by immunoblotting with Tau-5, TIA-1, TTP, or G3BP.  
B.  
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Section Two: 5x-FAD Amyloid Transgenic Mice 
There are no striking changes in SG pathology in response to Aβ insult 
To investigate the evolution of SG biology during the course of β-amyloid-linked 
disease, we examined the distribution of markers for SGs and Aβ42 in Tg 5x-FAD mice at 
varying stages of disease. Tg 5x-FAD mice have 5 mutations (3 in amyloid precursor 
protein (APP), and 2 in Presenilin1 an enzyme that cleaves APP) that lead to the over-
production of Aβ42 and its deposition as plaques. Staining of tissue slices with SG 
markers TIA-1, TTP, and G3BP suggest that there are no striking changes in SG 
pathology over the course of disease in these mice (Figure 28). This is supported by 
quantification of SG density, showing no significant changes (Figure 29). This led us to 
believe that the SG response might be dependent on changes in tau. 
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Figure 28: Stress granule reactivity in Tg 5x-FAD mice is not striking. 
Immunohistochemistry for stress granule proteins (TIA-1, TTP, or G3BP) (red), Aβ42 
(green), and nuclear staining, DAPI, (blue) was done in Tg 5x-FAD mice at mild (3 
month) and severe (8 month) disease.  
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Figure 29: Stress granule density does not significantly change over the course of 
disease in the Tg 5x-FAD mice. 
Density of stress granules does not vary with disease state in the Tg 5x-FAD mice. 
Density was determined using Fiji software to quantify SG puncta per 40x frame with a 
threshold set to >1 µm 2 (controlled for cell number). 
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Section Three: 3x-Tg AD Mice 
SG markers track and co-localize with tau pathology in a mouse model with both tau and 
amyloid overexpression 
Data thus far indicates that β-amyloid alone does not elicit a SG response, but that tau 
alone is able to. We wanted to examine the combined effect of these two pathogenic 
proteins in the Tg 3x-AD mouse, which has the same P301L mutation in tau, and two of 
the APP mutation seen in the Tg 5x-FAD mouse. Staining of tissue slices with SG 
markers TIA-1 and TTP indicate similar patterns of SG reactivity and colocalization as 
was seen in the TgJNPL3 mice (Figure 30). Interestingly, staining with G3BP showed 
enhanced colocalization with tau, as compared to what was seen in the rTg4510 mice. 
Quantification of SG density indicates significant increases in TIA-1, TTP, and G3BP 
over the course of the disease (Figure 31). With major increases in TIA-1 occurring 
earlier in the disease, and major increases in TTP occurring later in the disease course as 
was seen with the rTg4510. Quantification of colocalization with tau, indicates that TIA-
1, TTP, and G3BP all co-localize with tau, increasing over the course of the disease, with 
G3BP colocalization about 30% less under all conditions (Figure 32). Our analysis of the 
Tg 3x-AD mouse parallels the studies of the rTg4510 and TgJNPL3 mice, showing a 
strong correlation between SG formation and disease severity, as well as co-localization 
with pathogenic tau. The major difference is the increased association between tau and 
G3BP. We hypothesize that this may be due to the presence of intraneuronal Aβ deposits 
seen in these mice, but this has not yet been tested.  
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Figure 30: Stress granule pathology increases with disease severity and colocalizes 
with phospho-tau in Tg 3x-AD mice. 
Immunohistochemical staining for RNA binding proteins (TIA-1, TTP, and G3BP) (red), 
and phospho-tau protein (CP13, pTau S202) (green) is shown in mild disease (6 mo) and 
severe disease (18 mo) of Tg 3x-AD mice. Nuclei are identified with DAPI (blue). 
Sections were treated with Sudan Black to quench endogenous fluorescence.  
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Figure 31: Stress granule density increases with disease severity in Tg 3x-AD mice. 
Density of stress granules increase greatly at 6 months when mice begin to show 
pathology. Density was determined using Fiji software to quantify SG puncta per 40x 
field with a threshold set to >1 µm 2 (controlled for cell number). 
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Figure 32: The extent of colocalization between TIA-1, TTP, or G3BP  and phospho-
tau increases with disease severity in Tg 3x-AD mice. 
The percent of RNA granules that colocalized with PHF-1 was quantified using Fiji 
software. Data indicates that as the disease progresses there is an increased likelihood of 
colocalization between PHF-1 and RNA granules, with no colocalization at 2 months.  
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Section Four: Human Tissue 
SG markers co-localize with tau in post-mortem human brain tissue 
Next we investigated whether tau inclusions in brains (frontal cortex) of subjects with 
AD also co-localized with SG markers (Figure 33). Differentiating SG reactivity from 
lipofuscin can be challenging, so to overcome this problem we use Sudan Black to 
quench lipofuscin fluorescence (87). Use of Sudan Black highlights consolidated 
cytoplasmic TIA-1 reactivity, such as occurs in SGs, because this type of fluorescence 
tends to be very bright.   However, weaker fluorescence, such as the endogenous nuclear 
TIA-1 reactivity, tends to be quenched; hence nuclear TIA-1 is difficult to observe in 
tissues treated with Sudan Black (Figure 34).  We investigated a range of anti-tau 
antibodies, including antibodies detecting phosphorylated tau epitopes (PHF-1, CP-13), 
antibodies detecting pathological conformational tau epitopes (MC1, Alz-50), and 
antibody detecting total tau (Tau-5).  In each case, reactivity with the tau epitopes (Figure 
33, PHF-1, CP-13 and Tau-5) showed a strong degree of co-localization with TIA-1, a 
classic SG marker (Figure 33, Table 4). As was the case with the JNPL3 mice, larger tau 
inclusions were more likely to be co-localized with SG markers than the small tau 
inclusions.  When examining the brain sections from the cognitively normal control 
samples, some sparse tau reactivity was found throughout the frontal cortex as has been 
previously noted (107, 108). SGs were also present in older normal control brain tissues, 
but were small to medium in size, sparse, and not associated with tau pathology.  
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Figure 33: Colocalization of TIA-1 with tau pathology in human Alzheimer’s disease 
cortex. 
Frontal cortex from a subject with AD was probed with antibodies to tau (phospho-tau, 
CP-13, PHF-1; total tau, Tau-5, green) and TIA-1 (red). Nuclei are identified with DAPI 
(blue). Sections were treated with Sudan Black to quench endogenous fluorescence. 
Large inclusions containing TIA-1 colocalize with each of the markers of tau protein that 
were tested. Figures from AD case 5 shown (Table 3). Scale bar, 10 µm.  
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Figure 34: Endogenous TIA-1  nuclear fluorescence was quenched with Sudan 
Black. 
TIA-1 immunofluorescence in Alzheimer cortex (frontal) and Control cortex (occipital) 
treated with Sudan Black. The endogenous nuclear TIA-1 fluorescence is not evident in 
sections treated with Sudan Black. Scale bar, 10 µm. 
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SG markers in human AD and FTDP-17 brain show similar molecular pathology to 
JNPL3 tissue 
As with the JNPL3 mouse tissue, we note modest FUS and TDP-43 translocation and 
inclusion formation in the cytoplasm of the human AD brain (frontal cortex, Figures 35-
36).  FUS reactivity co-localized with TIA-1 moderately, however TDP-43 co-localized 
with TIA-1 inclusions infrequently (Figure 35). Strong G3BP and TTP signals were also 
evident in the human AD tissue (Figures 35-36). The G3BP signal did not co-localize 
with the SG marker, TIA-1 (Figure 35). We also examined the relationship to phospho-
tau.  Neither FUS, TDP-43, nor G3BP showed co-localization with PHF-1 reactivity, 
which is similar to the results obtained with the JNPL3 mouse (Figure 36). TTP also 
showed strong reactivity, and the reactivity partially co-localized with tau inclusions, 
which correlates with results observed in the most severe stage of pathology in the JNPL3 
mouse.  Similar results were also observed in 5 cases of FTDP-17 (Figure 37). 
The presence of SGs in multiple cell types in the JNPL3 mice led us to investigate the 
cell type distribution of TIA-1 in the brains of subjects with AD.  The cell type markers 
NeuN, Iba1, and GFAP were used as markers for neurons, microglia, and astrocytes 
respectively. In all the frontal cortex samples analyzed, TIA-1 positive SG formation was 
evident in all cell types with the predominance of SGs found in neurons (Figure 33). 
Marked microgliosis and astrocytosis was evident from the morphology of reactivity, and 
TIA-1 positive SGs were observed in both cell types, perhaps indicating three divergent 
roles for TIA-1 positive SGs in human AD tissue (Figure 38).  
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Figure 35: Expression of FUS, G3BP, TTP, and TDP-43 in the Alzheimer brain does 
not colocalize with TIA-1. 
Frontal cortex from a subject with AD was probed with antibodies to FUS, G3BP, and 
TDP-43 (green) and double labeled with anti-TIA-1 antibody (red). Nuclei are identified 
with DAPI (blue). Sections were treated with Sudan Black to quench endogenous 
fluorescence. FUS showed some colocalization with TIA-1, while neither G3BP nor 
TDP-43 showed significant colocalization with TIA-1. Control represents a health control 
cortex with donkey serum substituted for primary antibody; similar results were observed 
using AD cortex. Scale bar, 10 µm. 
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Figure 36: TTP colocalizes with PHF-1 positive tau in the human Alzheimer brain, 
while G3BP, TDP43, and FUS does not. 
A, Frontal cortex from a subject with AD probed with antibodies to FUS, G3BP, TDP-43, 
and TTP (red) and double labeled with PHF-1 antibody (green). Nuclei are identified 
with DAPI (blue). FUS, G3BP, and TDP-43 did not show significant colocalization with 
PHF-1, while TTP did partially colocalize with PHF-1. Control represents FTDP-17 
cortex with donkey serum substituted for primary antibody. Figures from AD cases 5 and 
10 shown (Table 3). Scale bar, 10 µm. B, Merged images from A shown at higher 
magnification. Red, RNA-binding protein; green, PHF-1; blue, DAPI. Scale bar, 5 µm. 
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Figure 37: Patterns of TIA-1, TTP, and G3BP reactivity in FTDP-17 patients are 
similar to that of Alzheimer brain and TgJNPL3 mice. 
Frontal cortex from different subjects with FTDP-17 (numerical identifications shown) 
probed with antibodies to TTP, TIA-1, and G3BP (green), and double labeled with PHF-1 
antibody (red). Nuclei are identified with DAPI (blue). Only the green and merged 
images are shown. Scale bar, 10 µm. 
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Figure 38: TIA-1-positive stress granules are evident in neurons, microglia, and 
astrocytes in the Alzheimer brain. 
A, Frontal cortex tissue from a subject with AD was incubated with antibodies (green) to 
NeuN, Iba-1, and GFAP to identify neurons, microglia, and astrocytes, respectively. TIA-
1-positive (red) reactivity was present in all three cell types. Nuclei are identified with 
DAPI (blue). Sections were treated with Sudan Black to quench endogenous 
fluorescence. B, A similar study performed in frontal cortex from a healthy, aged control. 
Figures from AD cases 5 and 10 and neurologically normal control case 1 are shown. 
Scale bar, 10 µm. 
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Section Five: TIA-1 Increases Consolidation of Pathological Tau in Neuron-like 
Cells 
Binding of TIA-1 to tau suggests that the two proteins might interact under 
physiological or pathophysiological conditions.  To investigate this putative interaction, 
SH-SY5Y cells were transfected with TIA-1 ± WT or P301L Tau. The following day the 
cells were treated ± arsenite (15 µM, a mild treatment) to induce formation of stress 
granules, and fixed after 24 hrs (87). The cells were double labeled with antibodies to 
PHF-1 and TIA-1 (Figure 39) Similar experiments were also performed using CP13 for 
the immunocytochemistry; the results observed with CP13 labeling were the same as for 
PHF-1 labeling (data not shown).  Phospho-tau inclusions (PHF-1 positive) were not 
observed under basal conditions, even when tau or TIA-1 was over-expressed (Figure 
39A, C).  However, TIA-1 positive inclusions were apparent in cells over-expressing 
TIA-1, which is similar to what we, and others, have observed previously (Figures 39-40) 
(87).  Interestingly co-expressing TIA-1 with tau (WT or P301L) yielded more TIA-1 
positive inclusions (Figure 39A, B).  Treating the cells with arsenite (15 µM, 24 hrs) 
greatly increased the number of inclusions positive for tau and TIA-1 (Figure 39B, C).   
Over-expressing tau with TIA-1 greatly increased the formation of PHF-1 positive 
inclusions compared to cells over-expressing tau alone, TIA-1 alone, or neither (Figure 
39A, B).  Some of the tau inclusions exhibited double labeling for TIA-1, however the 
fraction of tau inclusions showing robust co-localization with TIA-1 was less than unity 
(Figure 39A-C). Expressing tau also increased the number of TIA-1 positive inclusions, 
despite no striking differences evident in the levels of PHF-1 (or CP13) positive tau 
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(Figure 39A); no difference was observed in tau or SG inclusion formation between WT 
and P301L tau (Figure 39B).  These data suggest that the TIA-1 stimulates tau inclusion 
formation under stressful conditions, and that tau expression facilitates SG formation. 
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Figure 39: Coexpressing TIA-1 and tau induces inclusion formation in the context of 
exogenous stress. 
A, SH-SY5Y cells were transfected with TIA-1_tau (WT or P301L) and grown under 
basal conditions (left panels labeled “No Arsenite”) or with arsenite (“+Arsenite”, 15 
µM, 24 h). Immunocytochemistry for PHF-1 (green), eTIA-1 (red) or TIA-1-RFP. Nuclei 
are identified with DAPI (blue). Arrows point to examples of inclusions that formed. The 
white box delineates areas that are shown at higher magnification in the right-hand 
column. Scale bar, 3 µm. B, Quantification of the number of TIA-1-positive inclusions 
with a size 1 µm. C, Quantification of the number of PHF-1 tau-positive inclusions with a 
size >1 µm. 
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Section Six: Discussion 
Recent studies suggest that stress granules are a form of pathology associated with 
neurodegenerative diseases.  Studies of Huntington’s disease, Creutzfeldt-Jakob disease, 
and our recent study of ALS and frontotemporal dementia (FTLD-U) all exhibit 
inclusions composed of the pathological protein aggregate that are co-localized with TIA-
1, a marker of SGs (87, 88, 100). The current study examines the evolution of SG 
pathology in multiple transgenic mouse models of tauopathy and AD, in human cases 
with AD, and in human cases of FTDP-17. Our results indicate that TIA-1-positive SGs 
are abundant in cases of AD and FTDP-17, and they increase with disease severity in the 
TgJNPL3 mutant tau mouse and Tg 3x-AD mouse, but not in the 5x-FAD amyloid 
mouse. Combined, these results suggest that the SG response may be intimately linked to 
tau pathology, and that b-amyloid alone does not trigger a robust cellular stress response 
in vivo. 
In the Tg JNPL3 mice, co-localization of tau with TIA-1 positive SGs varies with 
disease severity.  Pathological tau and SGs occur in separate compartments when 
inclusions are small (1-3 µm), but co-localization increases dramatically with disease 
severity and SG size.  The absence of co-localization in mice with little or mild pathology 
partially reflects the prevalence of SGs at this stage in inflammatory cells, including 
microglia and astrocytes.  However, SGs are also present in neurons at the mild stage, 
which suggests that SGs and pathological tau (as defined by the epitopes of PHF-1, MC1, 
and Alz-50) form at physically distinct sites.  As the disease process progresses, SGs 
become larger, more strongly localized to neurons and more strongly co-localized with 
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pathological tau.  Thus, our study uncovers a complex evolution of SG pathology that 
varies by cell type and degree of co-localization with pathological tau depending on 
disease stage.  
The co-localization of SGs with tau pathology might reflect a functional interaction 
between SGs and tau.  Microtubule-associated proteins are known to regulate SG 
formation (109, 110).  Expansions of polyglutamine repeats in ataxin-2, a RNA binding 
protein, are associated with supranuclear palsy (99).  Our own data demonstrate that SG 
proteins, such as TIA-1 and TTP, bind phosphorylated tau, and that binding increases 
with disease severity.  Using the mouse models, we observed that TIA-1 and TTP 
inclusions appear at locations that are physically distinct from the initial inclusions of 
phosphorylated tau.  However, the transfection experiments suggest that TIA-1 can 
stimulate formation of tau inclusions under conditions of stress, and that some of these 
inclusions co-localize with TIA-1.  The reason for the difference between the in vivo and 
cellular experiments is unclear at this juncture, but might reflect the acute nature of the 
transfection experiments or stresses associated with transient transfection.  The inclusions 
that formed in transfected cells did not appear to be filamentous, which suggests that they 
do not contain mature, aggregated tau, such as might occur in NFTs. However, this 
putative interaction raises the possibility that SG proteins might contribute to generating 
tau pathology, perhaps by creating local environments with high concentrations of 
phospho-tau; conversely, tau pathology might stimulate formation of SGs through direct 
and indirect mechanisms.   
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The contrasting trajectory of SG evolution in neurons, astrocytes, and microglia 
provides insight into the disparate responses of these three cell types to disease 
progression.  Neurons exhibit steady increases in SGs throughout the disease course.  In 
contrast, microglia exhibit a bell shaped SG evolution, with levels of microglial SGs 
peaking early in the disease course and decreasing with disease severity. The reduction in 
SGs among inflammatory cells might reflect the evolution of inflammation with disease 
state. SG proteins, such as TTP, have been shown to associate with transcripts for 
inflammatory proteins, such as COX-2 and TNF-α, and they appear to function as 
translational silencers of the pro-inflammatory cascade (68, 111). Extending this scenario 
to the brain raises the possibility that SGs function in inflammatory cells as part of a 
mechanism to dampen the inflammatory response.  As the disease progresses, protein 
aggregates and degenerating neurons might overcome the immunosuppressive defenses, 
inhibit SG formation in inflammatory cells and activate the inflammatory response.  In 
contrast, neuronal SGs are thought to promote the stress response, by shifting protein 
synthesis towards uncapped mRNA, which includes protective proteins such as heat 
shock proteins (112).  Thus, increasing neuropathology could lead to a widespread SG 
response in neurons but a dampened SG response in inflammatory cells.  
The differential patterns of expression of SG proteins are a particularly novel finding 
in our study.  This is the first study to compare the evolution of RNA granule formation 
by different RNA binding proteins with the course of disease. Our study highlights a 
close relationship between TIA-1 positive granules and tau pathology. In contrast, TTP 
and G3BP also show strong disease-linked increases in cytoplasmic levels and granule 
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formation with increasing disease severity, but the inclusions often occur separately from 
classic markers of pathological tau. TDP-43 and FUS show modest increases, and FMRP, 
SMN and HuR exhibit no increase in levels or granule formation with disease severity.   
Cytoplasmic granules composed of TTP and G3BP are particularly striking because 
they become more abundant and widely distributed as disease severity progresses, yet 
G3BP does not co-localize with tau inclusions at all, and TTP co-localizes only late in the 
disease process.  The presence of RNA granules that accumulate in tauopathies, but are 
not co-localized with tau pathology, points to novel types of molecular neuropathology 
that is not associated with classic markers of disease pathology.  This contrasting 
localization of TIA-1/Tau, G3BP, and TTP pathologies might also reflect independent 
mechanisms controlling the process of aggregation.  The tendency of TIA, G3BP, and 
TTP to aggregate contrasts with the behavior of FMRP, SMN and HuR, yet all of these 
proteins have similar structures and a similar tendency to stimulate formation of SGs in 
cell culture, and they can also be observed in other types of granules in healthy neurons 
(87).  The differential responses in tauopathies highlight potentially different signaling 
pathways regulating each type of protein. 
The RNA binding proteins addressed in this study (TIA-1, G3BP, TTP, FUS and 
TDP-43) are essential players in RNA metabolism, with the messenger ribonucleoprotein 
particles (mRNPs) forming a dynamic regulatory system for all aspects of the life of an 
mRNA including nuclear processing, transport, translation, and decay (60). These 
proteins are key in the coordination of gene expression of many proteins, and their 
disruption could impair cell function and interfere with appropriate distribution and 
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translation of mRNA in response to signaling (60, 74, 103). These proteins are able to act 
either as activators, repressors, or both with substrate selectivity. Of particular interest to 
the scope of this paper are the function of TIA-1 and TTP in the repression of 
inflammatory transcripts COX-2 and TNF-α, thus dampening the cellular inflammatory 
response (discussed above) (68, 113, 114). In contrast, G3BP is able to act as either an 
activator or repressor in a transcript dependent manner, and has been shown to be 
involved in cell proliferation, cytoskeletal reorganization, cell adhesion, and protein 
trafficking (74, 102, 115). The knockout of G3BP gene is embryonically lethal, indicating 
the integral role G3BP plays in development and basic cell functions (74). The 
relationship of G3BP to protein turnover could be particularly important to disease 
processes. G3BP is able to function as regulator of the ubiquitin-specific protease, USP-
10, a component of the de-ubiquitinating complex (116). The interaction of G3BP with 
USP-10 rescues Sec23 and β-COP transcripts from degradation, maintaining the activity 
of anterograde and retrograde protein secretion pathways (77, 117). Thus, G3BP might 
form cytoplasmic granules in neurons as part of a stress response that promotes survival. 
G3BP was also found to bind tau mRNA and stabilize the transcript, increasing its 
translation, which promotes microtubule stability, neurite outgrowth, and cytoskeletal 
remodeling (118). The presence of cytoplasmic G3BP granules in neurons that are PHF-1 
negative raises the possibility that G3BP might function to protect against 
hyperphosphorylated tau (specifically) or pathological tau (more generally) and related 
dysfunction of the microtubule network.  
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This study of SG evolution in tauopathies highlights previously uncharacterized 
molecular pathologies in the brains of patients with AD and in animal models of FTDP-
17.  SG biology offers multiple potentially important avenues of further study.  The 
process of protein aggregation leading to SG formation can be rapidly reversed through 
signal transduction mechanisms, such as pathways regulated by eIF2α (119).  Such signal 
transduction pathways highlight potentially novel targets for therapeutic development in 
AD.  The differential expression of RNA binding proteins in tauopathies also suggests 
that these proteins might represent novel biomarkers whose expression, aggregation, or 
post-translational modification might reflect distinct elements of the disease process. It 
would appear that SG markers could be used to identify injured neurons independent of 
classical pathological markers, such as antibodies (e.g., PHF-1) or chemical probes (e.g., 
thioflavin-S) recognizing pathological tau.   Finally, SG biology highlights a potentially 
important interplay between the evolution of inflammatory and neurodegenerative 
biology in tauopathies.  
Our results from this chapter suggest that the biology of tau in mouse models of AD 
may be intimately linked to TIA-1, with the proteins accumulating concomitantly with 
each other, and this is further documented in human post-mortem brain tissue. This 
relationship is a novel finding in the field and will benefit the community to elucidate. 
The association between SG and tau aggregation (or other disease-related proteins) may 
be causal with the SG associated proteins functioning as a foundation for aggregation of 
disease-linked proteins, or coincidental as a result of the cellular stress associated with 
the disease state. Our results indicate that SGs do not stimulate NFT formation, as we see 
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NFTs in the mild Tg mouse phenotype before substantial SG formation. However, it is 
possible that the presence of SG can induce further tau aggregation, deposition, and co-
localization. This is a plausible suggestion given that it is well known that anionic agents 
are able to induce tau tangle formation, and SGs contain large quantities of negatively 
charged RNA species (46). 
It is also possible that tau may have an effect on SG formation and localization, as 
SGs rely on the microtubule network for transport, and tau plays an intricate role in MT 
stability and structure.  In AD, it is possible that SGs become mislocalized due to the 
breakdown of MT as the disease progresses, further increasing the likelihood of SG 
colocalization with tau. SG formation and dynamics are mediated by the MT network, 
and is required for spatial organization of SGs, involving the fusion of smaller stress 
granules, and the recruitment of essential nuclear-localized SG components to the 
cytoplasm (63). However, once assembled the maintenance of SG does not require MT, 
but the disassembly is a MT-dependent process (120). The disruption in MTs could cause 
a slowing of SG assembly and the dynamic sorting of its contents. MT disruption may 
also result in the inability to disassemble SGs, leading to static long-lived ‘pathogenic 
SGs’, which could become a seed for aggregating proteins.  
In the remaining chapters, we will assess the relationship between tau and SGs using 
in vitro approaches.  We place emphasis on determining under what conditions TIA-1 
and tau interact, how each protein modulates the other’s biology, and to determine what 
effect this interaction has on cell viability.  
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CHAPTER FOUR: TAU EXPRESSION INCREASES TIA-1 STRESS GRANULE 
FORMATION AND ALTERS GRANULE TRAFFICKING 
RNA binding proteins (RBPs) are a class of about 800 proteins that function in the 
nucleus to regulate mRNA maturation, including splicing, RNA helicase activity, RNA 
polymerase elongation and nuclear export (60).  RBPs also function in the cytoplasm 
where they regulate RNA translation, trafficking, sequestration and degradation. RBP 
function is strongly regulated by the multiple signaling cascades integrated with RNA 
translation/protein synthesis, which will be referred to as “translational signaling”.   The 
cytoplasmic actions of RBPs play a particularly large role in neurobiology because of the 
large distance between the soma and synapse demand a proportionately large role of 
RBPs in trafficking transcripts (121).  
Increasing evidence links neurological disease processes to dysfunctional or 
dysregulation of neuronal RBPs, RNA granules and SGs (121-124). RBPs, such as TIA-
1, contain prion-like, poly-glutamine rich domains, which promote a process of 
aggregation of these proteins that is normally physiological and reversible (52, 53, 112).  
The process of SG formation begins with nucleation by a subset of RBPs, which includes 
TIA-1, followed by enlargement of the complex as secondary RBPs co-aggregate SGs are 
a key component of stress-induced translational suppression. They play a dynamic role in 
mRNA triage by sorting sequestered mRNAs for re-initiation, storage, or degradation, 
and may be required to allow optimal translation of stress-responsive anti-apoptotic 
mRNAs. Non-translating mRNAs, translation initiation components, and many additional 
proteins effecting mRNA function are shuttled into SGs nucleated by RBPs..   
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Mutations in TDP-43, FUS, ATXN2, hnRNPA1/B2, optineurin, matrin-3, ANG, and 
SMN all cause motor neuron diseases, including ALS (125).  Expansion of the 
trinucleotide repeats in FMRP cause Fragile X Syndrome (126). Many of the mutations in 
RBPs that are linked to disease appear to increase the tendency of these proteins to 
aggregate (104, 127, 128).  Studies from our lab and others show that the mutations also 
increase RNA granule formation, leading to SGs that are larger and more abundant, as 
well as larger and slower transport granules (129-132).  
Work from our laboratory, and other laboratories, indicates that SG proteins, 
including TIA-1, co-localize with neuropathology in brain tissue of subjects with AD, 
FTDP-17, FTLD-TDP, ALS, Huntington’s disease, Creutzfeld-Jacob disease and 
spinomuscular atrophy, as well as in animal models of some of these diseases (112, 124, 
129, 133, 134).  Our results from Chapter Three suggest that the biology of tau in mouse 
models of AD may be intimately linked to TIA-1, with the proteins accumulating 
concomitantly with each other. Tau is necessary for maintaining MT stability and 
structure in cells. It is possible that in addition to presenting a cellular stress that leads to 
SG induction, tau may also have a direct effect on SG assembly and localization, as SGs 
rely on the MT network for transport and localization. SG trafficking is especially 
important in neurons, where granules are dynamically trafficked along processes and are 
involved with local translation at the synapse. In Chapter Four we will examine the 
effects of tau on SG formation, first in dividing cells, and we will follow up this data in 
primary hippocampal neurons using TIA-1 and tau viral expression to examine SG 
formation, localization, and trafficking.  
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Section One: Tau Increases TIA-1 positive Stress Granules in vitro 
Tau increases SG number and size 
To determine whether tau co-localizes with RNA granules, tau (4R0N, WT and 
P301L) was co-transfected ± TIA-1-RFP, a core nucleating RBP. HT22 cells, which are 
derived from mouse hippocampal neurons, were transfected and examined ± arsenite (15 
µm, 6 hrs) to induce SGs.  Tau expression strongly increased RNA granule formation 
under basal and stressed conditions (Figure 40A-B).  Similar results were observed 
transfecting Tau alone, and imaging endogenous TIA-1 (Figure 41). Double labeling of 
these TIA-1 granules demonstrated that they are bona-fide SGs because they are positive 
for 3 SG markers: TIA-1, PABP and eIF3A; in addition, pretreatment with 10 µg/ml 
cycloheximide prevented formation of the tau/SG complexes, while treatment with 25 
µM salubrinal enhanced SG levels (Figures 40-41); salubrinal is a GADD34 inhibitor that 
increases and prolongs SG formation (135).   
Tau had a similar effect in Tau -/- primary hippocampal neurons transduced with 
TIA-1-GFP or EGFP lentivirus ± AAV9 WT Tau-V5 or P301L Tau-V5. Neurons lacking 
tau exhibited few TIA-1 granules, while neurons over-expressing tau and TIA-1 exhibited 
abundant dendritic stress granules (Figure 42A). Quantification shows that P301L tau 
significantly increased the size of TIA-1 SGs compared to WT tau, but produced fewer 
SGs than WT tau (Figure 42A-C). The larger size and reduced number of inclusions is 
analogous to similar effects produced by disease-linked mutations in RBPs, such as TDP-
43 (130). These data demonstrate that tau is a novel regulator of the SG response. 
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Figure 40: Tau increases TIA-1 positive SG formation in HT22 cells^.  
A, Immunocytochemistry for TIA-1, PABP and tau (Tau13 antibody) in HT22 
immortalized hippocampal cells with tau positive granules (identified with the Tau13 
antibody) formed by co-expressing TIA-1 ±  WT or P301 tau followed by arsenite 
treatment (50 µM, 18 hrs) or arsenite + cycloheximide (CHX, 5 µM). Beta-gal resulted in 
virtually no TIA-1 or tau inclusions. Scale bar: 10 µm.  B, Quantification of tau (Tau13), 
TIA-1 and PABP positive inclusions in cells from “A”.  N=50.  **p<0.01, ***p<0.001.  
^Figure and data produced by Dan Apicco. 
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Figure 41: Tau increases SG density and size in HT22 cells. 
A, Immunocytochemistry for endogenous TIA-1 in HT22 cells transfected with EGFP, 
WT, or P301L Tau-EGFP treated with DMSO vehicle or 25 µM salubrinal. Inset shows 
higher magnification, with arrows pointing to TIA-1 granules. B, Fluorescence imaging 
of TIA-1-RFP transfected in HT22 cells co-transfected with EGFP, WT Tau, or P301L 
Tau-EGFP treated with DMSO vehicle or 25 µM Salubrinal, with arrows pointing to 
TIA-1 granules. C, Quantification of TIA-1 positive granule density for both endogenous 
TIA-1 labeling and exogenous TIA-1-RFP fluorescence. D, Quantification of TIA-1 
positive granule size for both endogenous TIA-1 labeling and exogenous TIA-1-RFP 
fluorescence. Scale bar, 10 µm low mag, 2µm high mag. * p<0.05, **p<0.01, 
***p<0.001. 
 
	  	   	   134	  
 
 
Figure 42: Tau increases SG number and size in primary hippocampal neurons. 
A, Immunocytochemistry for V5 (Tau, red) and MAP2 (blue) in primary hippocampal 
Tau knockout neurons transduced with TIA-1-GFP lentivirus ± AAV9-WT Tau-V5 or 
AAV9-P301L Tau-V5. Images at low magnification and inset at high magnification 
indicate tau increases TIA-1 movement into processes and SG formation. B, WT or 
P301L Tau increases the number of TIA-1 granules. Granule density was determined 
using ImageJ to quantify TIA-1 puncta per neuron for both endogenous TIA-1 staining 
and exogenous TIA-1-GFP fluorescence. C, WT or P301L Tau viral expression increases 
the size of TIA-1 granules. Granule size was determined using ImageJ. **p<0.01, 
***p<0.001. Scale bar, 10 µm. 
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Phospho-tau is necessary for the regulation of SGs 
Phosphorylation is known to modulate tau biology.  Use of phospho-mimetic tau 
constructs demonstrated a striking role for tau phosphorylation in modulating SG 
formation. Transfections were performed using phospho-mimetic (PMIM) or phospho-
null (PNULL) tau constructs in which 14 sites exhibiting increased phosphorylation in 
AD were replaced with either aspartate or alanine (136). HT22 cells were transfected 
with P301L, P301L PMIM, or P301L PNULL tau-EGFP ± TIA-1-RFP.  Cells were 
treated ± 25 µM salubrinal and SG were imaged for endogenous TIA-1 (Figure 43A) or 
transfected TIA-1-RFP (Figure 43B). Imaging showed a more SGs in the presence of 
phospho-mimetic tau, while phospho-null tau promoted fewer, but larger SGs (Figure 
43A-D). Salubrinal treatment increased the number of SGs in all conditions.  
The role of phosphorylation in tau-mediated SG regulation was also evident using 
kinase inhibitors. Proline directed kinases are known to regulate the phosphorylation of 
tau (137, 138). Chemical inhibitors of GSK3β, CDK5, p38, MARK and Fyn all 
significantly inhibited formation of granules positive for TIA-1 and PHF-1 (Figure 44).  
The strongest effect was observed with the p38 inhibitor, which is known to act 
downstream of each of these kinases (139).  In combination, these data point to 
phosphorylation of tau as a key trigger for enhanced SG formation, which is consistent 
with the known role of phosphorylation in tau biology. 
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Figure 43: Phosphorylation of tau increases SG number in HT22 cells. 
A, Immunocytochemistry for endogenous TIA-1 in HT22 cells transfected with EGFP, 
P301L, P301L-PMIM (phospho-mimetic), or P301L-NULL (phospho-null) Tau-EGFP 
treated with vehicle (DMSO) or 25 µM salubrinal shows a increased TIA-1 positive SGs 
with phospho-mimetic tau, while phospho-null tau exhibit fewer SGs, scale bar 10µm. 
Inset shown at higher magnification, scale bar 2µm. B, Fluorescence imaging of TIA-1-
RFP transfected in HT22 cells co-transfected with EGFP, P301L, P301L-PMIM 
(phospho-mimetic), or P301L-NULL (phospho-null) Tau-EGFP treated with vehicle or 
25 µM salubrinal shows increased TIA-1 positive SGs with PMIM tau, while phospho-
null tau exhibits fewer SGs, scale bar 10µm. Inset shown at higher magnification, scale 
bar 2µm.  C, Quantification of SG density. D, Quantification of SG area. Granule 
quantification was determined using ImageJ. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 44: Tau phosphorylation inhibitors decrease SG formation in HT22 cells^. 
A, Fluorescence imaging of TIA-1-RFP transfected in HT22 cells co-transfected with WT 
Tau and treated with p38 MAPK inhibitor, 250 nM. Staining for PHF-1 (green) and 
nuclear stain DAPI (blue). B, Quantitative assessment of inhibition of SGs (upper panel) 
and PHF-1 inclusions (lower panels) by each of 5 inhibitors:  5 µM GSK3β Inhibitor 
XXVI (EMD Millipore), 5 µM CDK 2/5 (EMD Millipore), 250 nM p38 MAPK 
(Invitrogen), 20 µM MARK/Par-1 (EMD Millipore), or 20 nM Fyn (Invitrogen). 
**p<0.01, ***p<0.001. ^Figure and data produced by Dan Apicco. 
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Section Two: Tau and TIA-1 interact biochemically 
TIA-1 and Tau are found in a complex together 
Immunoprecipitations were performed to test whether TIA-1 associates with tau. 
HT22 cells were transfected with WT tau (4N0R) and TIA-1, then the complex was 
immunoprecipitated (IP).  IP with Tau13, a total human tau antibody, followed by TIA-1 
immunoblot, as well as IP with TIA-1 followed by immunoblotting with Tau13 both 
produced evidence indicating robust associations (Figure 45).  Similar results were also 
observed using primary hippocampal Tau -/- neurons transduced with AAV9-WT or 
P301L tau ± AAV1-TIA-1-mRFP (or mRFP). IP with TIA-1 indicated that both total tau 
(Tau13) and phospho-tau (PHF-1) bound exogenous and endogenous TIA-1 (Figure 46). 
Pre-treating the lysate with RNAse, or use of a TIA-1 construct lacking the 3 RNA 
recognition motifs abolished the association, indicating that tau associated with TIA-1 
through an RNA intermediate (Figure 47, data for RNAse A treatment shown).  The role 
of RNA intermediates supports the hypothesis that tau participates in RNA granule 
biology.  
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Figure 45: TIA-1 and tau are found in a complex in HT22 cells. 
A, Immunoblots showing levels of Tau13, TIA-1, and actin in lysates from HT22 cells 
transfected with β-gal, WT Tau, or P301L ± TIA-1-RFP. B, Immunoprecipitation of total 
human tau with Tau13 antibody, followed by immunoblotting with Tau13 and TIA-1. C, 
Immunoprecipitation of TIA-1, followed by immunoblotting with Tau13 and TIA-1.   
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Figure 46: TIA-1 and tau are found in a complex in primary cortical neurons. 
A, Immunoblots showing levels of total tau (Tau13), phosphorylated tau (PHF-1), TIA-1, 
and actin in lysates from primary hippocampal Tau knockout neurons transduced AAV1-
TIA-1-RFP ± AAV9-WT or P301L Tau. B, Immunoprecipitation of TIA-1, followed by 
immunoblotting with Tau13 and TIA-1. C, Immunoprecipitation of MC1 Tau, followed 
by immunoblotting with Tau13, PHF-1, and TIA-1.   
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Figure 47: Tau is associated with TIA-1 through an RNA intermediate^. 
Immunoprecipitation with HA-antibody in lysates from HT22 cells transfected with TIA-
1-HA ± WT tau, and treated ± RNaseA. Total lysate shows positive transfection of the 
conditions. IP: Anti-HA shows pull down for TIA-1-HA also precipitating tau, this 
interaction is abolished with RNaseA treatment indicating that RNA in part mediates the 
interaction. ^Figure and data produced by Peter Ash. 
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Tau increases TIA-1 insolubility and aggregation in HT22 cells 
RBPs are known to form detergent insoluble aggregates upon granule formation. 
These granules can become amyloidogenic in disease and irreversibly aggregate with 
disease-linked proteins (124, 140). We proceeded to explore whether tau promotes the 
aggregation of detergent insoluble TIA-1. Phospho-tau constructs were transfected into 
HT22 cells, and lysates fractionated with 1% sarkosyl buffer. It is evident from the whole 
cell lysate that TIA-1 promotes the clearance of tau that will be addressed in Chapter Five 
(Figure 48A). Expressing tau increased levels of insoluble TIA-1, but did not effect 
soluble TIA-1 levels (Figure 48B-C, more evident with P301L tau). Tau expression 
increased both endogenous and exogenous insoluble TIA-1, with a high molecular weight 
complex of TIA-1 found in nearly all conditions with tau expression. This high MW 
complex of TIA-1 may be evidence of amyloidogenic pathological SG formation that can 
self-propagate and act as a nidus for further aggregation. It is interesting to note that 
although exogenous expression of TIA-1 promotes soluble tau clearance, there is a steady 
or increased level of insoluble tau, perhaps indicating the latter point that these TIA-1 
aggregates may provide a nidus for insoluble tau deposition (Figure 48). These data lends 
support to a scenario where the seeding of pathological TIA-1 positive SG aggregates 
may increase the deposition of insoluble tau, a prion-like mechanism that has been 
previously shown for TIA-1 with Sup35 (53, 141). The effect of TIA-1 on tau deposition 
will be further explored later in this manuscript.   
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Figure 48: Tau increases TIA-1 insolubility and aggregation in HT22 cells. 
A, Immunoblots showing levels of Tau13, TIA-1, and actin in lysates from HT22 cells 
transfected with EGFP, WT Tau, WT Tau-phosphomimetic, P301L Tau, P301L Tau - 
phosphomimetic, or P301L Tau - phosphonull ± TIA-1-RFP. B, Immunoblots showing 
levels of Tau13 and TIA-1 in 1% sarkosyl soluble fractions from the HT22 lysates. C, 
Immunoblots showing levels of Tau13 and TIA-1 in 1% sarkosyl insoluble fractions from 
HT22 lysates.  
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Section Three: Tau Alters TIA-1 positive Granule Localization and Trafficking 
Tau promotes granule movement into processes 
When examining TIA-1 distribution, tau promotes TIA-1 granule movement into the 
processes (Figure 42 image, Figure 49A quantification) in Tau -/- primary hippocampal 
neurons transduced with TIA-1-GFP or EGFP lentivirus ± AAV9-WT Tau-V5 or AAV9-
P301L Tau-V5. Upon closer examination of these TIA-1 granules we find that in the 
presence of tau larger granules accumulate close to the soma, with the P301L mutation in 
tau resulting in larger granules (0.50 µm 2 (TIA-1, Figure 49B) vs. 1.06 µm 2  (WT tau, 
Figure 49C) vs. 1.51 µm 2 (P301L tau, Figure 49D). The appearance of larger aggregates 
closer to the soma is reminiscent of the aggregation of tau in the soma, which has been 
postulated to result in synaptic abnormalities and toxicity (136). The larger size of 
inclusions is also similar to the effects of disease-linked mutations in RBPs, such as TDP-
43 (130). 
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Figure 49: Tau promotes TIA-1 granule distribution away from soma in primary 
hippocampal neurons. 
A, Hippocampal Tau knockout neurons were transduced with TIA-1-GFP lentivirus ± 
AAV9-WT Tau-V5 or AAV9-P301L Tau-V5. TIA-1 granule distance from the soma was 
measured using Imaris Bitplane (N=20/condition). B-D, Scatter plots of TIA-1 positive 
granule area vs. distance from soma for: B, TIA-1-GFP transduced neurons (N=20), 
showing no trend. C, WT Tau/TIA-1-GFP co-transduced neurons, showing a slight trend 
that larger granules localize close to the soma. D, P301L Tau/TIA-1-GFP co-transduced 
neurons, showing a slight trend that larger granules localize close to the soma. 
***p<0.001.  
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Tau decreases TIA-1 granule dynamics in primary hippocampal neurons 
The ability of tau to regulate TIA-1 RNA granule formation suggests a biological role 
for tau in RNA granule physiology, which was investigated using live cell imaging. Tau  
-/- neurons (DIV 3) were transduced with AAV1-TIA-1-mRFP ± AAV9-WT or P301L 
tau, and at DIV 21, the neurons were imaged. Compiled traces showing particle 
localization and tracks of TIA-1 granules show decreased granule movement with tau 
expression (Figure 50A, E). Tau expression reduced net displacement and velocity of 
TIA-1 granules in both the anterograde (+) and retrograde (-) directions, although tau 
expression increased the proportion of TIA-1 granules moving in the anterograde 
direction  (Figure 50B-D).  Granule size was inversely correlated with granule velocity, 
with the trend particularly pronounced with P301L tau where the granule area velocity 
graph shows a distinct inflection at about 1.2 µm2 (Figure 50F-H). We recently noted a 
similar relationship between size and granule movement among TDP-43 granules (130). 
The reduction in RNA granule velocity with tau expression is reminiscent of the role of 
tau in stress-induced inhibition of mitochondrial transport, observed by Mucke’s group 
(142). Taken together, these studies point to an important role of tau in regulating 
trafficking of RNA granules, particularly of SGs.  
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Figure 50: Tau decreases TIA-1 granule movement in primary hippocampal 
neurons. 
A, Compiled traces showing particle localization and tracks of TIA-1-RFP granules ± 
WT Tau or P301L Tau. B, Analysis of the directionality of granule movement between 
time-points, presented as an average percentage of time the granules spent moving in 
either direction (N=20 neurons). C, Quantification of average net displacement of TIA-1 
granules in both the anterograde (+) and retrograde (-) directions (N=20 neurons). D, 
Quantification of average granule velocity in both the anterograde (+) and retrograde (-) 
directions (N=15). E, Quantification of the number of moving TIA-1 granules (N=20 
neurons).  F-H, Scatter plots of TIA-1 granule area vs. average granule velocity for: F, 
TIA-1-RFP transduced neurons, showing a slight trend that larger granules move slower 
(m = - 0.886, R2 =0.17). G, WT Tau/TIA-1-RFP co-transduced neurons, showing a 
prominent trend that larger granules move slower (m = -2.749, R2 = 0.52). H, P301L 
Tau/TIA-1-RFP co-transduced neurons, showing a prominent trend that larger granules 
move slower (m = -2.951, R2 = 0.53). 10µm. ***p<0.001. 
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Section Four: Discussion 
In Chapter Three we demonstrated a strong relationship between TIA-1 and tau over 
the course of tauopathy, with the proteins co-aggregating with disease severity (133). 
Here we report that tau promotes the formation and stability of RNA granules, including 
SGs, resulting in alterations in localization and trafficking. We present multiple 
independent lines of evidence demonstrating that TIA-1 associates with tau, and that the 
interaction between TIA-1 and tau regulates RNA granule biology. Immunocytochemical 
studies of both endogenous and exogenous tau, in cell lines and in primary cultures of 
neurons, show co-localization of tau with TIA-1 positive granules.  Double labeling with 
independent markers of SGs, such as PABP, combined with the ability of cycloheximide 
to disperse the granules, demonstrates that these granules are bona-fide SGs. The 
association of tau with RBPs, such as TIA-1, is consistent with two prior studies noting 
the association of tau with RBPs (143, 144).  The studies presented above suggest that tau 
participates in the regulation of mRNA metabolism and RNA translation, and is co-
regulated by translational signaling.  
The role of tau in RNA granule biology is illuminated by our studies investigating the 
regulation of RNA granules by tau.   Neurons use RNA granules to traffic RNA along 
dendrites from the soma to the synapse.  Tau is normally predominantly axonal, but 
translocates to the soma and dendrite in response to stress (136).  Previous studies 
demonstrated a role for tau in slowing transport of mitochondria and other organelles in 
response to stress (142, 145).  Our current studies demonstrate that tau exhibits a similar 
activity with respect to RNA granule trafficking, slowing transport of TIA-1 positive 
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RNA granules. The response of RNA granule biology to stress also includes formation of 
SGs.  Our studies demonstrate a robust role for tau in stimulating SG formation, with 
over-expression increasing SG levels and deletion reducing SG levels.  The data also 
point to a robust role for tau phosphorylation in SG formation. The role of tau in 
modulating neuronal SGs provides a cogent explanation for the strong accumulation of 
SGs in tauopathies.  The link of tau with SGs also suggests that the pathophysiology of 
tauopathies might share significant overlap with the pathophysiology of the many other 
RBPs linked to neurodegenerative diseases. In Chapter Five we will investigate the 
converse to identify if TIA-1 modulates pathological changes in tau, and whether these 
interactions result in cellular toxicity or protection. 	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CHAPTER FIVE: TIA-1 EXPRESSION MODULATES PATHOLOGICAL 
CHANGES IN TAU AND SUBSEQUENT NEURODEGENERATION IN VITRO * 	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CHAPTER FIVE: TIA-1 EXPRESSION MODULATES PATHOLOGICAL 
CHANGES IN TAU AND SUBSEQUENT NEURODEGENERATION IN VITRO 
The reversible prion-like aggregation of RBPs presents a process that could be highly 
sensitive to the protein aggregates that accumulate in disease. This point seems highly 
relevant when considering that RBPs linked to neurodegenerative diseases, including 
TDP-43, FUS, and ataxin-2, all associate with SGs. In addition, SG proteins, including 
TIA-1, co-localize with neuropathology in brain tissue of subjects with FTDP-17, FTLD-
TDP, and ALS, or animal models of these diseases (112, 124, 134). Recently our lab, 
proposed that the aggregation of many pathological, intracellular proteins, including 
TDP-43, FUS, or Tau, proceeds through the SG pathway. Mutations in genes coding for 
SG associated proteins or prolonged physiological stress, lead to enhanced SG formation, 
which accelerates the pathophysiology of protein aggregation in neurodegenerative 
diseases. Alternatively, the formation of long-lived stable insoluble protein aggregates 
seen in disease may lead to accelerated, long-lived SG formation. This over-active stress 
granule formation could act to sequester functional RBPs and/or interfere with mRNA 
transport and synthesis, each of which might potentiate neurodegeneration (124, 140). 
Thus, the dysfunctions seen in many neurodegenerative diseases may actually be linked 
to dysregulation of RNA granules, as has already been shown in ALS, SMA, and FXR.  
Our work presented in Chapter Three suggests that the biology of tau in mouse 
models of FTLD may be intimately linked to TIA-1, with the proteins accumulating 
concomitantly with each other over the course of the disease, and this was further shown 
in human post-mortem brain tissue (133). We hypothesized that there could be a co-
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regulation of protein aggregation of TIA-1 on tau aggregation, and tau on SG formation 
in the context of neurodegeneration. In Chapter Four presented evidence that tau 
promotes SG formation in a phospho-dependent manner, provoking alterations in TIA-1 
localization and granule trafficking. In Chapter Five we will now look at the converse, 
hypothesizing that the presence of SGs can induce further tau aggregation, deposition, 
and co-localization.  
Section One: TIA-1 Increases Tau Misfolding and Deposition 
TIA-1 promotes Tau inclusions positive for MC1 
The ability of TIA-1 to modulate levels of misfolded tau prompted investigation of 
the relationship between SGs and tau misfolding.  The responses of tau to TIA-1 differed 
depending on whether the focus was on tau inclusions or diffuse tau. 
Immunocytochemistry for MC1-positive tau in HT22 cells transfected with WT tau or 
P301L tau ± dsRed or TIA-1-RFP, showed fewer cells with diffuse MC1 tau reactivity in 
TIA-1 transfected cells, perhaps reflecting tau clearance (Figure 51 A-C). However, the 
subset of cells that were MC1-positive had more inclusions, which also co-localized with 
TIA-RFP (Figure 51 A, D, F). When examining whether the MC1-positive inclusions 
occurred concomitantly with SGs, we found that nearly all MC1-positive inclusions co-
localized with TIA-1, while not all SGs were MC1-positive (Figure 51 E, F). These 
results suggest that TIA-1 reduces diffuse tau, but promotes the accumulation of 
misfolded tau in TIA-1 positive SGs.  
Results in tau -/- hippocampal neurons were equally robust. The neurons were 
transduced with WT or P301L tau AAV9 and TIA-1-GFP or GFP lentivirus, and 
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immunolabeled for MC1 tau and TIA-1. Imaging demonstrated that neurons co-
expressing tau and TIA-1 displayed abundant MC1-positive granules in processes that 
were not apparent in neurons expressing tau alone, and that co-expressing TIA-1 
increased the size of the granules (Figure 52). 
Super-resolution microscopy, which enables imaging at the nanometer scale, was 
used to investigate the co-localization of tau and TIA-1. DIV21 mouse hippocampal tau -
/- neurons were transduced with AAV1-TIA-1-mRFP and AAV9-WT or P301L tau, fixed 
and labeled with MC1. The results showed an intimate association between TIA-1 and 
tau (Figure 53). Treatment with 25 µM Salubrinal increased SG formation, and 
consolidated the MC1 inclusions further (Figure 54, bottom panels). Conversely, in 
absence of tau, TIA-1 exhibited reduced consolidation (Figure 53, top panels). These data 
indicate that TIA-1 increases the number and size of MC1-positive granules in primary 
neurons, perhaps reflecting the ability of TIA-1 to promote regulated protein aggregation, 
which is known to occur with TIA-1 SGs (53).  In this context, it is notable that both tau 
and TIA-1 have large stretches of low-complexity sequences that can foster prion-like 
aggregation.   
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Figure 51: TIA-1 promotes consolidation of misfolded tau into SGs.  
Immunocytochemistry for MC1 (misfolded) tau (green) in HT22 cells transfected with: 
A, dsRed plus EGFP, WT tau-EGFP or P301L Tau-EGFP, B, TIA-1-RFP plus EGFP, 
WT tau-EGFP or P301L Tau-EGFP. Bottom panels show examples of cells that have 
inclusions, with higher magnification insets contain arrows indicating areas of MC1-
positive/TIA-1 positive inclusions. Scale bars, 10µm, high magnification, 2µm. C, 
Quantification of the percentage of MC1-positive transfected cells per condition, 
indicates TIA-1 decreases MC1-positive HT22 cells. D, Quantification of the percentage 
of MC1-positive cells that have inclusions, indicates TIA-1 increases MC1 inclusions. E, 
Quantification of the percentage of SGs that are MC1-positive in SG+/MC1-positive cells 
using eTIA-1 (dsRed) and TIA-1-RFP, indicating that not all SGs are MC1-positive. F, 
Quantification of the percentage of MC1-positive puncta that are TIA-1 positive in 
SG+/MC1-positive cells, indicating that nearly all MC1-positive inclusions are TIA-1 
positive. ***p<0.001.  
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Figure 52: TIA-1 promotes MC1-positive tau inclusions in primary hippocampal 
neurons. 
A, Immunocytochemistry for MC1 tau (red) and MAP2 (blue) in primary Tau -/- 
hippocampal neurons transduced with AAV9-WT or P301L Tau co-transduced with 
EGFP or TIA-1-GFP lentivirus. High magnification inset of dendritic process shows 
MC1 staining. B, Quantification of MC1 granule count per neuron. C, Quantification of 
average MC1 granule area. Scale bar, 10µm low mag; 4µm high mag. *p<0.05, 
***p<0.001.  
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Figure 53: Super resolution imaging shows MC1 deposition within TIA-1-rich areas. 
Super resolution imaging of Tau knockout primary hippocampal neurons transduced with 
AAV19-TIA-1-RFP ± AAV9-WT or P301L Tau immunostained with MC1 (green). 
Bottom panel had 25 µM Salubrinal treatment to increase and prolong SG formation. 
Imaging was done using the Vutara SR 200 (Vutara Inc., Salt Lake City, UT). Boxes 
reveal high magnification insets, with arrows pointing to MC1 inclusions. Scale bar, 
2µm. 
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Mutations in TIA-1 further increase pathological consolidation of tau 
Recently, a single missense mutation in TIA-1 (p.E384K) was found that causes a 
rare disease, Welander Distal Myopathy (WDM). The mutation in TIA-1 is present in the 
prion-rich C-terminal domain, which is required for the self-assembly of TIA-1. In vitro 
assessments of mutant E384K TIA-1 indicates that the mutation is able to increase stress 
granule formation slightly, and that these stress granules exhibit altered trafficking (69). 
We obtained plasmids for both WT and E384K mutant TIA-1, including the a and b 
alternative splice variants of TIA-1, to test whether this pathologic mutation in TIA-1 
could effect pathological changes in tau. We first tested the effect of the TIA-1 mutation 
on SG formation in HT22 cells, and found similar results to the initial studies by 
Hackman et al (69). We find that the mutant TIA-1 slightly increases SG formation under 
basal conditions, but significantly increases SG formation under conditions simulating 
stress (Salubrinal treatment) (Figure 54A, B). Mutant TIA-1 also forms larger SGs, with 
variant B forming larger SGs than variant A (Figure 54A, C).  
We then wanted to test whether the mutant’s increased tendency to form SGs would 
result in alterations in phospho- or misfolded tau. We co-transfected the TIA-1 variants 
with WT or P301L tau in HT22 cells and examined phospho-tau (PHF-1) and 
conformational tau (MC1) reactivity. We find that the mutant TIA-1 variants do not 
effect the amount of cells displaying PHF-1 reactivity, but significantly increases the 
deposition of PHF-1 into inclusions for both WT and P301L mutant tau (Figures 55-56). 
Interestingly in the P301L conditions, when comparing WT TIA-1 to the EGFP control, 
there is a significant decrease in diffuse cytoplasmic PHF-1 consistent with a clearance 
	  	   	   160	  
effect we see biochemically. This decrease is no longer seen with the mutant tau, 
indicating a potential ‘loss of function’ of the mutant TIA-1 (Figure 55B, 56B). This 
effect was not evident with WT tau, perhaps due to the enhanced tendency of P301L tau 
to aggregate and interact with TIA-1.  
Similar trends were found when examining conformation MC1-positive tau, although 
results for WT tau are hard to interpret due to such a small fraction of the cells having 
MC1 reactivity (Figure 57). Focusing on the P301L conditions, we find that mutant TIA-
1 increases MC1 reactivity in cells, while WT TIA-1 has a clearance effect on diffuse 
cytoplasmic tau (Figure 58A, B). The mutation in TIA-1 increases the formation of MC1 
inclusions in these cells (Figure 58A, C). Together these data indicate that a pathogenic 
mutation in TIA-1 that results in enhanced SG formation, stabilizes phospho- and 
conformation tau resulting in increased tau inclusion formation. This is a striking result 
suggesting that the tendency for tau to aggregate may strongly influenced alterations in 
TIA-1 granule formation.  
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Figure 54: Mutant TIA-1 exhibits increased SG formation under stress. 
A, Fluorescence imaging of EGFP tagged TIA-1 constructs transfected in HT22 cells 
(EGFP control, WT TIA-1a, WT TIA-1b, Mutant TIA-1a, Mutant TIA-1b treated with 
DMSO vehicle or 25 µM Salubrinal. B, Quantification of the average number of TIA-1 
positive SGs per cell. C, Quantification of the average size of the SGs. Scale bar, 10 µm. 
* p<0.05, **p<0.01. 
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Figure 55: Mutant TIA-1 further promotes PHF-1 inclusion formation of WT tau. 
A, Immunocytochemistry for PHF-1 tau (blue) in HT22 cells transfected with WT Tau 
and EGFP, WT TIA-1a-EGFP, WT TIA-1b-EGFP, Mutant TIA-1a-EGFP, or Mutant 
TIA-1b-EGFP. B, Quantification of the percentage of cells transfected with tau that are 
PHF-1 positive per condition. C, Quantification of the percentage of PHF-1 positive cells 
that have inclusions, indicates TIA-1 increases PHF-1 inclusions, with mutant TIA-1 
further increasing this. Scale bar, 10µm. **p<0.01. 
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Figure 56: Mutant TIA-1 further promotes PHF-1 inclusion formation of P301L 
tau. 
A, Immunocytochemistry for PHF-1 tau (blue) in HT22 cells transfected with P301L Tau 
and EGFP, WT TIA-1a-EGFP, WT TIA-1b-EGFP, Mutant TIA-1a-EGFP, or Mutant 
TIA-1b-EGFP. B, Quantification of the percentage of cells transfected with tau that are 
PHF-1 positive per condition. C, Quantification of the percentage of PHF-1 positive cells 
that have inclusions, indicates TIA-1 increases PHF-1 inclusions, with mutant TIA-1 
further increasing this. Scale bar, 10µm. *p<0.05, ***p<0.001. 
	  	   	   164	  
 
 
Figure 57: Mutant TIA-1 does not have a striking impact on WT Tau misfolding. 
A, Immunocytochemistry for MC1 misfolded tau (blue) in HT22 cells transfected with 
WT Tau and EGFP, WT TIA-1a-EGFP, WT TIA-1b-EGFP, Mutant TIA-1a-EGFP, or 
Mutant TIA-1b-EGFP. There is little to no MC1 reactivity with WT tau. B, 
Quantification of the percentage of cells transfected with tau that are MC1-positive per 
condition. C, Quantification of the percentage of MC1-positive cells that have inclusions. 
Scale bar, 10µm. 
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Figure 58: Mutant TIA-1 does not promote MC1 clearance and increases MC1 
inclusion formation of P301L tau. 
A, Immunocytochemistry for MC1 misfolded tau (blue) in HT22 cells transfected with 
P301L Tau and EGFP, WT TIA-1a-EGFP, WT TIA-1b-EGFP, Mutant TIA-1a-EGFP, or 
Mutant TIA-1b-EGFP. B, Quantification of the percentage of cells transfected with tau 
that are MC1-positive per condition, shows WT TIA-1 promoting tau clearance, while 
mutant TIA-1 results in an increase in MC1-positive cells. C, Quantification of the 
percentage of MC1-positive cells that have inclusions, indicates TIA-1 increases MC1 
inclusions, with mutant TIA-1 further increasing this. Scale bar, 10µm. *p<0.05, 
**p<0.01, ***p<0.001. 
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Dendritic tau and RNA granules respond to translational signaling 
The interaction between tau and TIA-1, and regulation by translational signaling, was 
particularly evident in dendrites. Primary cultures of tau -/- hippocampal neurons were 
transduced with AAV9-WT tau or P301L tau ± AAV1-mRFP or TIA-1-mRFP (Figure 
59). Neurons expressing WT or P301L tau and mRFP control exhibited tau that was 
spread relatively diffusely along processes, with only weak granules evident (Figure 
59A). However, co-transducing WT or P301L tau with TIA-1 resulted in processes with 
large granules positive for tau and TIA-1, and little to no diffuse tau (Figure 59A, 
arrows).  Comparison of the effects of two different translational inhibitors highlighted 
the role of translational signaling.  Puromycin promotes SG formation because it causes 
release of mRNA from the ribosome, while cycloheximide inhibits mRNA translation 
without causing mRNA release, and thereby inhibits SGs. Neurons were treated at DIV21 
and immunolabeled for Tau13 and MAP2 and imaged (Figure 59 B, C). Treatment with 
puromycin yielded larger and more abundant granules that were particularly accentuated 
with TIA-1 over-expression (Figure 59B). Conversely, treatment with cycloheximide (10 
µg/ml) yielded dendritic tau (and TIA-1) that was spread diffusely with only small, less 
defined granules apparent (Figure 59C). These results add to the previous data indicating 
that the biology of tau is regulated in part by translational signaling, and that puromycin 
induced SG formation enhances tau mislocalization and inclusion formation, while 
inhibiting SG formation with cycloheximide led to a more normal tau morphology.  
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Figure 59: Dendritic tau mislocalizes to forms granule with TIA-1, in a SG 
dependent manner. 
Immunocytochemistry for Tau (Tau13 antibody, green) and MAP2 (blue) in primary 
cultures of tau -/- hippocampal neurons transduced with AAV1 RFP or AAV1-TIA-1-
mRFP ± AAV9-WT or P301L Tau.  The columns on the right show images at high 
magnification (arrows identify tau granules). A, No treatment. B, Puromycin, a 
translation inhibitor that results in SG formation. C, Cycloheximide, a translation 
inhibitor that prevents SG formation. Scale bars: 10 µm, high magnification 2µm. 
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Knockdown or knockout of TIA-1 increases tau levels and inhibits formation of tau 
inclusions 
Comparison of levels of endogenous mouse tau in cortex from 10-month-old TIA -/- 
vs. WT mice (C57Bl/6J, the genetic background) demonstrated that endogenous TIA-1 
expression levels regulate tau protein levels. Immunoblots showed a lack of eTIA-1 in the 
TIA-1-/- mice, and a corresponding increase in tau levels compared to the control strain 
(Figure 60).  Similar results were observed using TIA-1 knockdown. HT22 cells were 
transfected with WT or P301L tau ± shRNA for TIA-1 or a control nonsense sequence. 
Immunoblot of TIA-1 demonstrated ~90% knockdown of TIA-1 (Figure 61A).  Total tau 
levels (Tau13) were elevated upon TIA-1 vs. control knockdown (Figure 61A). IP of 
MC1, followed by probing with Tau13 showed a corresponding increase in levels of 
misfolded tau (Figure 61B).  Analysis of MC1 positive (MC1-positive) inclusions by 
imaging indicated that TIA-1 knockdown increased the percentage of MC1-positive cells 
(Figure 62A, B), while reduced the number of MC1-positive inclusions (Figure 62A, C).  
These data indicate that TIA-1 reciprocally regulates levels of tau (total and misfolded) 
and tau granules.   
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Figure 60: TIA-1-/- mice have higher tau levels than background control strain. 
Immunoblots showing higher levels of total tau (Tau-5 antibody) in the cortex of TIA-1 -
/- vs. C57Bl/6J (control) mice. 
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Figure 61: Knockdown of TIA-1 results in increased total and pathogenic tau levels. 
A, Immunoblots showing higher levels of total tau (Tau13 antibody) with TIA-1 
knockdown in lysates from HT22 cells transfected with EGFP, WT Tau, P301L Tau co-
transfected with shControl or shTIA-1. B, Immunoprecipitation of tau with the MC1 
antibody from above lysates, followed by immunoblotting with the Tau13 antibody 
showing an increase in MC1 tau with TIA-1 knockdown. 
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Figure 62: TIA-1 knockdown increases diffuse MC1 reactivity but decreases tau 
inclusion formation in HT22 cells. 
A, Immunocytochemistry for MC1 tau (blue) and eTIA-1 (red) in HT22 cells transfected 
with EGFP, WT Tau, or P301L Tau (visualized via EGFP) and co-transfected with 
shControl (scrambled, left panel) and shTIA-1 (right panel). B, Quantification of the 
percentage of MC1-positive transfected cells per condition. C, Quantification of the 
percentage of MC1-positive cells that have inclusions. Scale bars, 10µm. ***p<0.001. 
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Section Two: TIA-1 Effects Tau Biochemically 
TIA-1 regulates tau catabolism in a phospho-dependent manner 
Our previous biochemical figures have shown TIA-1 expression promoting clearance 
of tau with a more profound effect on P301L tau. We wanted to further investigate this 
phenomenon and determine if phosphorylation is key for this, as we know that tau 
phosphorylation is key for enhanced SG formation. We first examined hTau (Tau13) and 
phospho-tau (PHF-1) levels in response to exogenous TIA-1 expression in HT22 cells 
transfected with the P301L, P301L PMIM, or P301L PNULL constructs.  
The ability of TIA-1 to promote removal of general tau was demonstrated by 
immunoblot. Steady state levels of tau were lower in HT22 cells co-transfected with TIA-
1, as were levels of phospho-tau (Figure 63A). To determine whether TIA-1 has a 
preferential effect for interacting and clearing phospho-tau we did co-
immunoprecipitations with TIA-1 and MC1. We found that the P301L PMIM construct 
fostered the greatest amount of interaction with TIA-1, followed by the P301L construct 
(Figure 63B). There was very minimal interaction with the phospho-null construct 
indicating that tau phosphorylation may be a prerequisite for the TIA-1/tau interaction, 
and thus the clearance and lack of effect on SG formation (as shown in Figure 43). We 
still see TIA-1 promoting the clearance of the PNULL construct, perhaps due to its 
phosphorylation outside of the mutated sites. TIA-1 was also able to promote the 
clearance of MC1 (misfolded tau), in a phospho-dependent manner with the PNULL 
conditions showing the least effect, and both exogenous and endogenous TIA-1 were 
found bound to MC1 in all conditions, with increased binding to the P301L and P301L 
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PMIM conditions (Figure 63C).  
Prior reports indicate that turnover of tau occurs in a manner that is dependent on 
phosphorylation and the ubiquitin proteasomal system (146). Consistent with these 
observations, the decreases in tau levels were partially prevented by treatment with the 
proteasomal inhibitor MG132, while treatment with the autolysosomal inhibitor, 
bafilomycin, had little effect (Figure 64). These data suggest that TIA-1 associates with 
tau (enhanced with phosphorylation), and promotes its degradation, in part through a 
UPS-dependent mechanism.  
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Figure 63: TIA-1 preferentially interacts with phospho-tau and is found bound to 
misfolded tau in HT22 cells. 
A, Immunoblots showing levels of Tau13, PHF-1, TIA-1, and actin in lysates from HT22 
cells transfected with EGFP, P301L Tau, P301L Tau - phosphomimetic, or P301L Tau - 
phosphonull ± TIA-1-RFP. B, Immunoprecipitation of TIA-1, followed by 
immunoblotting with Tau13 and TIA-1. C, Immunoprecipitation of MC1 tau, followed by 
immunoblotting with Tau13 and TIA-1. 
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Figure 64: TIA-1 promotes tau clearance in part through a UPS-dependent 
mechanism. 
Immunoblots showing levels of total tau (Tau13), phosphorylated tau (PHF-1), TIA-1-
RFP, endogenous TIA-1 (eTIA-1) and actin in lysates from HT22 cells transfected with 
EGFP, P301L Tau, P301L Tau-PMIM, or P301L Tau-NULL ± TIA-1-RFP, then treated 
overnight with 5 µM MG132 or 50 µM chloroquine. 
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TIA-1 increases tau stability and insolubility  
The ability of TIA-1 to stimulate tau clearance, yet promote tau inclusions led us to 
hypothesize that TIA-1 increased the stability of tau in inclusions. To test this hypothesis, 
we generated a WT 4N0R photoactivatable tau (PA-Tau) construct that stably converts 
from cyan to green, transfected hippocampal neurons (DIV 7) with the PA-Tau ± TIA-1, 
performed the photoactivation at DIV 21, and then imaged for 6 hrs.  Neurons transfected 
with PA-Tau (plus mCherry as ballast) exhibited green tau fluorescence present both 
diffusely and in inclusions.  The tau fluorescence decreased steadily over 6 hrs down to a 
level of approximately 40% of the original fluorescence levels (Figure 65).  In contrast, 
hippocampal neurons transfected with PA-Tau + TIA-1 exhibited greatly reduced decay 
rates, with PA-Tau fluorescence above 80% at 6 hrs (Figure 65).  Expressing tau with 
TIA-1 also caused a higher proportion of the tau to localize to inclusions, consistent with 
Figures 52.  These data indicate that TIA-1 stabilizes tau in inclusions.  
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Figure 65: TIA-1 stabilizes tau localized in inclusions^. 
A, Live cell imaging of PA-Tau following photo-conversion, neurons were imaged for up 
to 6 hrs.  Representative images are shown for the 0 and 6 hr time points showing 
stabilization of tau in granules in cells co-expressing TIA-1.  B, Quantification of PA-Tau 
from neurons at varying time points after photo-conversion (N=8 per condition). Scale 
bar, 2µm. *p<0.05, ** p<0.01. ^PA-Tau construct was created by Shamol Saha, Ph.D. 
and data and figure was produced by Katherine Youmans, Ph.D. 
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Association with TIA-1 promotes formation of insoluble tau 
 The stabilization of tau in inclusions combined with the presence of misfolded, MC1 
positive tau in SGs raised the possibility that TIA-1 increases formation of insoluble tau 
in inclusions. To test this hypothesis, HT22 cells were transfected with WT tau, WT 
PMIM tau, P301L tau, P301L PMIM tau ± TIA-1-RFP. The TIA-1 was 
immunoprecipitated and the resulting precipitates biochemically fractionated into soluble 
and insoluble TIA-bound and non-TIA-bound. Over-expressing TIA-1 promoted the 
clearance of tau in all fractions but the insoluble-TIA-bound (Figure 66A, B). There was 
an increase in the amount of insoluble tau (WT, WT PMIM, and P301L) associated with 
TIA-1 (Figure 66A, B). No significant effect was observed with P301L PMIM, perhaps 
reflecting its enhanced tendency to form insoluble tau independent of TIA-1. Thus our 
findings suggest that association with TIA-1 promotes formation of insoluble tau, which 
is thought to be a key step in forming neurofibrillary tangles. 
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Figure 66: Association with TIA-1 promotes the formation of insoluble tau. 
 A, Immunoprecipitation of TIA-1 followed by 1% sarkosyl fractionation of the non-TIA-
1 bound (non-bead bound) lysate, and a 1% sarkosyl fractionation of the TIA-1-bound 
(bead-bound) protein complexes. Immunoblots showing levels of Tau13 in 1% sarkosyl 
soluble and insoluble fractions of the Non-TIA-1 bound and TIA-1 bound proteins. B, 
Quantification of the ratio of insoluble to soluble tau levels, using ImageJ, shows that 
there is an increase in the ratio of insoluble to soluble tau in the fraction bound to TIA-1. 
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Section Three: Co-expressing TIA-1 and Tau Results in Neurotoxicity 
TIA-1 decreases dendritic length of tau expressing primary hippocampal neurons 
Our results suggest a functional interaction between TIA-1 and tau, with tau 
promoting formation of TIA-1 positive SGs, and that TIA enhancing both tau catabolism 
and tau consolidation. We wanted to further study whether these interactions also modify 
processes linked to neurodegeneration. Hippocampal neurons (DIV3) were transduced 
with AAV9-WT or P301L tau ± AAV1-TIA-1-mRFP or mRFP and imaged for MAP2 at 
DIV21 (Figure 67A). Co-expressing TIA-1 with tau significantly decreased dendrite 
lengths, but did not have an effect independent of tau (Figure 67A, B).  
Deletion of TIA-1 caused reciprocal effects, highlighting the importance of 
endogenous TIA-1 in tau toxicity. Hippocampal neurons (DIV3) from TIA-1 -/- mice 
were transduced with AAV9-WT or P301L tau ± AAV1-TIA-1-mRFP or mRFP and 
imaged for MAP2 at DIV21. Mutant P301L tau reduced dendritic length in C57Bl/6J 
neurons, as reported previously, but had no effect on dendritic length in TIA -/- neurons.  
These data indicate that TIA-1 expression is necessary for dendrite shortening associated 
with expression of P301L tau (Figure 67C).  
Induction of toxicity was also apparent using biochemical assays. We examined 
levels of synaptic and apoptotic markers by immunoblot in WT primary cortical neurons 
transduced with mRFP or TIA-1-mRFP ± WT tau or P301L tau.  Markers examined 
included synaptophysin, PSD-95, caspase-3, and cleaved caspase-3. The data indicate a 
striking loss in pre-synaptic marker, synaptophysin in tau and TIA-1 co-transduced 
neurons, indicating a corresponding loss of axonal terminals. Levels of cleaved caspase-3 
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were also elevated in TIA-1 and tau co-transduced neurons indicating enhanced toxicity. 
Interestingly, changes in post-synaptic marker PSD-95 levels were not prominent (Figure 
68).  These data suggest that the interaction of TIA-1 with tau can promote 
neurodegeneration under conditions where SG formation is enhanced, such occurs with 
TIA-1 over-expression.  
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Figure 67: Expression of TIA-1 with tau reduces dendrite lengths in primary 
hippocampal neurons. 
A, Representative dendrite traces of hippocampal neurons (primary culture, DIV21) using 
MAP2 labeling from WT or Tau -/- mice, transduced with AAV1-TIA-1-mRFP ±. 
AAV9-mRFP, AAV9-WT or P301L Tau. B, Quantification of dendrite lengths 
(N=30/condition). C, Quantification of dendrite lengths in C57Bl/6J and TIA-1 -/- 
primary hippocampal neurons transduced with WT or P301L Tau (N=30/condition). 
**p<0.01.     
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Figure 68: Co-expression of TIA-1 and tau results in loss of synaptophysin and 
increased caspase cleavage in primary cortical neurons. 
Immunoblots showing levels of synaptophysin, PSD-95, caspase-3, and cleaved caspase-
3 in WT primary cortical neurons transduced with AAV1-mRFP or AAV1-TIA-1-mRFP 
± AAV9-WT or P301L Tau. 
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Aβ potentiates toxicity mediated by TIA-1 and tau 
Recent studies suggest that Aβ stimulates eIF2α phosphorylation and the SG 
response (147, 148). To test whether this might feed into tau biology, tau -/- primary 
hippocampal neurons (DIV3) were transduced with mRFP or TIA-1-mRFP ± WT tau or 
P301L tau, and then treated at DIV21 for 24 hrs with 500 nM Aβ or 25 µM Salubrinal. 
Quantification of cleaved caspase 3/7 showed that TIA-1 increased caspase cleavage only 
in tau expressing neurons, in a manner that was potentiated by treatment with 500 nM Aβ 
or 25 µM Salubrinal (Figure 69A). Similarly, analysis of DNA fragmentation as a 
measure of apoptosis showed that TIA-1 also increased apoptosis in tau expressing 
neurons, in a manner that was potentiated by treatment with 500 nM Aβ or Salubrinal 
(Figure 69B).  These data suggest that TIA-1 and tau interact to potentiated neurotoxicity 
induced by Aβ, as measured by dendrite shortening, loss of synaptophysin, increased 
caspase cleavage, and apoptosis.  
  
	  	   	   185	  
 
Figure 69: TIA-1 and tau coexpression results in increased caspase cleavage and 
apoptosis that is potentiated by Abeta or Salubrinal treatment. 
A, Luminescent quantification of caspase cleavage (Caspase-Glo 3/7 Assay kit, 
Promega). Comparison of the amount of caspase cleavage in Tau -/- primary 
hippocampal neurons (DIV21) transduced with AAV1-TIA-1-mRFP or mRFP ± AAV9-
WT or P301L treated with 500 nM Aβ or 25 µM Salubrinal. B, Colorimetric 
quantification of DNA fragmentation to measure apoptosis (TiterTACS Colorimetric 
Apoptosis Detection kit, Trevigen). Tau -/- primary hippocampal neurons (DIV21) 
transduced with AAV1-TIA-1-mRFP or mRFP ± AAV9-WT or P301L Tau under basal 
conditions and treatments with 500 nM Aβ or 25 µM Salubrinal. **p<0.01, ***p<0.001. 
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TIA-1 and Tau linked toxicity is SG-dependent 
We next wanted to investigate whether the toxicity was SG-dependent or a byproduct 
of translation inhibition. Tau -/- and TIA-1 -/- primary hippocampal neurons were 
transduced with WT tau or P301L tau ± TIA-1-mRFP or mRFP, and at DIV21 treated 
with translation inhibitors puromycin (5 µg/ml) or cycloheximide (10 µg/ml) for 24 
hours. Translation inhibition with cycloheximide did not affect dendrite length, while 
treatment with puromycin, which potentiates SGs, potentiated the decrease in dendrite 
length associated with TIA-1/tau over-expression (Figure 70A-B).  
In order to follow up our finding that the TIA-1-induced toxicity was dependent on 
SG formation, we compared the amount of apoptosis under basal conditions and 
treatments with Cycloheximide or Puromycin. Results indicate that a translation inhibitor 
that does not cause SG formation (Cycloheximide) does not further increase apoptosis in 
TIA-1/tau co-expressing neurons, but that a translation inhibitor that causes SG formation 
(Puromycin) causes a further increase in apoptosis, confirming our findings that the TIA-
1-induced increase neurotoxicity is potentiated by SG formation (Figure 70C).  
  
	  	   	   187	  
 
Figure 70: TIA-1 induced increase in neurotoxicity is potentiated by SG formation. 
A, Quantification of the % change in dendrite lengths in hippocampal neurons (primary 
culture, DIV21) from tau -/- mice transduced with AAV1-TIA-1-mRFP ±. AAV9-mRFP, 
AAV9-WT or P301L Tau and treated with translation inhibitors puromycin (SG-
promoting) or cycloheximide (SG inhibiting).  Comparison is to neurons from C57Bl/6J 
(control) mice. (N=30/condition). B, The same experiment as in D, but done in TIA-/- 
mice (N=30/condition). C, Comparison of the amount of apoptosis in tau knockout 
primary hippocampal neurons transduced with AAV9-mRFP or AAV9-TIA-1-mRFP ± 
AAV9-WT Tau or AAV9-P301L Tau under basal conditions and treatments with 
Cycloheximide, a translation inhibitor that does not cause SG formation, or Puromycin, a 
translation inhibitor that causes SG formation. ***p<0.001. 
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Taxol rescues toxicity mediated by TIA-1 and Tau 
Based on our imaging results, we hypothesized that TIA-1 may be inducing a 
breakdown in MT stability, as evidenced by tau fragmentation and consolidation into 
granules, and further supported by our dendritic length measurements.  We repeated the 
dendritic length experiments after 24 or 72-hour treatment with Taxol (a MT stabilizer). 
We found that this can rescue the toxicity in a time dependent manner, indicating that the 
toxicity may be a result of MT breakdown (Figure 71A).  
We then compared the amount of caspase cleavage under basal conditions to 24h 
treatments with Taxol (MT stabilizer) or Nocodazol (MT destabilizer). A MT destabilizer 
(Nocodazol) does not further increase the amount of cleaved caspase-3 in TIA-1/tau co-
expressing neurons, but that a MT stabilizer (Taxol) is able to partially rescue the 
increase in cleaved caspase-3, supporting our hypothesis that TIA-1 may cause 
neurotoxicity by promoting MT breakdown (Figure 71B). 
We then compared the amount of apoptosis under basal conditions to 24h treatments 
with Taxol or Nocodazol. Nocodazol does not further increase apoptosis in TIA-1/tau co-
expressing neurons, but that Taxol is able to rescue the increase in apoptosis, further 
supporting our hypothesis that TIA-1 may cause neurotoxicity by promoting MT 
breakdown (Figure 71C). Interestingly, 24h treatment with Taxol is able to fully rescue 
the TIA-1/tau co-expressing neurons from apoptosis, but only partially rescue the caspase 
3 cleavage. It is plausible that a longer treatment would be able to fully rescue the 
caspase cleavage, similar to what was seen with the dendrite shortening that 24h 
treatment partially rescued and 72h fully rescued the phenotype.  
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Figure 71: TIA-1 induced neurotoxcity can be rescued with Taxol treatment. 
A, Quantification of average total dendrite lengths of tau knockout neurons transduced 
with: AAV9-WT Tau or AAV9-P301L Tau ± AAV9-TIA-1-mRFP under basal 
conditions, or with 24h or 72h of Taxol (MT stabilizer) treatment (N=30/condition). B, 
Comparison of the amount of caspase cleavage in tau knockout primary hippocampal 
neurons transduced with AAV9-mRFP or AAV9-TIA-1-mRFP ± AAV9-WT Tau or 
AAV9-P301L Tau under basal conditions and treatments with Taxol (a MT stabilizer) or 
Nocodazol (a MT destabilizer). C, Comparison of the amount of apoptosis in tau 
knockout primary hippocampal neurons transduced with AAV9-mRFP or AAV9-TIA-1-
mRFP ± AAV9-WT Tau or AAV9-P301L Tau under basal conditions and treatments 
with Nocodazol or Taxol. **p<0.01, ***p<0.001. 
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Section Four: Discussion 
Taken together these data complement the previous data presented to you, and 
demonstrate that an interaction between TIA-1 and tau results in neurotoxicity in primary 
neurons. Tau is able to effect TIA-1 positive SG formation and localization. At the same 
time, TIA-1 is able to promote tau misfolding and deposition into aggregates at the site of 
SGs, this is accompanied by MT destabilization and breakdown. Together these 
interactions result in neurotoxicity potentiated by SG formation as measured by dendrite 
shortening, loss of synaptophysin, increased caspase cleavage, and apoptosis, which can 
be rescued by treatment with a MT stabilizer.  
Our work shows a novel role for the SG response in stimulating formation of tau 
inclusions, tau aggregation and tau misfolding.  Expressing TIA-1 or treating with 
arsenite or puromycin, both of which induce SGs, cause a striking increase in formation 
of tau inclusions. Most of the MC1 positive inclusions, which contain misfolded tau, co-
localize with SGs; this raises the possibility that the environment of the SG promotes or 
stabilizes tau misfolding.  We also observe increased insoluble WT tau associated with 
SGs; P301L tau insolubility was not potentiated by SGs, possibly because it already 
exhibits a strong tendency to misfold.   Support for putative role of SGs in inducing tau 
misfolding originates in data showing that RNA blocks the assembly of MTs in a tau-
dependent manner (44, 45). Other groups have shown that RNA is able to stimulate tau 
aggregation (46, 47). 
Tau misfolding is a hallmark of tauopathies, yet the mechanism through which 
misfolding occurs is fundamentally unknown. Previously we introduced the concept of 
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“Regulated Protein Aggregation" to describe the biology of RNA granules and SGs, 
which use aggregation as a regulated, physiological mechanism controlling protein 
synthesis and mRNA trafficking (124). The bidirectional interaction between tau and 
TIA-1 suggests a novel paradigm for understanding the genesis of tauopathies, which 
places tau misfolding in the general pathway of “regulated protein aggregation” (124), 
and provides a biological context and a physiological pathway in which tau misfolding 
occurs. It is well known that the aggregation-prone and prion-related domains of RBPs 
have a propensity to interact with one another (149, 150). Our results show that TIA-1 
and tau are present in complex with the presence of either protein promoting the insoluble 
aggregation of the other. We suggest that the aggregation of RBPs in SGs promotes the 
misfolding and aggregation of tau, potentiating the pathophysiology of tauopathies. 
The genesis of tau-mediated degeneration might precede overt aggregation.  Early tau 
related deficits are thought to result of synaptic abnormalities caused by the accumulation 
of hyper-phosphorylated tau within intact dendritic spines, where it disrupts normal 
synaptic function (136, 151). Tau mediated caspase activation is thought to be an early 
step in the degenerative process (152).  An interesting possibility is that SGs or other 
types of RNA granules might regulate the location of hyper-phosphorylated tau, 
promoting movement of tau into the dendritic compartments, where it becomes available 
for caspase cleavage.  Dendritic tau appears to disrupt trafficking of RNA granules, 
which are necessary for local translation and proper function at the synapse.  Our studies 
show that TIA-1 potentiates tau toxicity, activating caspases and stimulating dendritic 
retraction. The resistance of TIA-1 knockout neurons to tau toxicity highlights the 
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importance of TIA-1 in tau toxicity.  More generally, the ability of puromycin to 
potentiate the degenerative response points to the involvement of translational signaling.  
Dendritic mislocalization of tau is also postulated to be associated with microtubule 
breakdown (136, 151, 153). The connection between microtubules and RBPs is supported 
by studies in yeast, where Li and colleagues identified a tubulin-associated complex 
containing the TIA-1 orthologue, Pub1, tubulin mRNA and components of translation 
machinery (154). Translational control appears to be integrated with the microtubule 
system in neurons, particularly in response to stress, with tau functioning as a key 
intermediate. The interaction of tau with translational systems and SGs might mediate 
synaptic loss, dendritic retraction, and a vicious cycle of tau potentiating an overactive 
SG response, and SGs further exacerbating tau pathology and trafficking abnormalities.  
Collectively our findings suggest that tauopathies can be added to the list of diseases 
where the dysfunction in RBPs or RNA granules contributes to pathophysiology of 
neurodegeneration.  
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CHAPTER SIX: SUMMARY, KEY FINDINGS, AND FUTURE DIRECTIONS 
Section One: Summary 
The pathophysiology of neurodegenerative diseases and many aging processes are 
characterized by the continual presence of oxidative stress. The stress response in 
eukaryotic cells involves the activation of defense mechanisms that either promote 
survival or the initiation of apoptosis. The cellular response depends on the type of stress 
presented, and can be finely tuned by the response of RBPs and their ability to control 
translation in both a global and transcript dependent manner (60, 112, 123). A key 
component of stress-induced translational suppression, SGs play a dynamic role in 
mRNA triage by sorting sequestered mRNAs for re-initiation, storage, or degradation, 
and may be required to allow optimal translation of stress-responsive anti-apoptotic 
mRNAs. Non-translating mRNAs, translation initiation components, and many additional 
proteins effecting mRNA function are shuttled into SGs nucleated by RBPs, including 
TIA-1, which contain prion-like and poly-glutamine rich domains, and their aggregation 
mirrors that of proteins linked to neurodegenerative diseases (52, 53, 112).  
The reversible prion-like aggregation of RBPs presents a process that could be highly 
sensitive to the protein aggregates that accumulate in disease. This point seems highly 
relevant when considering that RBPs linked to neurodegenerative diseases, including 
TDP-43, FUS, and ataxin-2, all associate with SGs. In addition, SG proteins, including 
TIA-1, co-localize with neuropathology in brain tissue of subjects with FTLD-TDP, and 
ALS, or animal models of these diseases (112, 124, 134). Recently our lab, proposed that 
the aggregation of many pathological, intracellular proteins, including TDP-43 and FUS 
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proceeds through the SG pathway. Mutations in genes coding for SG associated proteins 
or prolonged physiological stress, lead to enhanced SG formation, which accelerates the 
pathophysiology of protein aggregation in neurodegenerative diseases. Alternatively, the 
formation of long-lived stable insoluble protein aggregates seen in disease may lead to 
accelerated, long-lived SG formation. This over-active stress granule formation could act 
to sequester functional RBPs and/or interfere with mRNA transport and synthesis, each 
of which might potentiate neurodegeneration (124, 140). Thus, the dysfunctions seen in 
many neurodegenerative diseases may actually be linked to dysregulation of RNA 
granules, as has already been shown in ALS, SMA, and FXR. No such investigation had 
been done in the context of AD and related tauopathies, but we hypothesized that we 
would see SG pathology accumulating across the disease, and aimed to investigate this in 
Chapter Three.  
Our results from Chapter Three suggests that the biology of tau in mouse models of 
FTD may be intimately linked to TIA-1, with the proteins accumulating concomitantly 
with each other over the course of the disease, and this was further shown in human post-
mortem brain tissue. Interestingly this relationship was specific for tau pathology, no 
significant SG response was seen with Aβ pathology. Preliminary in vitro experiments in 
SH-SY5Y cells found that SG formation stimulates formation of phosphorylated tau 
inclusions, and tau stimulates SG formation, affirming a strong link between tauopathies 
and SGs (133). We hypothesized that the presence of SGs can induce further tau 
aggregation, deposition, and co-localization. This is a plausible suggestion given that it is 
well known that anionic agents are able to induce tau tangle formation, and SGs contain 
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large quantities of negatively charged RNA species (46). It is also possible that tau may 
have an effect on SG formation and localization, as SGs rely on the microtubule network 
for transport, and tau plays an intricate role in MT stability and structure (21, 63). We 
aimed to investigate and address this co-regulation of protein aggregation of tau on SG 
formation, and TIA-1 on tau aggregation in the context of neurodegeneration in Chapters 
Four and Five respectively.  
We report that tau promotes SG formation in a phospho-dependent manner, 
provoking alterations in TIA-1 localization and granule trafficking. Concomitantly, TIA-
1 binds and promotes the consolidation and misfolding of tau at the site of SGs, which 
may provide a nidus for a prion-like pathological induction. Taken together, the 
interaction of TIA-1 and tau results in a breakdown of microtubules in a SG-dependent 
manner resulting in neurotoxicity in primary neurons.  We provide the first report of the 
dysregulation of an RNA binding protein promoting misfolding and aggregation of a 
disease-linked protein resulting in neurodegeneration, in which there are no known 
mutations linked to the disease. 
Section Two: Key Points 
Our findings represent three novel concepts for the field:  
1) "Regulated Protein Aggregation" - RNA binding proteins use protein aggregation 
as part of a normal regulated, physiological mechanism controlling protein synthesis. Our 
work indicates that aggregation of TIA-1, contributes to the pathophysiology of 
tauopathies and also indicates that the same processes impact on tau misfolding. This 
provides novel approaches to investigate and intervene in the pathophysiology of tau.  
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2) Recent studies indicate that exposure to extracellular pre-aggregated tau and pre-
aggregated α-synuclein can induce further aggregation of tau in cell culture (155). 
However, the initial mechanism through which tau might become aggregated remains a 
mystery. Our study is perhaps the first to identify a mechanism that induces tau pathology 
in cell culture de novo, with TIA-1 inducing MC1-positive misfolding.  
3) The link between tau pathology and RBPs raises the possibility that the 
pathophysiology of tauopathies affects patterns of RNA splicing, degradation and 
translation. How ribostasis is altered via the pathophysiology of tau represents a novel 
line of investigation for the field, which will undoubtedly identify many novel changes 
occurring during the course of tauopathies 
Section Three: Future Directions 
In Chapter Five, we find that the hyperactive SG response results in neuronal toxicity 
as we see tau fragmentation and MT breakdown. In Chapter Three, we note that when 
immunoprecipitating tau we find TIA-1 bound to total tau in WT control conditions, 
perhaps reflecting a normal intersection of the protein functions. Recently, Li and 
colleagues identified a tubulin-associated complex containing the TIA-1 orthologue, 
Pub1 that normally exists in yeast. They found that this prionogenic Pub1 complex, 
contains tubulin mRNA and components of translation machinery, and is important for 
the integrity of the cytoskeleton (156). Interestingly they found that the disruption of 
Pub1 in the complex lead to cytoskeletal defects. The authors hypothesize that the 
complex is implicated in protein synthesis at the site of microtubule assembly, and would 
thus be crucial for MT stability and cytoskeletal reorganization (156). This finding lends 
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to the possibility that the sequestration of TIA-1 in pathological SGs would disrupt MT 
stability resulting in cytoskeletal deficits. Our data supports this with TIA-1 and over-
active SG formation resulting in tau fragmentation and MT breakdown. A particularly 
interesting hypothesis to investigate is that under normal conditions, specific 
phosphorylation sites on tau could promote the recruitment of different RNA granule 
components, where during cytoskeletal reorganization translation and ribosomes could be 
recruited. In response to the hyper-phosphorylation of tau in disease there is an over-
active dysfunctional SG response, resulting in a dysregulation of cytoskeletal 
maintenance, loss of tau function, resulting in misfolding and aggregation.  
One method by which our lab is gathering data to learn more about the intersection of 
TIA-1 and tau biology is to use our in vitro single transfections and co-transfections of 
TIA-1 and tau and compare IP/mass-spectroscopy of the proteins that interact with tau in 
the absence and presence of TIA-1 under both basal and stress conditions and the 
converse TIA-1 in the absence and presence of Tau. This will both allow us to investigate 
binding partners of each protein that may mediate the release of tau from MTs, or specific 
phosphorylation-sites that may be key for this interaction.  
In Chapter Four we present data showing alterations in TIA-1 positive granule 
trafficking and dynamics, and report there is increased SG density and size in the 
presence of tau. A key unanswered question is whether this increase in SG density is the 
result of and increase in SG formation in response to a stress or a decrease in SG 
clearance after the stress is removed. We are actively doing live cell imaging experiments 
in transfected HT22 cells comparing TIA-1-RFP ± WT or P301L tau. We are adding 
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arsenite and visualizing SG formation over-time, and then washing out the arsenite and 
watching the recovery over-time. 
 We are actively breeding mouse colonies to begin in vivo experiments to investigate 
whether viral injection of TIA-1-mRFP AAV compared to mRFP-AAV into the cortex of 
rTg4510 mice will actively exacerbate tau pathology and toxicity. We hypothesize that 
there will be increased deposition of pathogenic tau at earlier ages and we will see a 
robust response in measures of neurotoxicity. Another possibility for studying this is to 
cross the TIA-1 -/- mice with a tau transgenic mouse, and see if the converse will delay 
the onset of tau pathology and offer protection, in which case decreasing or disrupting the 
TIA-1-tau complex may be a worthy drug target. Along these lines, we are currently 
developing an inducible TIA-1/Tau stable cell line for the purposes of starting a drug 
screen to identify compounds that will either inhibit the interaction of TIA-1 and tau or 
prevent the TIA-1 induced aggregation of tau and associated neurotoxicity. 
 One final interesting avenue to explore is the role of translation inhibition in tau-
induced neurodegeneration. As described in the introduction, SG formation is dependent 
on eIF2α phosphorylation, and recent studies in prion mice have shown that high levels 
of eIF2α phosphorylation leads to neurodegeneration through sustained, uncompensated 
repression of protein synthesis,  which is catastrophic in this context because of a critical 
decline in levels of key proteins including synaptic proteins. GADD34 is a phosphatase 
that dephosphorylates eIF2α.  GADD34 is transcriptionally induced by eIF2α. 
Phosphorylation and serves within a negative feedback loop to restore protein synthesis 
(157). The viral expression of GADD34 led to increased survival and decreased 
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neurodegeneration in prion mice, while prolonging eIF2α phosphorylation with 
salubrinal treatment exacerbated neurodegeneration (158). We are also interested in using 
our Tg TIA-1 and Tg Tau mice to see if we can rescue the phenotype induced with TIA-1 
and Tau by viral expression of GADD34. 
 Section Four: Conclusions 
The high prevalence of prion-like domains in RBPs creates a large genetic target for 
pathogenic mutations that create hyper-aggregation variants with downstream toxic 
effects. The role of RBPs in degenerative pathologies may be quite common, as 10 of the 
top 20 human RBPs predicted to have prionogenic domains have been linked to some 
form of degenerative disease (140).  This prevalence suggests that hyperassembly or 
persistence of SG aggregates may be a causative event in disease progression. The self-
perpetuation of such toxic assemblies might be pathological, at least in part, because they 
disrupt RNA homeostasis. First, pathogenic SG formation could reduce the functional 
pool of the RBPs. Second, by sequestering associated mRNAs, SG aggregates could 
alter the population of mRNAs available for translation. Third, pathologic SG aggregates 
could sequester other mRNA-binding regulatory factors, including other mRNA-binding 
proteins, miRNAs, and recruited signaling proteins, such that they are not available for 
their normal functions (124, 140). Thus the elucidation of the mechanisms of toxicity in 
RBP-linked diseases may provide opportunities for pharmacological intervention that 
will be broadly applicable to many neurodegenerative conditions 
Our work puts forward a new paradigm for understanding the genesis of tauopathies, 
which places tau misfolding in the general pathway of regulated protein aggregation, 
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which provides a biological context and a physiological pathway in which tau misfolding 
occurs. It is well known that aggregation-prone and prion-related domains from different 
proteins have a propensity to interact with one another (124). Our results show that TIA-1 
and tau are present in complex with the presence of either protein promoting the insoluble 
aggregation of the other in the context of regulated protein aggregation resulting in 
neurotoxicity (summary Figure 72). We suggest that prion-like aggregation of TIA-1 is a 
seed for the misfolding and aggregation of tau, as displayed by our super resolution 
imaging of the tau/TIA-1 complexes. Tau protein itself is highly disordered and requires 
binding partners for its stabilization and function, in the case of MT stability tau is bound 
to tubulin allowing it to become ordered and regulate cytoskeletal organization. In 
disease, aberrant post-translational modifications cause tau to lose its normal functions, 
resulting in mislocalized tau that is able to interact and aggregate with TIA-1 and SG 
complexes, forming long-lived insoluble complexes. The data in this dissertation present 
novel insights to the molecular mechanisms underlying tauopathies, providing evidence 
that the hyper-aggregation of SGs is actively leading to toxicity in tauopathies, a disease 
where no known mutations in RBPs have been found to be causative.  This dissertation 
opens a new door of discovery intersecting the fields of tauopathies and RNA granule 
biology shedding light on critical unanswered research questions that may be highly 
relevant to a further understanding the pathophysiology of neurodegeneration. 
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Figure 72: Regulated protein aggregation of TIA-1 
and tau results in neurotoxicity. 
Our results show that TIA-1 and tau are present in 
complex with the presence of either protein promoting 
the insoluble aggregation of the other. Our data suggests: 
1) Tau promotes SG formation. 2) Prion-like aggregation 
of TIA-1 is a seed for the misfolding and aggregation of 
tau. 3) These interactions result in toxicity including 
caspase activation, apoptosis, MT destabilization, and 
loss of axonal synapses. Adapted from (50). 
The process of SG formation is best understood for
pathways mediated by phosphorylation of eIF2α. Stress-
ful conditions prompt phosphorylation of eIF2α at serine
51, which inhibits formation of a complex containing
eIF2, GTP and tRNAi
met [31]. Stress also induces trans-
location of many RNA binding proteins from the nu-
cleus to the cytoplasm. During stressful conditions,
capped mRNA remains bound to the pre-initiation com-
plex, which contains the other elongation factor binding
proteins EF-4A, E and G (Figure 4). This mRNA-protein
complex is bound by eIF3, poly-A and nucleating RNA
binding proteins, such as TIA-1, TIAR, tristetraprolin
(TTP) or GTPase activating protein binding protein
(G3BP), which bind the “naked” transcripts in the cyto-
plasm (Figure 4) [28]. The SGs are initially small, but in-
crease in size as the RNA binding proteins consolidate
by binding to each other through the glycine rich pro-
tein aggregation domains. This process of secondary
maturation of SGs specifically containing G3BP is a
prominent cytoplasmic function of TDP-43 [32]. Muta-
tions in RNA binding proteins appear to increase their
propensity to aggregate and to form SGs. For instance,
disease-linked mutations of TDP-43, FUS and ataxin-2
promote aggregation, either by directly increasing the ten-
dency of the protein to aggregate, or (for many FUS muta-
tions) by preventing nuclear translocation [16,17,33-37].
The SG complex initially forms a structure that is concep-
tually analogous to a tree, with the glycine rich aggrega-
tion domains forming the core of the structure, and the
mRNA bound to the RRMI, hanging off the RNA binding
proteins. The complex of aggregated RNA binding pro-
teins grows with time as other RNA binding proteins are
recruited through binding to the associated transcripts
and binding to the protein aggregation domains of other
RNA binding proteins (Figure 4). Mature granules contain
many RNA binding proteins recruited after the initial
Figure 4 Mechanism of normal and pathological stress granule formation. A) In normal, physiological conditions, neurons synthesize
specialized proteins from capped transcripts. The proteins eIF4A, E and G complex to form the eIF4F pre-initiation complex, which interacts with
the ribosome (40S) as well as other translational regulators to synthesize proteins. Association with the 60S ribosome complex allows protein
synthesis to begin. B) Stress leads to phosphorylation of eIF2α, dissociation of ribosomes and many of the translation initiation factors, leaving
mRNA bound eIF4G and poly-A binding protein. Nucleating RNA binding proteins bind the free RNA and also form protein/protein complexes,
which initiate stress granule formation. Once initiated, other RNA binding proteins bind to the mRNA and to the nucleating RNA binding pr teins
to increase the size and complexity of SGs. These SGs are rapidly reversible upon removal of the stress, however prolonged SG formation affects
cell biology by interacting with biological systems regulating apoptosis, signaling and RNA decay. C) Pathological proteins, such as TDP-43, FUS
and tau, have a strong tendency to form oligomers, and then fibrils. The consolidation of RNA binding proteins during SG formation might
promote oligomerization by creating cellular domains with higher concentrations of these proteins. Conversely, the increased stability of
oligomers and fibrils might serve as a nidus for SG formation, leading to over-active SG formation. Microtubule associated protein tau also
participates in this process because it mislocates to the soma and dendritic arbor leading to interactions with SG proteins and potentially
stimulating SG formation [41]. Tau also directly binds RNA [42].
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